# **EXHIBIT D**

Page 1 SUPERIOR COURT OF THE STATE OF CALIFORNIA FOR THE COUNTY OF KERN --000--COLLEEN M. PERRY, Plaintiff, No. 1500-cv-27912 LHB vs. HUNG T. LUU, M.D.; JOHNSON & JOHNSON, a New Jersey corporation; ETHICON, INC., a New Jersey corporation; and DOES 1-60, Defendants. DEPOSITION OF TERI A. LONGACRE, M.D. DATE: December 19, 2014 9:00 a.m. TIME: LOCATION: THE STANFORD TERRACE INN 531 Stanford Avenue Palo Alto, CA 94306 LISA R. KEELING REPORTED BY: Certified Shorthand Reporter License No. 10518

	Page 2		Page 4
3 4 5 For ET 7 8 9 10 11 12 For For ET	A P P E A R A N C E S  the Plaintiff: WAGSTAFF & CARTMELL BY: NATE JONES, ESQ. 4740 Grand Avenue Suite 300 Kansas City, MO 64112 (816) 701-1100 njones@wcllp.com  the Defendant: TUCKER ELLIS, LLP, HICON, INC., BY: JOSHUA J. WES, ESQ. 515 South Flower Street 42nd Floor Los Angeles, CA 90071-2223 (213) 430-3400 joshua.wes@tuckerellis.com BUTLER SNOW, LLP BY: M. ANDREW SNOWDEN, ESQ. 150 3rd Avenue South Suite 1600 Nashville, TN 37201 (615) 651-6700 Andy.Snowden@butlersnow.com  the Defendant: BOYCE SCHAEFFER MAINIERI, LLP ING T. LUU, M.D. BY: LAURA L. COTA, ESQ. 500 Esplanade Drive Suite 900 Oxnard, CA 93036 (805) 988-9200 lcota@boyceschaefferlaw.com	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	INDEX OF EXHIBITS  Exhibit Description Page Exhibit L-7 Teri A. Longacre, M.D. Invoice, Dated 10-13-14 68  Exhibit L-8 Curriculum Vitae of Teri A. Longacre, M.D. 75  Exhibit L-9 Operation/Procedure Report by Hung T. Luu, M.D., Dated 3-23-11 139  Exhibit L-10 Operation Report by Charles Allen, M.D., 1-17-12 139
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	INDEX OF EXAMINATION Examination by: Page Mr. Jones 5 Ms. Cota 112 Mr. Jones 139 Ms. Cota 143 Mr. Wes 145 INDEX OF EXHIBITS Exhibit Description Page Exhibit L-1 Opinions of Teri Longacre, M.D. 14 Exhibit L-2 Bakersfield Pathology Report, Dated 3-23-11 33 Exhibit L-3 Dignity Health/Bakersfield Memorial Hospital Pathology Report, Dated 1-17-12 33 Exhibit L-4 USB Flash Drive of Documents Produced (Retained by Attorney Jones) 55 Exhibit L-5 Plaintiff's Notice of Oral Deposition of Expert Teri A. Longacre, M.D. 67 Exhibit L-6 Defendant's Objections to Plaintiff's Notice of Deposition of Teri A. Longacre and Request	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	PROCEEDINGS: TERIA. LONGACRE, M.D., the Witness herein, having been duly and regularly sworn by the Certified Shorthand Reporter, deposed and testified as follows:  EXAMINATION BY MR. JONES MR. JONES: Q. Good morning, Doctor. A. Good morning. Q. You've been retained by Ethicon's law firm to give opinions in this case, correct? A. Correct. Q. And are you here today to discuss those opinions? A. Yes, I am. Q. Are you here today to discuss the bases for those opinions? A. Yes, I am. Q. And you understand this is the plaintiff's opportunity to ask you questions about your opinions and the bases of those opinions? A. Yes, I do. Q. Are you prepared to give all of your opinions and the bases for those opinions today? A. Yes, I am. Q. I take it you spent some time preparing for your

2 (Pages 2 to 5)

	Page 6		Page 8
1	A. Yes, I did.	1	A. I met with yesterday, the day before. I think
2	Q. What did that preparation entail?	2	the last three days.
3	A. Review of slides, hospital records, pathology	3	Q. So you've met with attorneys for three days?
4	reports, associated literature and discussions with	4	A. Yes.
5	Mr. Snowden predominantly.	5	Q. Who did you meet with?
6	Q. Okay. So we have I want to break that down.	6	A. Mr. Snowden.
7	We have slides, right?	7	Q. Okay.
8	A. Correct.	8	A. And most recently with Mr
9	Q. Path reports?	9	MR. WES: Mr. Wes.
10	A. Correct.	10	THE WITNESS: I know his first name, but I didn't
11	Q. Relevant medical literature?	11	know his last name.
12	A. Yes.	12	MR. JONES: Q. Yeah, sure. When were you first
13	Q. Talked with Mr. Snowden?	13	contacted by Ethicon attorneys to work on this particular
14	A. Correct.	14	case?
15	Q. Anything I'm missing?	15	A. I think it was mid summer of this year.
16	A. Operative reports, other medical records	16	Q. Mid summer 2014?
17	Q. Okay.	17	A. Yes.
18	A of course, and then there were discussions	18	Q. Who contacted you?
19	with some other attorneys, whose names escape me.	19	A. Mr. Snowden.
20	Q. Sure. Did you review any deposition testimony?	20	Q. Prior to mid summer 2014, did you have any
21	A. Yes, I did.	21	contact with attorneys representing Ethicon?
22	Q. Whose deposition testimony did you review?	22	A. Yes.
23	A. Mrs. Perry's, Mr. Perry's, the I'm not sure I	23	Q. When was that?
24	know how to pronounce their names, the surgeons.	24	A. The first part of the year, I believe.
25	Q. You reviewed some of the treating physicians'	25	Q. Early 2014?
1	Page 7  A. Yes, exactly.	1	Page 9  A. Yes.
2	Q depositions in this case?	2	Q. Who contacted you then?
3	A. Correct. Yes.	3	A. Mr. Snowden.
4	Q. Did you review any internal corporate Ethicon	4	Q. Was that related to this particular case?
5	documents?	5	A. No.
6	A. I may have reviewed some, yes.	6	Q. I take it it was related to another Ethicon case?
7	Q. Fair to say that wasn't the focus of your	7	MR. WES: Object to form.
8	preparation in rendering your opinions in this case?	8	THE WITNESS: No.
9	A. Correct.	9	MR. JONES: Q. What was it related to?
10	Q. The focus was on the pathology records, the	10	A. It was the initial contact was to see if I
11	pathology slides, relevant medical literature and the	11	would be interested in examining or being an expert
12	treating physicians' depositions?	12	witness in some of these cases, but there was no specific
13	MR. WES: Object to form.	13	case at that time.
14	You can answer.	14	Q. Okay. So early 2014 Ethicon attorneys contact
15	THE WITNESS: Yes, that's that's the focus and	15	you to gauge your availability and interest to work on
16	then supporting background literature. That's it.	16	cases involving transvaginal mesh?
17	MR. JONES: Q. Okay.	17	A. Correct.
18	A. That was my	18	Q. And then in mid summer 2014, Ethicon attorneys
19	Q. Did you review any depositions of Ethicon	19	contact you, and you agree to work on this particular
20	employees?	20	case?
	A. No, I don't think so.	21	A. Correct.
21	O OL D'I	22	Q. Prior to early 2014 had you been contacted by any
	Q. Okay. Did you meet with attorneys prior to today		
21	to prepare for your deposition?	23	other attorneys representing Ethicon?
21 22			

3 (Pages 6 to 9)

	Page 10		Page 12
1	manufacturers other than Ethicon?	1	MR. JONES: Q. Okay.
2	A. No.	2	A. I read it, but I'm not all that good with
3	Q. I take it you started your work in this case mid	3	numbers.
4	summer 2014 or shortly thereafter?	4	Q. Sure. You're focused more on the pathology
5	A. Probably shortly thereafter, yes. Correct.	5	A. Correct.
6	Q. Maybe late summer 2014 you started to work on	6	Q aspects?
7	this case?	7	A. Correct.
8	A. That would be correct.	8	Q. Not so much the design features of the TVT
9	Q. Okay. When did you first start to review the	9	Abbrevo device?
10	medical records in this case?	10	A. That's correct, yes.
11	A. I believe it was August.	11	Q. Do you know do you know how the mesh and the
12	Q. When did you first start to review deposition	12	TVT Abbrevo device is cut?
13	testimony in this case?	13	MR. WES: Object to form.
14	A. It may have been August or September.	14	THE WITNESS: I'm not sure what you're asking.
15	Q. Same for relevant medical literature?	15	MR. JONES: Q. I'll ask a better question.
16	A. I had started reviewing some of the medical	16	A. Okay.
17	literature after the January or the early the first	17	Q. Do you know whether the mesh in the TVT Abbrevo
18	meeting that we had in January or February of the year but	18	device is mechanical cut mesh or laser cut mesh?
19	nothing that was specifically associated with this case.	19	A. I believe it's laser.
20	Q. Just to get generally familiar with the topics	20	Q. Okay. Are you familiar with any of the aspects
21	that you would be touching base on?	21	of a laser cut mesh?
22	A. Correct.	22	MR. WES: Object to form. It's outside the
23	Q. Yeah. Are you aware that the device in question	23	scope.
24	in this case is the TVT Abbrevo?	24	MR. JONES: Q. Fair to say you're not going to
25	A. Yes.	25	be offering opinions as to the aspects of the laser cut
			Page 13
1		1	Page 13 mesh device?
1 2	Q. Have you seen a TVT Abbrevo device?	1 2	mesh device?
	<ul><li>Q. Have you seen a TVT Abbrevo device?</li><li>A. I've seen mesh that's been removed from the TVT.</li></ul>		mesh device?  A. That would be fair to say, yes.
2	<ul><li>Q. Have you seen a TVT Abbrevo device?</li><li>A. I've seen mesh that's been removed from the TVT.</li><li>Q. Have you seen the TVT Abbrevo device in its</li></ul>	2	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight
2	<ul><li>Q. Have you seen a TVT Abbrevo device?</li><li>A. I've seen mesh that's been removed from the TVT.</li></ul>	2	mesh device?  A. That would be fair to say, yes.
2 3 4	<ul><li>Q. Have you seen a TVT Abbrevo device?</li><li>A. I've seen mesh that's been removed from the TVT.</li><li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li><li>A. No.</li></ul>	2 3 4	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I
2 3 4 5	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT</li> </ul>	2 3 4 5	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?
2 3 4 5	<ul><li>Q. Have you seen a TVT Abbrevo device?</li><li>A. I've seen mesh that's been removed from the TVT.</li><li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li><li>A. No.</li></ul>	2 3 4 5 6	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.
2 3 4 5 6 7	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> </ul>	2 3 4 5 6 7	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept,
2 3 4 5 6 7 8	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> </ul>	2 3 4 5 6 7 8	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm
2 3 4 5 6 7 8	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> </ul>	2 3 4 5 6 7 8	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.
2 3 4 5 6 7 8 9	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> </ul>	2 3 4 5 6 7 8 9	mesh device?  A. That would be fair to say, yes. Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.  MR. JONES: Q. Perfect. Thank you.
2 3 4 5 6 7 8 9 10	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> <li>Q. How about postplacement?</li> </ul>	2 3 4 5 6 7 8 9 10	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.  MR. JONES: Q. Perfect. Thank you.  How does tissue inside the vagina react to
2 3 4 5 6 7 8 9 10 11 12	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> <li>Q. How about postplacement?</li> <li>A. I think I probably have in the gross room, yes,</li> </ul>	2 3 4 5 6 7 8 9 10 11	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.  MR. JONES: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?
2 3 4 5 6 7 8 9 10 11 12 13	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> <li>Q. How about postplacement?</li> <li>A. I think I probably have in the gross room, yes, but just portions of the mesh, not the entire.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.  MR. JONES: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?  MR. WES: Object to form.
2 3 4 5 6 7 8 9 10 11 12 13 14	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> <li>Q. How about postplacement?</li> <li>A. I think I probably have in the gross room, yes, but just portions of the mesh, not the entire.</li> <li>Q. What type of mesh is used in the TVT Abbrevo?</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.  MR. JONES: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?  MR. WES: Object to form.  THE WITNESS: The tissue response to polypropylene in the vagina is probably not dissimilar to tissue response to polypropylene anywhere in the body. I
2 3 4 5 6 7 8 9 10 11 12 13 14	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> <li>Q. How about postplacement?</li> <li>A. I think I probably have in the gross room, yes, but just portions of the mesh, not the entire.</li> <li>Q. What type of mesh is used in the TVT Abbrevo?</li> <li>A. I'm not sure the question you're asking me.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.  MR. JONES: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?  MR. WES: Object to form.  THE WITNESS: The tissue response to polypropylene in the vagina is probably not dissimilar to tissue response to polypropylene anywhere in the body. I mean, it made some variations, but generally it's a
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> <li>Q. How about postplacement?</li> <li>A. I think I probably have in the gross room, yes, but just portions of the mesh, not the entire.</li> <li>Q. What type of mesh is used in the TVT Abbrevo?</li> <li>A. I'm not sure the question you're asking me.</li> <li>Q. What is the material that makes up the mesh in</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.  MR. JONES: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?  MR. WES: Object to form.  THE WITNESS: The tissue response to polypropylene in the vagina is probably not dissimilar to tissue response to polypropylene anywhere in the body. I mean, it made some variations, but generally it's a foreign body reaction.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> <li>Q. How about postplacement?</li> <li>A. I think I probably have in the gross room, yes, but just portions of the mesh, not the entire.</li> <li>Q. What type of mesh is used in the TVT Abbrevo?</li> <li>A. I'm not sure the question you're asking me.</li> <li>Q. What is the material that makes up the mesh in the TVT device?</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.  MR. JONES: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?  MR. WES: Object to form.  THE WITNESS: The tissue response to polypropylene in the vagina is probably not dissimilar to tissue response to polypropylene anywhere in the body. I mean, it made some variations, but generally it's a foreign body reaction.  Q. Okay. There's nothing unique as far as the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> <li>Q. How about postplacement?</li> <li>A. I think I probably have in the gross room, yes, but just portions of the mesh, not the entire.</li> <li>Q. What type of mesh is used in the TVT Abbrevo?</li> <li>A. I'm not sure the question you're asking me.</li> <li>Q. What is the material that makes up the mesh in the TVT device?</li> <li>A. Polypropylene.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.  MR. JONES: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?  MR. WES: Object to form.  THE WITNESS: The tissue response to polypropylene in the vagina is probably not dissimilar to tissue response to polypropylene anywhere in the body. I mean, it made some variations, but generally it's a foreign body reaction.  Q. Okay. There's nothing unique as far as the tissue or inside the vagina that would alter the body's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> <li>Q. How about postplacement?</li> <li>A. I think I probably have in the gross room, yes, but just portions of the mesh, not the entire.</li> <li>Q. What type of mesh is used in the TVT Abbrevo?</li> <li>A. I'm not sure the question you're asking me.</li> <li>Q. What is the material that makes up the mesh in the TVT device?</li> <li>A. Polypropylene.</li> <li>Q. Do you know how much polypropylene makes up the</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Ma. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.  MR. JONES: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?  MR. WES: Object to form.  THE WITNESS: The tissue response to polypropylene in the vagina is probably not dissimilar to tissue response to polypropylene anywhere in the body. I mean, it made some variations, but generally it's a foreign body reaction.  Q. Okay. There's nothing unique as far as the tissue or inside the vagina that would alter the body's reaction to polypropylene as compared to, say, the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> <li>Q. How about postplacement?</li> <li>A. I think I probably have in the gross room, yes, but just portions of the mesh, not the entire.</li> <li>Q. What type of mesh is used in the TVT Abbrevo?</li> <li>A. I'm not sure the question you're asking me.</li> <li>Q. What is the material that makes up the mesh in the TVT device?</li> <li>A. Polypropylene.</li> <li>Q. Do you know how much polypropylene makes up the TVT Abbrevo mesh?</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Mar. Jones: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?  MR. WES: Object to form.  MR. WES: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?  MR. WES: Object to form.  MR. Jones: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?  MR. WES: Object to form.  THE WITNESS: The tissue response to polypropylene in the vagina is probably not dissimilar to tissue response to polypropylene anywhere in the body. I mean, it made some variations, but generally it's a foreign body reaction.  Q. Okay. There's nothing unique as far as the tissue or inside the vagina that would alter the body's reaction to polypropylene as compared to, say, the stomach?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> <li>Q. How about postplacement?</li> <li>A. I think I probably have in the gross room, yes, but just portions of the mesh, not the entire.</li> <li>Q. What type of mesh is used in the TVT Abbrevo?</li> <li>A. I'm not sure the question you're asking me.</li> <li>Q. What is the material that makes up the mesh in the TVT device?</li> <li>A. Polypropylene.</li> <li>Q. Do you know how much polypropylene makes up the TVT Abbrevo mesh?</li> <li>A. No, not at the not off the top of my head.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.  MR. JONES: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?  MR. WES: Object to form.  THE WITNESS: The tissue response to polypropylene in the vagina is probably not dissimilar to tissue response to polypropylene anywhere in the body. I mean, it made some variations, but generally it's a foreign body reaction.  Q. Okay. There's nothing unique as far as the tissue or inside the vagina that would alter the body's reaction to polypropylene as compared to, say, the stomach?  MR. WES: Object to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> <li>Q. How about postplacement?</li> <li>A. I think I probably have in the gross room, yes, but just portions of the mesh, not the entire.</li> <li>Q. What type of mesh is used in the TVT Abbrevo?</li> <li>A. I'm not sure the question you're asking me.</li> <li>Q. What is the material that makes up the mesh in the TVT device?</li> <li>A. Polypropylene.</li> <li>Q. Do you know how much polypropylene makes up the TVT Abbrevo mesh?</li> <li>A. No, not at the not off the top of my head.</li> <li>Q. You don't know how long the mesh is in the TVT Abbrevo device prior to implementation?  MR. WES: Object to form.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.  MR. JONES: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?  MR. WES: Object to form.  THE WITNESS: The tissue response to polypropylene in the vagina is probably not dissimilar to tissue response to polypropylene anywhere in the body. I mean, it made some variations, but generally it's a foreign body reaction.  Q. Okay. There's nothing unique as far as the tissue or inside the vagina that would alter the body's reaction to polypropylene as compared to, say, the stomach?  MR. WES: Object to form.  THE WITNESS: Well, there may be vaginal
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	<ul> <li>Q. Have you seen a TVT Abbrevo device?</li> <li>A. I've seen mesh that's been removed from the TVT.</li> <li>Q. Have you seen the TVT Abbrevo device in its package form as it's delivered to surgeons?</li> <li>A. No.</li> <li>Q. Have you held the mesh that makes up the TVT Abbrevo device in your own hands?</li> <li>A. Preplacement? No.</li> <li>Q. Preplacement?</li> <li>A. No.</li> <li>Q. How about postplacement?</li> <li>A. I think I probably have in the gross room, yes, but just portions of the mesh, not the entire.</li> <li>Q. What type of mesh is used in the TVT Abbrevo?</li> <li>A. I'm not sure the question you're asking me.</li> <li>Q. What is the material that makes up the mesh in the TVT device?</li> <li>A. Polypropylene.</li> <li>Q. Do you know how much polypropylene makes up the TVT Abbrevo mesh?</li> <li>A. No, not at the not off the top of my head.</li> <li>Q. You don't know how long the mesh is in the TVT Abbrevo device prior to implementation?</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	mesh device?  A. That would be fair to say, yes.  Q. Okay. Are you familiar with the lightweight large pore concept in mesh surgery?  A. Yes, I  MR. WES: Object to form, outside the scope.  THE WITNESS: I am familiar with that concept, but that's not again, this is not an area that I'm offering an opinion on.  MR. JONES: Q. Perfect. Thank you.  How does tissue inside the vagina react to polypropylene?  MR. WES: Object to form.  THE WITNESS: The tissue response to polypropylene in the vagina is probably not dissimilar to tissue response to polypropylene anywhere in the body. I mean, it made some variations, but generally it's a foreign body reaction.  Q. Okay. There's nothing unique as far as the tissue or inside the vagina that would alter the body's reaction to polypropylene as compared to, say, the stomach?  MR. WES: Object to form.

4 (Pages 10 to 13)

#### Page 16 Page 14 although the overall foreign body reaction would be the 1 1 that distinction. 2 same. The adjacent tissue that it's sort of associated 2 Q. Can I stop you right there, Doctor. Do you mind 3 with will be different. I don't know that I'm answering 3 if we switch copies so that you have the copy with the 4 4 deposition exhibit sticker on it? your question. 5 5 MR. JONES: Q. Okay. A. Sure. 6 6 A. But that's the best I can do. MR. JONES: Is that fine with you, Counsel? 7 7 (Counsel did not verbally respond.) Q. Sure. I appreciate it. That's probably a bad 8 8 THE WITNESS: Sure. That's fine. question. 9 In the interest of being as efficient as possible 9 MR. JONES: Thank you. That allows me to mark up 10 10 this copy without it showing up in the records. with everyone's time here today, did you bring a sheet 11 THE WITNESS: Good. 11 with the opinions you intend to offer in this case with 12 12 MR. JONES: Q. All right. So before I you today? 13 interrupted you were discussing the acute versus chronic 13 A. Yes, I did. 14 Q. Are you willing to share that sheet --14 inflammatory reaction. 15 15 A. Yes. A. Correct. And the types of cells that you see in 16 16 Q. -- with me? acute inflammation versus chronic inflammation. 17 Q. And is it fair to say then that the first portion 17 A. Yes, I am. 18 18 MR. JONES: I'm going to mark the Summary of under the heading "Inflammatory Response and Foreign Body 19 Response with Implant" is a discussion of the acute versus 19 Opinion of Dr. Teri Longacre as Exhibit L-1. 20 (Whereupon, Exhibit L-1 was marked for 20 chronic inflammatory reaction in the cells and some of the 21 21 terminology that would be applicable in that area? identification.) 22 22 MR. JONES: Q. You have a copy of this in front A. Correct. 23 Q. And then under letter B you have "Factors 23 of you, Doctor? 24 24 A. Yes. Yes, I do. impacting wound healing." Q. Let's go through this Summary of Opinion of 25 What do you intend to talk about related to 25 Page 17 Page 15 Dr. Teri Longacre. 1 factors impacting wound healing? 1 2 2 What is the first opinion you intend to offer in A. Well, again, just in general things that can 3 3 affect how well a wound heals include obviously genetic 4 A. I don't know that there's necessarily an order of 4 predisposition, but factors that can prevent wound healing 5 5 the opinions. As you see I've set forth at the Roman or impair it are lack of nutrition. You need amino acids 6 6 Numeral I just an itemized, I guess, list of what to heal, protein. Smoking has been shown to impact 7 7 constitutes the inflammatory response and a foreign body collagen formation. Diabetes. All of these may have 8 8 response that's associated with implant material, and this played a role in wound healing in Mrs. Perry. 9 really is just by way of making sure that we're all using 9 There are other things that can impact wound 10 10 healing that I haven't listed. Steroid therapy, et the same terminology. 11 So the typical reaction is there may be an acute 11 cetera. I don't think that that played a role. 12 12 inflammatory infiltrate, but generally it roughly -- or Q. How about genetics? You mentioned genetics. Do 13 fairly soon shifts to a more chronic inflammatory 13 you think that played a role in this case? 14 14 infiltrate. A. It may or may not. 15 By acute, I mean neutrophils. By chronic, I'm 15 Q. Okay. 16 referring to other inflammatory cells. They're usually 16 A. Some people heal faster than others. It's 17 monocytes which can differentiate into macrophages, 17 variable, so one doesn't really know. 18 18 lymphocytes, mast cells, et cetera. Q. Okay. How about diabetes? 19 Chronic inflammation, the term itself really 19 A. Yes, diabetics can have impaired wound healing, 20 20 denotes a description of the cells, not necessarily and it's all about -- well, it's pretty complex, but it's 21 longstanding. It may be longstanding, but you know, we --21 in part due to vascular insufficiency. You need vascular 22 22 generally we think about chronic being a long-term supplying oxygen to the tissue for adequate wound healing. 23 23 And that's, again, sort of why smoking is a risk process. 24 24 When you're talking about inflammatory cells, factor for poor wound healing because smoking releases 25 it's a specific type of cell. So I just wanted to make 25 carbon monoxide and impairs oxygenation of tissue.

#### Page 20 Page 18 1 So anything that impairs oxygenation of tissue person, the more you smoke, one would assume the worst of 1 2 and delivery of nutrients will impair wound healing. 2 side effects, correct. 3 Q. Okay. Are you familiar with whether or not 3 MR. JONES: Q. So if I understand this 4 4 Ms. Perry smokes? correctly, there are patient-specific factors that would 5 A. I don't know if she currently smokes, but there 5 alter the wound healing process on top of diabetes, 6 6 was a record of it historically. smoking, asthma, allergies, and nutrition? 7 7 Q. So you don't know one way or the other whether MR. WES: Object to form. 8 8 she currently smokes cigarettes? THE WITNESS: Yeah, I'm not sure what -- there 9 A. As of today, no, I don't know. But during her 9 are other factors meaning? 10 10 surgery she was a smoker, and after her surgery for her MR. JONES: Q. Meaning -- here's what I'm 11 getting at. The -- we talked earlier about Ms. Perry not 11 mesh she was. 12 12 Q. How often did she smoke cigarettes? being -- smoking a pack of cigarettes a day. 13 13 A. I don't recall. It varied depending on the A. Correct. Q. And there's reference in the medical records that 14 medical record. It didn't sound like it was a pack a day. 14 Q. She's a very light smoker, right? she may have smoked less than a pack a day, correct? 15 15 16 16 MR. WES: Object to form. A. Correct. 17 Q. And when I asked you whether the amount of 17 THE WITNESS: I think -- as a physician I don't 18 18 know that I'm going to answer that to a yes. I'm sorry. cigarettes she smoked would have an impact on the wound 19 19 MR. JONES: Q. That's fine. healing, meaning the more cigarettes you smoke, it would 20 A. Any smoking is bad. So yes, she was not a pack a 20 have a greater impact on the wound healing versus the less 21 cigarettes you smoke having a smaller impact on the wound 21 day. 22 Q. Okay. And that was a relative term that I used. 22 healing, and your answer was, well, it's -- there's 23 23 A. Correct. patient-dependent factors involved, too, correct? 24 24 Q. It probably wasn't the best way to ask the A. Correct. 25 25 question, but you understand what I'm getting at, is that Q. So without knowing -- I guess what I'm getting at Page 19 Page 21 1 the amount that you smoke has an impact on what we're 1 what are those patient-dependent factors that you 2 2 talking about here, wound healing, correct? discussed? 3 MR. WES: Object to form. 3 MR. WES: Object to form. THE WITNESS: Yeah. So I guess I'm still not --4 THE WITNESS: It may or may not. Again, it's 4 5 individual. Individual response. So what may impact one 5 I don't know that we're communicating very well right now. 6 6 MR. JONES: Q. Okay. patient may not -- you know, may not impact another 7 7 patient at all. So a pack a day may be a huge impact on A. I was -- one individual that has vascular 8 8 one patient whereas another patient two or three insufficiency for whatever reason and smokes could have --9 cigarettes. 9 even if it's a couple of cigarettes, it may have a much 10 She has some history of asthma and some history 10 larger impact than someone who does not have an underlying 11 of allergies, so she may actually be more impacted by her 11 vascular insufficiency. That's all -- that's the only cigarette smoking than someone who doesn't have allergies 12 12 point I was trying to make. Nothing more than that. 13 or a history of episodic asthma. 13 Q. Okay. Are you going to be giving an opinion in 14 14 So again, it's all genetic, so I can't really this case that Ms. Perry's smoking behavior impacted her 15 fairly give an answer to that. 15 wound healing? 16 MR. JONES: Q. Okay. You said asthma and 16 A. It may have. 17 allergies may impact. Is that going to be an opinion 17 Q. It may have? 18 18 you're going to be offering in this case? A. Sure. Yeah. 19 A. To the extent that I just did, yes. 19 Q. Are you reasonably certain that her smoking 20 20 Q. It doesn't make a difference if a person smokes impacted her wound healing? 21 two cigarettes a day versus a pack a day for wound 21 MR. WES: Object to form. 22 22 THE WITNESS: I'm reasonably certain that it may healing? 23 MR. WES: Object to form. 23 well have. 24 THE WITNESS: I suspect -- yes. Yes. We're not MR. JONES: Q. It may well have. 2.4 25 comparing one person to another, but in an individual 25 A. Yes.

Page 24 Page 22 Q. Will you be giving an opinion that Ms. Perry's 1 you can see, quote, chronic inflammation, closed quote, in 2 diet affected her wound healing? 2 normal tissue, and it doesn't necessarily imply anything 3 A. It may well have, yes. 3 pathologic at all. And this is particularly true in areas 4 Q. It may have. 4 of mucosa. 5 Well, let's move on to C. "Inflammation occurs 5 So in this particular example, vaginal mucosae, 6 6 with any surgery - even absent mesh." That's pretty you would expect to see in normal vaginal mucosa a small 7 7 straightforward. complement of what we refer to as chronic inflammatory 8 A. Yes, I think so. 8 9 Q. Okay. And your point there is that there's an 9 Q. Fair to say chronic inflammation isn't 10 10 inflammatory reaction to the mesh that's used with a TVT necessarily indicative of any unintended consequences of 11 Abbrevo device, correct? 11 the TVT Abbrevo implant? 12 12 A. Correct. MR. WES: Object to form. 13 13 Q. But that doesn't distinguish it from other THE WITNESS: I think that's what I'm trying to 14 surgeries that may treat stress urinary incontinence? 14 say. I think that summarizes it, yes. 15 15 MR. WES: Object to form. MR. JONES: Q. Okay. Would it be incorrect to 16 MR. JONES: Q. Flush that out -- flush that out 16 say the inflammatory reaction to the mesh and the TVT 17 for me. 17 Abbrevo device is minimal? 18 A. So that's actually not the point. 18 A. In this case, yes. 19 19 Q. Yeah. Q. Would it be incorrect to say the inflammatory 2.0 A. So the point is just because you have 20 response to the mesh used in the TVT Abbrevo device is 21 inflammation doesn't necessarily mean it's associated with 21 transitory? 22 the mesh. There is -- in fact, there is some inflammation 22 MR. WES: Object to form. 23 THE WITNESS: It's partially correct and 23 associated with the mesh in the slides that -- of the mesh 24 that was removed from Mrs. Perry, but you can have other 24 partially incorrect. So when you put the device in --25 25 kinds of inflammation that aren't related to the mesh, and these implants, any foreign material in, there is an Page 23 Page 25 1 that was the point. 1 initial, quote, transitory, closed quote, inflammatory 2 2 Q. Okay. There's inflammation in the medical response that often includes mast cells and probably some 3 records, but it doesn't necessarily mean it's from the 3 neutrophils as well as the lymphocytes and the 4 mesh? 4 macrophages. 5 A. Correct. 5 Over time that acute process dissipates and what 6 6 Q. Okay. remains is a layer, if you will, a thin layer of chronic 7 7 A. Yes. inflammatory cells, typically lymphocytes and macrophages 8 Q. We'll skip D and move on to E, "Chronic 8 that sort of make a nice little layer around the foreign 9 Inflammation." Can you flush that out for us? 9 material, walling it off from the normal tissue. 10 A. Definitely. So the first point is, is that if it 10 So that does persist, but that acute sort of 11 is, in fact, part of the normal healing response, you 11 initial response to the body, that is transitory. 12 would expect it to occur. It would be abnormal if there 12 MR. JONES: Q. You mentioned walling it off. Is 13 wasn't some chronic inflammation in a healing wound. 13 that, I guess, a plate, a scar plate, or is this 14 In fact -- well, that's all -- immunosuppressed 14 different? Are we talking about two different things? 15 individuals, part of the problem with their wound healing 15 A. We're talking about two different things. It's 16 is they don't have the inflammatory cells to mount that 16 not a scar plate. It's a layer of cells that's -- and 17 17 there is often a very thin -- well, I won't say often. In 18 And you can see chronic inflammation after 18 this case because -- you know, there may be instances 19 surgery, but you obviously can see it without surgery for 19 where you don't see what I'm describing, but in this a variety of other causes. I just wanted to be sure that 20 20 particular case and what you'd like to see is a very thin 21 that was clear. 21 layer -- a very thin layer of fibrosis -- fibrous tissue 22 Q. Okay. 22 associated with that chronic inflammation, and that's it. 23 A. It is considered a normal and expected reaction 23 Not a thick layer. 24 to any implanted foreign material anywhere on the body. 24 Q. Is there always a chronic inflammatory reaction 25 And the other point I really wanted to emphasize, 25 when the TVT Abbrevo mesh is implanted inside the body?

#### Page 28 Page 26 1 A. There should -- I would -- I expect as a 1 absorbable mesh just as there would be to a permanent 2 pathologist anytime I see foreign material removed from 2 polypropylene mesh? 3 the body that has been there for more than a few hours to 3 MR. WES: Object to form. 4 4 THE WITNESS: Well, there is a -- so there is a have an inflammatory response. Absolutely. Every single 5 5 time. foreign body reaction to absorbable material as well as 6 6 Q. Same for chronic foreign body response? nonabsorbable material. Whether that response lasts 7 7 A. That's exactly what I'm talking about, yes. decades after that suture's been completely absorbed, I 8 8 Q. Same thing -can't -- I really don't know that. 9 A. I would expect to see some kind of chronic 9 But in my practice I have seen where, you know, 10 10 response. It would be -- in fact, if I don't see it, it there's -- there's a persistence of that foreign body 11 tells me that that foreign material has been very, very 11 reaction. I don't see any suture anymore. Now, maybe if 12 12 recently placed. you do sophisticated studies, you could find little 13 13 Q. Did you happen to review any of the advertising particles, I don't know, but you can see the residual sort 14 Ethicon uses for the TVT devices in this case? 14 of response even though the suture's gone. MR. WES: Object to form, outside the scope. 15 15 Q. Will you be offering an opinion in this case that 16 16 THE WITNESS: I -- I don't specifically recall there is a difference in the foreign body response between 17 17 reviewing advertising, but I may have read some inserts. an absorbable mesh and a nonabsorbable mesh? 18 MR. JONES: Q. So you don't have any recall of 18 A. No, I will not. 19 19 Ethicon in their marketing materials for the TVT devices Q. Okay. 20 stating there would be no chronic foreign body response to 20 A. The only point is that anytime any foreign 21 the mesh? 21 material gets introduced in the body, there will be a 22 MR. WES: Object to form, outside the scope. 22 response. THE WITNESS: I don't --23 23 Q. Okay. 24 MR. WES: Misstates --24 A. And it may even last after the material's been 25 THE WITNESS: Yeah, I don't recall reading that 25 Page 29 Page 27 there would not be one, no. 1 O. Topic G. Have we covered that topic in some of 1 2 MR. JONES: Q. Let's move on to F, "Foreign body 2 our discussions already, or is there anything additional 3 reaction expected with the implant." 3 that you'd like to share about topic G? 4 Can you flush that one out? 4 A. The only other point, again, is about 5 5 A. That's just, again, emphasizing basically what we terminology. 6 6 just discussed, that I would expect to see some sort of Q. Okay. 7 7 reaction always to any foreign material. And in fact, A. Pathologists try to be very specific in the terms 8 8 that they use, and I just wanted to emphasize that sometimes normal tissue gets in the wrong spot in the 9 body, and you would expect to see a foreign body reaction 9 fibrosis is different from dense scarring, and that's 10 to that as well. An ingrown hair follicle, you know, if 10 different from fibroconnective tissue. They really mean 11 the hair shaft or keratin gets embedded in the connective 11 somewhat different things. 12 Q. Scarring, scarification, scar plate is different 12 tissue of the dermis will incite a foreign body reaction. 13 13 And that's all self tissue, but it's in the wrong spot. than fibrosis? 14 14 MR. WES: Object to form. So anything that's occurring in the wrong spot 15 should elicit some reaction. 15 THE WITNESS: Generally, yes. It really -- I 16 Q. You talk about foreign body reaction remaining 16 mean, obviously part of that dense -- fibrosis is part of 17 that dense scarring, but there are degrees of fibrosis 17 after an absorbable suture has been absorbed. 18 quite honestly. 18 A. Yes. I've even seen that, yes. 19 MR. JONES: Q. Okay. 19 Q. Okay. So if someone were to make the argument 20 20 A. And fibroconnective tissue is normal tissue. that using a partially absorbable implant in a TVT Abbrevo 21 21 device would not cause a chronic foreign body response --Q. Okay. There's nothing abnormal about fibrosis 22 22 occurring after a transvaginal mesh surgery? A. No. 23 A. There is nothing -- you would expect fibrosis 23 Q. -- that would be incorrect? 24 after a wound. So if there's been surgery, yes. That's 2.4 A. That would be incorrect, yeah. 25 not abnormal. That's part of the healing process, 25 Q. There's a chronic foreign body response to an

#### Page 30 Page 32 1 A. So if you see adipose tissue in the hernia repair 2 2 Q. Topic H, "Risk of infection following surgery is and you don't see it in the vaginal mesh, that doesn't 3 well known." 3 mean there's anything wrong. It means there's no adipose 4 tissue there to begin with. Just to make that clear. 4 A. Correct. 5 5 Q. That is what it is? That's all I meant. 6 6 Q. Sure. I appreciate that. We'll move on to topic A. Yes. 7 7 O. We don't need to flush it out? III. "No gross findings because nothing but slides to 8 8 A. Yeah, nothing else. review." 9 Q. Okay. Moving to heading Roman Numeral II, 9 What do you mean by that? 10 10 "Tissue of the Vaginal Wall." You talk about the four A. Well, when we talk about gross findings in 11 11 layers of tissue in the vaginal wall, correct? pathology, we're talking about the tissue that comes in 12 12 through the OR. So in this case it would have been that A. Correct. 13 13 Q. Can you explain those terms and why it's mesh material that was removed during the mesh removal or 14 important that you have included the four layers of the 14 the mucosal tissue that was removed at the tying of the 15 15 tissue of vaginal wall in your summary of opinions? mesh placement, and that I don't -- that was already done 16 16 A. Well, I think it's important to realize that as by a different pathologist. So my gross finding is really 17 just the slides. That's all that means. 17 we -- as you suggested earlier in one of your earlier 18 questions that perhaps vaginal tissue is different from Q. You talk about the slides you reviewed. 18 19 19 stomach tissue. This was just to emphasize that vaginal A. Yes. 2.0 tissue is a mucosal tissue, so there's a mucosal layer 20 Q. What slides did you review? 21 A. They were recut slides from blocks that were made 21 that's different from skin. It's certainly different from 22 22 from the initial procedure when the mesh was placed and stomach, different from hernia repairs, that kind of 23 23 when the tissue -- the mesh was removed. So two different thing. 24 24 And then just to emphasize that there's the surgical procedures. 25 25 mucosal layer, and then beneath that what's referred to as Q. Were there any conclusions or findings noted on Page 31 Page 33 1 submucosa, and there's a muscle layer and then the outer 1 those pathology records? 2 2 adventitia. There's really no adipose tissue present in A. Do you mean the pathology reports? 3 the vaginal tissues. 3 Q. (Nods head.) 4 Q. Why is that important to note? 4 A. Yes. There were pathology diagnoses on both of 5 A. Well, I think sometimes people extrapolate 5 them, yes. Q. Do you recall what those diagnoses were? 6 6 findings from mesh in one organ site to another organ 7 7 site. Again, that was one of the questions you asked. A. Yes, I have them in front of me. MR. JONES: Okay. Why don't we go ahead and mark 8 And although in many respects, I think that it's a similar 8 9 response. You would not expect it to be completely 9 those very quickly. We'll mark as exhibit L-2 Bakersfield 10 identical if you're putting it in a different kind of 10 Pathology Medical Group Pathology Report dated 3-25-2011. 11 tissue. 11 (Whereupon, Exhibit L-2 was marked for 12 So if you see adipose tissue associated with mesh 12 identification.) 13 material in a ventral hernia, that would be expected, but 13 MR. JONES: We'll mark as Exhibit L-3 Bakersfield 14 you would not expect to see adipose tissue in a vaginal 14 Memorial Hospital Pathology Report with the date of 15 tissue that contained a mesh material. 15 January 18th, 2012. (Whereupon, Exhibit L-3 was marked for 16 Does that make sense? 16 17 17 identification.) A. And that would not be -- I mean, it would be 18 18 MR. JONES: Q. What was the diagnosis in Exhibit 19 abnormal to suddenly start seeing adipose tissue. 19 20 Q. It sounds like you're saying there's a 20 A. The pathology report diagnosis reads: 21 distinction between hernia repair, mesh and transvaginal 21 "Vaginal wall, comma, posterior, comma, excision. 22 22 "Hyperplastic squamous mucosa with patchy 23 A. No. I don't know necessarily about the mesh, but 23 submucosal mild chronic inflammation and prominent 24 the surrounding tissue. 24 vascular congestion. 25 Q. Okay. 25 "There is no evidence of viral cellular changes,

#### Page 34 Page 36 1 MR. WES: Object to form. comma, dysplasia or malignancy, period. 2 "All margins of excision are free of lesions and 2 THE WITNESS: Yes, I can try to do that. So 3 3 looking at the slides, there were -- first of all, all the Q. Do you have an opinion as to that diagnosis? 4 4 tissue that was submitted to the pathologist was actually 5 5 A. Yes, I do. submitted for a histological examination. Sometimes we 6 6 just do representative submission, but all of it -- all Q. What is that opinion? 7 7 A. Well, I agree that there is, in fact, squamous was submitted. I just wanted to be sure that I was 8 8 mucosa present and that it does, in fact, show patchy correct. 9 submucosal chronic inflammation. There's also some 9 Of that tissue -- of those tissue fragments, I 10 10 vascular congestion, which I interpret as likely actually have the numbers here now I noticed. Eight were 11 11 procedural during the -- i.e., it was introduced during from the vagina, and those vaginal fragments show changes 12 12 that are consistent with prolapse, which is bulging of the the surgical procedure. 13 13 There is some edema, and there was also some vagina usually distally, which is part of the reason 14 focal parakeratosis, which you often see in prolapsed 14 why -- indirectly part of the reason she was having 15 squamous tissue. 15 urinary incontinence. 16 16 Q. Okay. In addition, there were multiple fragments of 17 skin that was removed along the region of the opening of 17 A. There were also fragments of hair bearing skin 18 the vagina. And in fact, there were more fragments of 18 from the perineum in addition to the fragments of vaginal 19 19 mucosa. And, in fact, I think the predominant tissue was that than the vaginal tissue. There were 13 fragments of 20 20 actually perineal tissue, it wasn't vaginal tissue. 21 MR. JONES: Q. And other than your comment about 21 I think we counted, I don't know, 18 or 19 22 22 it being incomplete, you don't have any substantive fragments of tissue total, and I believe 13 of them were 23 disagreements? 23 the perineum, and it was -- the minor component was 24 24 A. That's correct. actually squamous mucosal tissue. 25 25 Q. What does that indicate to you as a pathologist? Q. Okay. Let's move on to Exhibit L-3, which is the Page 35 Page 37 1 A. It indicates there was a significant amount of 1 path report related to the explant surgery, right? 2 2 that perineal tissue that was removed during that A. Correct. 3 3 Q. What were the find -- final diagnosis in this 4 Q. Do you disagree with the diagnosis in this 4 pathology report related to the explant surgery? 5 5 pathology report? A. "One irregularly shaped portion of mesh-like 6 6 A. I agree with the diagnosis. I just think it's material with surrounding portions of fibroconnective and 7 7 incomplete because they didn't note that there was a fair focally non-keratinized squamous epithelial, back slash, 8 amount of skin there as well, but other than that, there's 8 mucosal tissue with mild chronic inflammation, back slash, 9 no substantive disagreement at all. 9 fibrosis with no dysplasia or malignancy identified." 10 Q. Okay. And if someone sitting on the jury asks 10 Q. Do you have any substantive disagreement with 11 for the most plain English way to communicate the findings 11 that diagnosis? 12 12 of this pathology report, what would your testimony be? A. No, I don't. I would add, if that's all right, 13 A. That there was -- let's stop. Ask the question 13 that the specimen -- the tissue's really fragmented and 14 14 again. the mesh material is really fragmented from the 15 Q. Here's what I'm getting at. These are some 15 processing. And so it's -- this particular pathologist 16 complicated concepts, terms that people aren't commonly 16 didn't make a lot of comments about the mesh, and that's 17 familiar with, right? 17 largely because it's -- it's a distorted specimen from 18 18 A. Correct. processing. 19 Q. Very specific to the pathology field? 19 Q. What processing are you speaking about? 20 20 A. Correct. A. The -- I think the removal and then the 21 Q. So if someone's sitting in the juror box and a 21 sectioning, the tissue sectioning. I think the way it was 22 22 juror says, "I don't understand anything that you just embedded and then the knife cut. It likely -- a 23 said," could you break it down in language that someone 23 combination of those factors. There is -- in addition, 24 24 who is not a pathologist could understand? That's what there was an area of mucosal disruption if -- I think 25 I'm getting at. 25 that's the best term to use.

### Page 38

And in association with that area of mucosal disruption, there was more inflammation than was evidenced around that actual mesh material. And there was some organizing fibrosis, which I interpret as a non-healing wound. And this was associated, of course, with the mucosal aspect, not the underlying mesh material, which was in the submucosal tissue.

Q. Okay. So there's some healing issues involved

- Q. Okay. So there's some healing issues involved here?
  - A. Yes. In this mucosal wound, yes.
- Q. Okay. And you talked earlier about smoking and diet and diabetes being related to healing, correct?
  - A. Correct.

2.0

2.2

2.4

Q. Will you be offering an opinion in this case that there was impaired wound healing from Ms. Perry and the cause of that impaired wound healing was her diet and her smoking behavior?

MR. WES: Object to form.

THE WITNESS: My opinion is that there is a non-healing wound, and it appears chronic. And there are a variety of factors that may contribute to non-healing wounds, and some of these factors are smoking, you know, diabetes. I mean, alcohol intake, I don't know that she's a big drinker, but I mean there's a whole lot of factors that could play into non healing, impaired vascular

Page 40

There was no evidence of a traumatic neuroma.

There was certainly no large nerve fiber.

- Q. What does that mean?
- A. So part of the reason she was having the mesh removal is pain. Certainly part of it was the husband, but she also had some pain. And although we often don't see an obvious cause of pain when we examine histologic tissue removed from patients with pain, sometimes we do see the cause of it, and one of them would be a large nerve sitting right next to a foreign body. You would assume -- or you would presume that that was probably impinging on that nerve.
  - Q. Okay. Impinging or entrapped or --
- A. Or just anything. Just pushing on it will cause pain, but there were no large nerves there.
  - Q. Okay.
- A. And then the only other thing is there was no real necrosis. Again, necrotic tissue will not heal, but I didn't see any necrosis.
- Q. Okay. You said that one of the reasons why Ms. Perry had the mesh removed was because of pain, correct?
  - A. Correct.
- Q. And you said often you won't see factors that would indicate pain in the histology, correct?

Page 39

1 supply, et cetera.

MR. JONES: Q. Okay. Have we covered all of the aspects of both pathology reports related to the opinions that you intend to offer in this case?

A. Well, there's a -- essentially we have, yes. Other than this non-healing wound and the thin layer of lymphocytes and macrophages around the mesh material, which you would expect to see, there really were very few giant cells.

There really wasn't a significant multinucleated sort of -- multinucleated giant cell reaction, foreign body giant cell reaction. There's nothing concerning about the response of the tissue to the mesh material.

Q. Okay.

A. There is normal vascularization of the tissue. There's no significant acute inflammation, and by that I imply there's no evidence of infection because infection would be one reason to have a non-healing wound, of course

There were also no large nerve fibers. I received several unstained slides. And I did an S-100 stain on one of the unstained slides, and there were small little nerve twigs, none of which were abnormal in configuration. They were in the appropriate distribution of the submucosal tissue.

Page 41

MR. WES: Object to form.

THE WITNESS: I think what I was trying to convey is that -- let's see. Clinical and histologic correlation or clinical pathologic correlation is not always perfect in cases of pain, first of all. We may not see any good cause of pain, and the patient has pain.

We may also see what we interpret as a cause of pain, i.e., a large nerve, and maybe the patient never had pain. You call up and you say, well, oh, that's interesting, the patient never complained about it.

So that correlation is not perfect. That doesn't mean we still don't try. That's the only point I was making

MR. JONES: Q. Sure. What does cause pain? MR. WES: Object to form.

THE WITNESS: That's a very complicated question.

MR. JONES: Q. Do we know what causes pain?

MR. WES: Object to form

MR. WES: Object to form.

THE WITNESS: Well, at so

THE WITNESS: Well, at some level we know that there are sensory nerves that if they are injured or sense obnoxious stimuli, we perceive pain. That's a simple way of talking about it, and I don't know that we want to go in much more depth.

24 MR. JONES: Q. No.

A. And that's really not in my area of what I want

11 (Pages 38 to 41)

	Page 42		Page 44
1	to be doing with my opinion.	1	foreign material that has not been associated with pain at
2	Q. Okay.	2	all.
3	A. If that's okay with you.	3	So I would not expect that to be associated with
4	Q. It is okay. Here Ms. Perry is complaining of	4	pain, either. Not only do I not see anything, I would not
5	pain, correct?	5	expect pain to be associated with this mesh
6	A. Correct.	6	Q. Okay.
7	Q. And is there anything in the pathology records	7	A based on all my experience and in this
8	that would indicate what the cause of her pain is?	8	particular case as well.
9	A. Okay. So I'm not so certain about the actual	9	Q. What experience are you referencing?
10	pathology reports, but I do think the abundant material of	10	A. Looking at all kinds of foreign materials that
11	that perineal, the skin around the vaginal introitus,	11	have been removed from all different organs.
12	suggests that perhaps the result resulted in too much	12	Q. What foreign materials?
13	narrowing of that opening, vaginal opening, and that will	13	A. Mesh as well as all kinds of medical devices.
14	certainly cause pain.	14	Q. What type of mesh?
15	Q. Will you be giving an opinion in this case that	15	A. Some of them would be propylene. I don't know
16	Ms. Perry's pain is caused by vaginal narrowing?	16	all the meshes.
17	A. I think to a certain extent it is, yes.	17	Q. So you've
18	Q. Is the mesh causing Ms. Perry any pain?	18	A. Any foreign material basically.
19	A. I see no histologic evidence for that, no.	19	Q. So you've examined explanted polypropylene mesh
20	Q. It doesn't mean that the mesh isn't causing her	20	from the vagina before?
21	pain, it just means you don't see anything in the	21	A. Yes.
22	histology that would	22	Q. And you've seen what have you seen when you've
23	MR. WES: Object to form.	23	examined explanted transvaginal mesh?
24	MR. JONES: Q be indicative of mesh causing	24	A. Often findings very similar to this. In some
25	the pain?	25	cases I've seen more inflammation. A couple of cases have
	Page 43		
	rage 13		Page 45
1	A. I think that's I think it's okay to say that,	1	Page 45 been removed for actually acute infection, and so you see
1 2		1 2	
	A. I think that's I think it's okay to say that,		been removed for actually acute infection, and so you see
2	A. I think that's I think it's okay to say that, yes.	2	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.
2	A. I think that's I think it's okay to say that, yes. Q. Okay.	2	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted
2 3 4	<ul> <li>A. I think that's I think it's okay to say that,</li> <li>yes.</li> <li>Q. Okay.</li> <li>A. There's nothing on the basis of what I see that I</li> </ul>	2 3 4	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?
2 3 4 5	<ul> <li>A. I think that's I think it's okay to say that, yes.</li> <li>Q. Okay.</li> <li>A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to</li> </ul>	2 3 4 5	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly
2 3 4 5 6	<ul> <li>A. I think that's I think it's okay to say that, yes.</li> <li>Q. Okay.</li> <li>A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.</li> </ul>	2 3 4 5 6	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and
2 3 4 5 6 7	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect	2 3 4 5 6	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do
2 3 4 5 6 7 8	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological	2 3 4 5 6 7 8	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.
2 3 4 5 6 7 8 9	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?	2 3 4 5 6 7 8	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've
2 3 4 5 6 7 8 9	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.	2 3 4 5 6 7 8 9	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur?
2 3 4 5 6 7 8 9 10	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.  THE WITNESS: I think that's correct, yes.	2 3 4 5 6 7 8 9 10	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur? What time frame?
2 3 4 5 6 7 8 9 10 11	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.  THE WITNESS: I think that's correct, yes.  MR. JONES: Q. Sometimes you look at the	2 3 4 5 6 7 8 9 10 11	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur? What time frame?  A. Oh, in the last as far as I can remember, I
2 3 4 5 6 7 8 9 10 11 12 13	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.  THE WITNESS: I think that's correct, yes.  MR. JONES: Q. Sometimes you look at the pathology and there's something there and you say, yep,	2 3 4 5 6 7 8 9 10 11 12 13	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur? What time frame?  A. Oh, in the last as far as I can remember, I don't really know.
2 3 4 5 6 7 8 9 10 11 12 13 14	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.  THE WITNESS: I think that's correct, yes.  MR. JONES: Q. Sometimes you look at the pathology and there's something there and you say, yep, this is causing the pain, correct?	2 3 4 5 6 7 8 9 10 11 12 13 14	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur? What time frame?  A. Oh, in the last as far as I can remember, I don't really know.  Q. Last 20 years?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.  THE WITNESS: I think that's correct, yes.  MR. JONES: Q. Sometimes you look at the pathology and there's something there and you say, yep, this is causing the pain, correct?  A. Oh, I see what you're asking. Yeah, on occasion	2 3 4 5 6 7 8 9 10 11 12 13 14	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur? What time frame?  A. Oh, in the last as far as I can remember, I don't really know.  Q. Last 20 years?  A. I've been practicing well, maybe not 20. Last
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.  THE WITNESS: I think that's correct, yes.  MR. JONES: Q. Sometimes you look at the pathology and there's something there and you say, yep, this is causing the pain, correct?  A. Oh, I see what you're asking. Yeah, on occasion we do. I guess the point I was trying to make about the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur? What time frame?  A. Oh, in the last as far as I can remember, I don't really know.  Q. Last 20 years?  A. I've been practicing well, maybe not 20. Last ten.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.  THE WITNESS: I think that's correct, yes.  MR. JONES: Q. Sometimes you look at the pathology and there's something there and you say, yep, this is causing the pain, correct?  A. Oh, I see what you're asking. Yeah, on occasion we do. I guess the point I was trying to make about the mesh not there's no evidence for the mesh being the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur? What time frame?  A. Oh, in the last as far as I can remember, I don't really know.  Q. Last 20 years?  A. I've been practicing well, maybe not 20. Last ten.  Q. Okay.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.  THE WITNESS: I think that's correct, yes.  MR. JONES: Q. Sometimes you look at the pathology and there's something there and you say, yep, this is causing the pain, correct?  A. Oh, I see what you're asking. Yeah, on occasion we do. I guess the point I was trying to make about the mesh not there's no evidence for the mesh being the etiologic the cause, if you will, of her pain is that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur? What time frame?  A. Oh, in the last as far as I can remember, I don't really know.  Q. Last 20 years?  A. I've been practicing well, maybe not 20. Last ten.  Q. Okay.  A. I mean, I don't remember that far. But it's just
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.  THE WITNESS: I think that's correct, yes.  MR. JONES: Q. Sometimes you look at the pathology and there's something there and you say, yep, this is causing the pain, correct?  A. Oh, I see what you're asking. Yeah, on occasion we do. I guess the point I was trying to make about the mesh not there's no evidence for the mesh being the etiologic the cause, if you will, of her pain is that number one, I don't see anything in the slides. That's	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur? What time frame?  A. Oh, in the last as far as I can remember, I don't really know.  Q. Last 20 years?  A. I've been practicing well, maybe not 20. Last ten.  Q. Okay.  A. I mean, I don't remember that far. But it's just in my regular practice, not any kind of not in the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.  THE WITNESS: I think that's correct, yes.  MR. JONES: Q. Sometimes you look at the pathology and there's something there and you say, yep, this is causing the pain, correct?  A. Oh, I see what you're asking. Yeah, on occasion we do. I guess the point I was trying to make about the mesh not there's no evidence for the mesh being the etiologic the cause, if you will, of her pain is that number one, I don't see anything in the slides. That's the first observation.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur? What time frame?  A. Oh, in the last as far as I can remember, I don't really know.  Q. Last 20 years?  A. I've been practicing well, maybe not 20. Last ten.  Q. Okay.  A. I mean, I don't remember that far. But it's just in my regular practice, not any kind of not in the context of a legal case by any
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.  THE WITNESS: I think that's correct, yes.  MR. JONES: Q. Sometimes you look at the pathology and there's something there and you say, yep, this is causing the pain, correct?  A. Oh, I see what you're asking. Yeah, on occasion we do. I guess the point I was trying to make about the mesh not there's no evidence for the mesh being the etiologic the cause, if you will, of her pain is that number one, I don't see anything in the slides. That's the first observation.  And the second observation is that based on all	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur? What time frame?  A. Oh, in the last as far as I can remember, I don't really know.  Q. Last 20 years?  A. I've been practicing well, maybe not 20. Last ten.  Q. Okay.  A. I mean, I don't remember that far. But it's just in my regular practice, not any kind of not in the context of a legal case by any  Q. That was going to be my next question. So in the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.  THE WITNESS: I think that's correct, yes.  MR. JONES: Q. Sometimes you look at the pathology and there's something there and you say, yep, this is causing the pain, correct?  A. Oh, I see what you're asking. Yeah, on occasion we do. I guess the point I was trying to make about the mesh not there's no evidence for the mesh being the etiologic the cause, if you will, of her pain is that number one, I don't see anything in the slides. That's the first observation.  And the second observation is that based on all my experience looking at lots and lots of foreign	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur? What time frame?  A. Oh, in the last as far as I can remember, I don't really know.  Q. Last 20 years?  A. I've been practicing well, maybe not 20. Last ten.  Q. Okay.  A. I mean, I don't remember that far. But it's just in my regular practice, not any kind of not in the context of a legal case by any  Q. That was going to be my next question. So in the course of your normal pathology practice, you've examined
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I think that's I think it's okay to say that, yes.  Q. Okay.  A. There's nothing on the basis of what I see that I would expect that that or attribute any of that pain to the mesh.  Q. And as we discussed before, there's not a perfect correlation there between what you see in the histological records and how it relates to pain?  MR. WES: Object to form.  THE WITNESS: I think that's correct, yes.  MR. JONES: Q. Sometimes you look at the pathology and there's something there and you say, yep, this is causing the pain, correct?  A. Oh, I see what you're asking. Yeah, on occasion we do. I guess the point I was trying to make about the mesh not there's no evidence for the mesh being the etiologic the cause, if you will, of her pain is that number one, I don't see anything in the slides. That's the first observation.  And the second observation is that based on all my experience looking at lots and lots of foreign material, this looks the response, the normal tissue	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	been removed for actually acute infection, and so you see it more in the way of acute inflammatory cells.  Q. How many times have you examined explanted transvaginal mesh?  A. I would I'm estimating. I would say grossly it would minimal would be probably a couple dozen and then microscopically half a dozen. We don't do microscopic examinations on all explanted mesh material.  Q. When did these 24 times, roughly, that you've examined explanted transvaginal mesh, when did that occur? What time frame?  A. Oh, in the last as far as I can remember, I don't really know.  Q. Last 20 years?  A. I've been practicing well, maybe not 20. Last ten.  Q. Okay.  A. I mean, I don't remember that far. But it's just in my regular practice, not any kind of not in the context of a legal case by any  Q. That was going to be my next question. So in the course of your normal pathology practice, you've examined roughly two dozen explanted transvaginal mesh?

	Page 46		Page 48
1	A. Yes.	1	That I can say, yes.
2	Q. But	2	Q. Let me ask a better question. When Ethicon sells
3	A. Likely more.	3	the TVT Abbrevo mesh, it's intended to be a permanent
4	Q. Likely more?	4	implant?
5	A. But minimum, yes.	5	A. I believe so, yes.
6	Q. Can you give a range?	6	MR. WES: Same objection.
7	A. Oh, no.	7	MR. JONES: Q. Let's get back to your opinion
8	Q. Ceiling floor?	8	summary. And we already talked about your overall
9	A. Oh, I don't think more than I would say	9	conclusions related to the pathology reports, correct?
10	probably not more than three dozen.	10	A. Yes, I think so.
11	Q. Okay.	11	Q. We've covered that. Are there any additional
12	A. But I mean, I could be wrong.	12	opinions related to the pathology slides that you reviewed
13	Q. When you've examined these explanted transvaginal	13	beyond the pathology report?
14	mesh implants, why were you doing that?	14	A. I don't think so. I'm not sure I'm understanding
15	A. Because they were submitted to pathology.	15	your question.
16	Q. Okay. Do you know why the mesh was removed?	16	Q. Yeah, let me ask a better question. What
17	A. Sometimes we do, and sometimes we don't.	17	opinions will you be giving related to the pathology
18	Q. Okay. It's fair to say women don't have mesh	18	slides in this case?
19	removed unless there's some sort of complication that	19	A. My opinion is that there is mesh material
20	presents itself that makes it appropriate to remove that	20	present, that it is lined by a very thin layer of
21	mesh, correct?	21	lymphocytes and macrophages with associated fibrous
22	MR. WES: Object to form, assumes facts not in	22	tissue, which is normal and expected.
23	evidence.	23	There is no other abnormality or concerning
24	THE WITNESS: It typically you would expect	24	finding associated with the mesh itself. However, there
25	that, but I don't know that that was always the case in	25	is a mucosal non-healing wound that is not attributed to
	and, out I don't mon and and was a ways are case in		is a macosal non neutring would that is not attributed to
	Page 47		Page 49
1	Page 47 some of the cases that I reviewed.	1	Page 49 the device itself but I think is likely a complication
1 2		1 2	
	some of the cases that I reviewed.		the device itself but I think is likely a complication
2	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have	2	the device itself but I think is likely a complication from the surgery on the prior incision.
2	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?	2	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall,
2 3 4	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.	2 3 4	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more
2 3 4 5	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel	2 3 4 5	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"
2 3 4 5 6	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there	2 3 4 5 6	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?
2 3 4 5 6 7	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no	2 3 4 5 6 7	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic
2 3 4 5 6 7 8	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical	2 3 4 5 6 7 8	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable
2 3 4 5 6 7 8	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why	2 3 4 5 6 7 8	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that
2 3 4 5 6 7 8 9	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.	2 3 4 5 6 7 8 9	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh
2 3 4 5 6 7 8 9 10	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.  MR. JONES: Q. Okay.	2 3 4 5 6 7 8 9 10	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh insertion.
2 3 4 5 6 7 8 9 10 11	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.  MR. JONES: Q. Okay.  A. Otherwise, I don't necessarily know why.	2 3 4 5 6 7 8 9 10 11	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh insertion.  However, at that area of the mucosal disruption,
2 3 4 5 6 7 8 9 10 11 12	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.  MR. JONES: Q. Okay.  A. Otherwise, I don't necessarily know why.  Q. When Ethicon sells the TVT Abbrevo mesh, it	2 3 4 5 6 7 8 9 10 11 12	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh insertion.  However, at that area of the mucosal disruption, there's more significant, more moderate it's a more
2 3 4 5 6 7 8 9 10 11 12 13 14	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.  MR. JONES: Q. Okay.  A. Otherwise, I don't necessarily know why.  Q. When Ethicon sells the TVT Abbrevo mesh, it doesn't intend for that mesh to be removed, correct?	2 3 4 5 6 7 8 9 10 11 12 13 14	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh insertion.  However, at that area of the mucosal disruption, there's more significant, more moderate it's a more striking and chronic inflammatory process, which is in
2 3 4 5 6 7 8 9 10 11 12 13 14	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.  MR. JONES: Q. Okay.  A. Otherwise, I don't necessarily know why.  Q. When Ethicon sells the TVT Abbrevo mesh, it doesn't intend for that mesh to be removed, correct?  MR. WES: Object to form, outside the scope of	2 3 4 5 6 7 8 9 10 11 12 13 14	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh insertion.  However, at that area of the mucosal disruption, there's more significant, more moderate it's a more striking and chronic inflammatory process, which is in keeping with this chronic non-healing wound.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.  MR. JONES: Q. Okay.  A. Otherwise, I don't necessarily know why.  Q. When Ethicon sells the TVT Abbrevo mesh, it doesn't intend for that mesh to be removed, correct?  MR. WES: Object to form, outside the scope of her opinions.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh insertion.  However, at that area of the mucosal disruption, there's more significant, more moderate it's a more striking and chronic inflammatory process, which is in keeping with this chronic non-healing wound.  Q. Let's move to 14. "No evidence of shrinkage of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.  MR. JONES: Q. Okay.  A. Otherwise, I don't necessarily know why.  Q. When Ethicon sells the TVT Abbrevo mesh, it doesn't intend for that mesh to be removed, correct?  MR. WES: Object to form, outside the scope of her opinions.  THE WITNESS: It really is outside my scope.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh insertion.  However, at that area of the mucosal disruption, there's more significant, more moderate it's a more striking and chronic inflammatory process, which is in keeping with this chronic non-healing wound.  Q. Let's move to 14. "No evidence of shrinkage of the mesh in vivo."
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.  MR. JONES: Q. Okay.  A. Otherwise, I don't necessarily know why.  Q. When Ethicon sells the TVT Abbrevo mesh, it doesn't intend for that mesh to be removed, correct?  MR. WES: Object to form, outside the scope of her opinions.  THE WITNESS: It really is outside my scope.  MR. JONES: Q. You don't know one way or the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh insertion.  However, at that area of the mucosal disruption, there's more significant, more moderate it's a more striking and chronic inflammatory process, which is in keeping with this chronic non-healing wound.  Q. Let's move to 14. "No evidence of shrinkage of the mesh in vivo."  What do you mean by that?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.  MR. JONES: Q. Okay.  A. Otherwise, I don't necessarily know why.  Q. When Ethicon sells the TVT Abbrevo mesh, it doesn't intend for that mesh to be removed, correct?  MR. WES: Object to form, outside the scope of her opinions.  THE WITNESS: It really is outside my scope.  MR. JONES: Q. You don't know one way or the other whether	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh insertion.  However, at that area of the mucosal disruption, there's more significant, more moderate it's a more striking and chronic inflammatory process, which is in keeping with this chronic non-healing wound.  Q. Let's move to 14. "No evidence of shrinkage of the mesh in vivo."  What do you mean by that?  A. I was asked was there evidence of shrinking, and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.  MR. JONES: Q. Okay.  A. Otherwise, I don't necessarily know why.  Q. When Ethicon sells the TVT Abbrevo mesh, it doesn't intend for that mesh to be removed, correct?  MR. WES: Object to form, outside the scope of her opinions.  THE WITNESS: It really is outside my scope.  MR. JONES: Q. You don't know one way or the other whether  A. It's not	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh insertion.  However, at that area of the mucosal disruption, there's more significant, more moderate it's a more striking and chronic inflammatory process, which is in keeping with this chronic non-healing wound.  Q. Let's move to 14. "No evidence of shrinkage of the mesh in vivo."  What do you mean by that?  A. I was asked was there evidence of shrinking, and first of all, I mean, I don't know how you'd know that
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.  MR. JONES: Q. Okay.  A. Otherwise, I don't necessarily know why.  Q. When Ethicon sells the TVT Abbrevo mesh, it doesn't intend for that mesh to be removed, correct?  MR. WES: Object to form, outside the scope of her opinions.  THE WITNESS: It really is outside my scope.  MR. JONES: Q. You don't know one way or the other whether  A. It's not  Q mesh is removed?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh insertion.  However, at that area of the mucosal disruption, there's more significant, more moderate it's a more striking and chronic inflammatory process, which is in keeping with this chronic non-healing wound.  Q. Let's move to 14. "No evidence of shrinkage of the mesh in vivo."  What do you mean by that?  A. I was asked was there evidence of shrinking, and first of all, I mean, I don't know how you'd know that other than obviously a huge retraction, which there's not.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.  MR. JONES: Q. Okay.  A. Otherwise, I don't necessarily know why.  Q. When Ethicon sells the TVT Abbrevo mesh, it doesn't intend for that mesh to be removed, correct?  MR. WES: Object to form, outside the scope of her opinions.  THE WITNESS: It really is outside my scope.  MR. JONES: Q. You don't know one way or the other whether  A. It's not  Q mesh is removed?  A implanted as a temporary. My understanding it	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh insertion.  However, at that area of the mucosal disruption, there's more significant, more moderate it's a more striking and chronic inflammatory process, which is in keeping with this chronic non-healing wound.  Q. Let's move to 14. "No evidence of shrinkage of the mesh in vivo."  What do you mean by that?  A. I was asked was there evidence of shrinking, and first of all, I mean, I don't know how you'd know that other than obviously a huge retraction, which there's not. But there's no dense scarring or fibrosis that would lead
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	some of the cases that I reviewed.  MR. JONES: Q. But it's fair to say women have mesh removed because of complications, right?  MR. WES: Same objection.  THE WITNESS: I I'm not sure I feel comfortable saying yes to that because, as I say, there was a fair number that we get the mesh in, and there's no clinical history. So I don't when I get a clinical history of a complication, yes, absolutely, that's why they're removing it.  MR. JONES: Q. Okay.  A. Otherwise, I don't necessarily know why.  Q. When Ethicon sells the TVT Abbrevo mesh, it doesn't intend for that mesh to be removed, correct?  MR. WES: Object to form, outside the scope of her opinions.  THE WITNESS: It really is outside my scope.  MR. JONES: Q. You don't know one way or the other whether  A. It's not  Q mesh is removed?  A implanted as a temporary. My understanding it is not considered you know, this is you know, like	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	the device itself but I think is likely a complication from the surgery on the prior incision.  Q. In jumping ahead to page 3, number III, "Overall, chronic inflammation is mild with focal area of more moderate inflammation at the site"  What do you mean by that?  A. Again, there's a very minimal chronic inflammation in the submucosal tissue, and it's comparable in amount to the presence of the chronic inflammation that was present in her vaginal tissue at the time of the mesh insertion.  However, at that area of the mucosal disruption, there's more significant, more moderate it's a more striking and chronic inflammatory process, which is in keeping with this chronic non-healing wound.  Q. Let's move to 14. "No evidence of shrinkage of the mesh in vivo."  What do you mean by that?  A. I was asked was there evidence of shrinking, and first of all, I mean, I don't know how you'd know that other than obviously a huge retraction, which there's not. But there's no dense scarring or fibrosis that would lead you to think that it's been compressed.

#### Page 52 Page 50 1 of the tissue that was removed and make a comparison to MR. JONES: Q. Will you be giving an opinion in 1 2 what normal mesh should be measuring, that that's a bit 2 this case that the mesh does not shrink? 3 inaccurate would be the polite way to say that. 3 A. No. MR. WES: Object to form. 4 As soon as you remove anything from the body, it 4 5 5 retracts. Any kind of tissue retracts. And then once MR. JONES: Q. Okay. Your opinion is I've 6 6 looked at the pathology records, I don't see anything it's in formalin, it retracts even more. Formalin 7 7 fixate -- fixation. And measurements in a gross are indicative of mesh shrinkage? 8 rough. They're using quick millimeters. They're not 8 A. Yes. If you mean the slides and the pathology in 9 doing exact measurements. So that's the only point I 9 the pathology reports, absolutely, yes. 10 10 Q. Okay. Have you reviewed any medical literature wanted to make. Surgeons are well aware of that. 11 Q. Have you reviewed any testing by Ethicon related 11 related to shrinkage of mesh in vivo? 12 to shrinking mesh? 12 A. Yes, I believe I have. 13 13 A. No. Q. What literature would that be? 14 Q. Okay. 14 A. I don't recall it off the top of my head, but I'm 15 15 A. Not that I recall. sure it's on that device that they -- the USB device that 16 would involve all the materials they provided me. 16 Q. So you don't know one way or the other if the 17 17 testing that you just described is inaccurate, whether Q. So we can take that thumb drive that you and Ethicon's run that actual testing or not? 18 counsel have provided, look at the medical literature 18 19 MR. WES: Object to form, outside the scope. 19 there and find articles related to mesh shrinkage that you 2.0 MR. JONES: Q. Meaning the gross measurements 20 have read and reviewed? 21 of look at the size pre-implant, look at the size 21 A. That I have reviewed. 22 22 post-implant, there's a difference, ah-ha, there must be Q. Okay. 23 23 shrinkage? That's what you were referring to as A. There's levels of review, yes. 24 inadequate or inaccurate, right? 24 Q. Okay. What levels of review? 25 A. Correct. 25 A. Well, again, this is not exactly in my area of Page 51 Page 53 1 MR. WES: Same objection. 1 expertise -- or at least it's not in the area of where I'm THE WITNESS: Yes. I'm not sure about -- no, I 2 2 forming my opinions. So I didn't focus my attention 3 don't know that an Ethicon study has done that. 3 chiefly on that. I focused my attention on the pathology. 4 MR. JONES: Q. Okay. 4 Q. Okay. And then the final entry on the summary of 5 A. That I'm aware of, no. 5 opinion under number 16. Can you explain what you mean 6 Q. Are you aware of any testimony from Ethicon 6 7 7 doctors, medical directors or engineers or internal A. Certainly I think I may have mentioned this 8 Ethicon documents that state the mesh used in the TVT 8 already. Number 16 basically reads: Other than a 9 shrinks up to 50 percent? 9 non-healing wound, which is present in the region of the 10 MR. WES: Object to form, outside the scope. 10 vaginal mucosa and not attributable to the device or to 11 THE WITNESS: It really is not part of my 11 the mesh itself, there is really no significant tissue 12 12 opinion. reaction to that mesh other than the thin layer of 13 MR. JONES: Q. So that doesn't matter to you 13 lymphocytes and macrophages that's expected. There's no 14 either way whether Ethicon itself says mesh shrinks? 14 dense fibrosis. 15 MR. WES: Same objections. Also, argumentative. 15 All those things that I said were not there are 16 MR. JONES: Q. Let me restate the question. 16 not there, and I think that that wound is likely a 17 Does it matter to you in forming your opinions in this 17 complication from the surgical procedure. The incision 18 case that Ethicon employees, including medical directors 18 may have healed initially but must have broke down. 19 and engineers, have stated that the mesh used in the TVT 19 'Cause it really does look like it's a chronic non-healing 20 Abbrevo device shrinks up to 50 percent? 20 wound to me. 21 MR. WES: Same objections. 21 Q. Any additional opinions you intend to offer in 22 THE WITNESS: In the formation of my opinion, 22 this case that we haven't discussed and are not included 23 looking at the slides, it has no relevance, yes. Those 23 on this summary of opinion sheet? 24 things may all be true, but that's not part of my opinion 24 A. No. 25 and --25 Q. We've covered it all?

	Page 54		Page 56
1	A. I believe we have.	1	Q. Did you review every single item on this thumb
2	Q. Okay.	2	drive? First off let me backtrack.
3	A. Either we have in this deposition or it's on this	3	Do you know what's on this thumb drive?
4	sheet, yes.	4	A. My understanding is it's everything that's been
5	Q. Okay. And excuse me. Just in an attempt to	5	sent to me.
6	try to break it down, there's some healing issues involved	6	Q. Did you review everything that was sent to you?
7	in this case, correct, in your opinion?	7	A. No, I have not reviewed everything. There's been
8	A. Yes.	8	a number of things that have been sent in the last few
9	Q. Impaired healing, correct?	9	days that I've not reviewed.
10 11	A. Correct.	10 11	Q. What's been sent in the last few days?
12	Q. And it's your opinion the mesh is not the cause of Ms. Perry's pain, correct?	12	A. I'm not even sure what they are. There was something that came last night. I have not opened it
13	MR. WES: Object to form. It assumes facts.	13	something that came last fight. I have not opened it
14	THE WITNESS: It's my opinion that it's highly	14	Q. Okay.
15	unlikely that the mesh is what's causing her pain. I	15	A. Some of it may be depositions
16	think that's true based on what I've seen and reviewed. I	16	Q. Hot off the press deposition
17	think that's true based on what I've seen and reviewed. I	17	A that I'm really not aware.
18	procedure.	18	Q transcripts perhaps.
19	MR. JONES: Q. Why do you say that?	19	A. Well, no, it's not always that. There's
20	A. For the reasons that I mentioned earlier. In	20	something
21	other words, the removal of all that skin tissue around	21	Q. Go ahead.
22	the vaginal opening causing that opening to be narrower	22	A the other day that wasn't
23	and tighter.	23	THE REPORTER: Okay. I couldn't get you both
24	Q. Okay. Let's move on to what you're relying on	24	talking at the same time.
25	for the opinions that you've discussed.	25	Go ahead.
	Page 55		Page 57
1	Counsel, did you bring with you some materials	1	MR. JONES: Q. How can I make a determination of
2	today that include her reliance materials		
1 _		2	what on this thumb drive you reviewed and what you haven't
3	MR. WES: Yes.	3	reviewed?
4	MR. WES: Yes. MR. JONES: that we can mark for the record?	3 4	reviewed?  A. I don't know.
4 5	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.	3 4 5	reviewed?  A. I don't know.  Q. Okay. I mean, you understand
4 5 6	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark	3 4 5 6	reviewed?  A. I don't know. Q. Okay. I mean, you understand A. I know.
4 5 6 7	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll	3 4 5 6 7	reviewed?  A. I don't know.  Q. Okay. I mean, you understand  A. I know.  Q I've got to know what you're relying on, what
4 5 6 7 8	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.	3 4 5 6 7 8	reviewed?  A. I don't know.  Q. Okay. I mean, you understand  A. I know.  Q I've got to know what you're relying on, what you reviewed, right?
4 5 6 7 8 9	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for	3 4 5 6 7 8	reviewed?  A. I don't know. Q. Okay. I mean, you understand A. I know. Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my
4 5 6 7 8 9	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)	3 4 5 6 7 8	reviewed?  A. I don't know.  Q. Okay. I mean, you understand  A. I know.  Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case
4 5 6 7 8 9	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)  MR. JONES: Q. On this thumb drive first off,	3 4 5 6 7 8 9	reviewed?  A. I don't know.  Q. Okay. I mean, you understand  A. I know.  Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case are really based on pathology, my review of the slides.
4 5 6 7 8 9 10	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)	3 4 5 6 7 8 9 10	reviewed?  A. I don't know.  Q. Okay. I mean, you understand  A. I know.  Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case
4 5 6 7 8 9 10 11	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)  MR. JONES: Q. On this thumb drive first off, Doctor, did you create this thumb drive?	3 4 5 6 7 8 9 10 11	reviewed?  A. I don't know.  Q. Okay. I mean, you understand  A. I know.  Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case are really based on pathology, my review of the slides. I'm really not opining on many of those things that were
4 5 6 7 8 9 10 11 12 13	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)  MR. JONES: Q. On this thumb drive first off, Doctor, did you create this thumb drive?  A. No.	3 4 5 6 7 8 9 10 11 12 13	reviewed?  A. I don't know.  Q. Okay. I mean, you understand  A. I know.  Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case are really based on pathology, my review of the slides. I'm really not opining on many of those things that were submitted to me.
4 5 6 7 8 9 10 11 12 13	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)  MR. JONES: Q. On this thumb drive first off, Doctor, did you create this thumb drive?  A. No.  Q. Counsel created this for you?	3 4 5 6 7 8 9 10 11 12 13 14	reviewed?  A. I don't know.  Q. Okay. I mean, you understand  A. I know.  Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case are really based on pathology, my review of the slides. I'm really not opining on many of those things that were submitted to me.  Yes, I'm relying on Ms. Perry's medical record
4 5 6 7 8 9 10 11 12 13 14	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)  MR. JONES: Q. On this thumb drive first off, Doctor, did you create this thumb drive?  A. No.  Q. Counsel created this for you?  A. Yes.	3 4 5 6 7 8 9 10 11 12 13 14	reviewed?  A. I don't know. Q. Okay. I mean, you understand A. I know. Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case are really based on pathology, my review of the slides. I'm really not opining on many of those things that were submitted to me.  Yes, I'm relying on Ms. Perry's medical record and all those issues that have been associated
4 5 6 7 8 9 10 11 12 13 14 15	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)  MR. JONES: Q. On this thumb drive first off, Doctor, did you create this thumb drive?  A. No.  Q. Counsel created this for you?  A. Yes.  Q. Have you looked at what's on this thumb drive?	3 4 5 6 7 8 9 10 11 12 13 14 15 16	reviewed?  A. I don't know.  Q. Okay. I mean, you understand A. I know.  Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case are really based on pathology, my review of the slides. I'm really not opining on many of those things that were submitted to me.  Yes, I'm relying on Ms. Perry's medical record and all those issues that have been associated with her initiating her mesh placement at the beginning and then the subsequent removal of that and some of that follow-up. Those things certainly I'm using.
4 5 6 7 8 9 10 11 12 13 14 15 16 17	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)  MR. JONES: Q. On this thumb drive first off,  Doctor, did you create this thumb drive?  A. No.  Q. Counsel created this for you?  A. Yes.  Q. Have you looked at what's on this thumb drive?  A. No.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	reviewed?  A. I don't know.  Q. Okay. I mean, you understand  A. I know.  Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case are really based on pathology, my review of the slides. I'm really not opining on many of those things that were submitted to me.  Yes, I'm relying on Ms. Perry's medical record and all those issues that have been associated with her initiating her mesh placement at the beginning and then the subsequent removal of that and some of that
4 5 6 7 8 9 10 11 12 13 14 15 16 17	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)  MR. JONES: Q. On this thumb drive first off, Doctor, did you create this thumb drive?  A. No.  Q. Counsel created this for you?  A. Yes.  Q. Have you looked at what's on this thumb drive?  A. No.  Q. Okay. You've relied on counsel to adequately put	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	reviewed?  A. I don't know.  Q. Okay. I mean, you understand A. I know.  Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case are really based on pathology, my review of the slides. I'm really not opining on many of those things that were submitted to me.  Yes, I'm relying on Ms. Perry's medical record and all those issues that have been associated with her initiating her mesh placement at the beginning and then the subsequent removal of that and some of that follow-up. Those things certainly I'm using.
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)  MR. JONES: Q. On this thumb drive first off, Doctor, did you create this thumb drive?  A. No.  Q. Counsel created this for you?  A. Yes.  Q. Have you looked at what's on this thumb drive?  A. No.  Q. Okay. You've relied on counsel to adequately put all your reliance materials on this thumb drive?	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	reviewed?  A. I don't know.  Q. Okay. I mean, you understand A. I know.  Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case are really based on pathology, my review of the slides. I'm really not opining on many of those things that were submitted to me.  Yes, I'm relying on Ms. Perry's medical record and all those issues that have been associated with her initiating her mesh placement at the beginning and then the subsequent removal of that and some of that follow-up. Those things certainly I'm using.  Q. That's an easy one.
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)  MR. JONES: Q. On this thumb drive first off, Doctor, did you create this thumb drive?  A. No.  Q. Counsel created this for you?  A. Yes.  Q. Have you looked at what's on this thumb drive?  A. No.  Q. Okay. You've relied on counsel to adequately put all your reliance materials on this thumb drive?  A. Yes.	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	reviewed?  A. I don't know.  Q. Okay. I mean, you understand A. I know.  Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case are really based on pathology, my review of the slides. I'm really not opining on many of those things that were submitted to me.  Yes, I'm relying on Ms. Perry's medical record and all those issues that have been associated with her initiating her mesh placement at the beginning and then the subsequent removal of that and some of that follow-up. Those things certainly I'm using.  Q. That's an easy one.  A. Right.  Q. Pathology slides A. Exactly.
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)  MR. JONES: Q. On this thumb drive first off,  Doctor, did you create this thumb drive?  A. No.  Q. Counsel created this for you?  A. Yes.  Q. Have you looked at what's on this thumb drive?  A. No.  Q. Okay. You've relied on counsel to adequately put all your reliance materials on this thumb drive?  A. Yes.  Q. Okay. So if there's a mistake, it's their fault, right?  A. Their mis	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	reviewed?  A. I don't know. Q. Okay. I mean, you understand A. I know. Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case are really based on pathology, my review of the slides. I'm really not opining on many of those things that were submitted to me.  Yes, I'm relying on Ms. Perry's medical record and all those issues that have been associated with her initiating her mesh placement at the beginning and then the subsequent removal of that and some of that follow-up. Those things certainly I'm using. Q. That's an easy one. A. Right. Q. Pathology slides A. Exactly. Q the pathology reports?
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	MR. WES: Yes.  MR. JONES: that we can mark for the record?  MR. WES: They are on this flash drive.  MR. JONES: Okay. I'm going to go ahead and mark this flash drive as L-4. I'll take it with me, but we'll mark it for the record as Exhibit L-4.  (Whereupon, Exhibit L-4 was marked for identification.)  MR. JONES: Q. On this thumb drive first off, Doctor, did you create this thumb drive?  A. No.  Q. Counsel created this for you?  A. Yes.  Q. Have you looked at what's on this thumb drive?  A. No.  Q. Okay. You've relied on counsel to adequately put all your reliance materials on this thumb drive?  A. Yes.  Q. Okay. So if there's a mistake, it's their fault, right?	3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	reviewed?  A. I don't know.  Q. Okay. I mean, you understand A. I know.  Q I've got to know what you're relying on, what you reviewed, right?  A. Well, to a certain extent, yes. But most of my opinions that I've expressed particularly about this case are really based on pathology, my review of the slides. I'm really not opining on many of those things that were submitted to me.  Yes, I'm relying on Ms. Perry's medical record and all those issues that have been associated with her initiating her mesh placement at the beginning and then the subsequent removal of that and some of that follow-up. Those things certainly I'm using.  Q. That's an easy one.  A. Right.  Q. Pathology slides A. Exactly.

15 (Pages 54 to 57)

	Page 58		Page 60
1	A. Of course, yes.	1	looked at is on this drive. We just need to tell you
2	Q Ms. Perry's deposition and Mr. Perry's	2	basically what
3	deposition?	3	MR. JONES: Yeah.
4	A. Yes.	4	MR. WES: is on this drive that that she
5	Q. Earlier I asked you did you review medical	5	MR. JONES: There's the road.
6	literature related to mesh shrinkage, and you answered	6	MR. WES: didn't necessarily look at.
7	yes, right?	7	MR. JONES: There's the road. At the moment I
8	A. I think I have, yes.	8	have no way
9	Q. And then I asked you what literature that was,	9	MR. WES: So we will narrow that down for you.
10	and you couldn't recall.	10	Whether it makes more sense to produce another one of
11	A. Correct.	11	these probably it makes more sense for us to just tell
12	Q. And then I said I'll be able to go to this thumb	12	you, you know, here's the items on the drive.
13	drive and look at the literature related to mesh shrinkage	13	MR. JONES: Okay. And you'll endeavor to do
14	that you reviewed?	14	that?
15	A. Correct.	15	MR. WES: We will do that.
16	Q. But you didn't review everything on this thumb	16	MR. JONES: Okay. I appreciate that.
17	drive, right?	17	Q. So it sounds like once we get a list of materials
18	MR. WES: And Counsel, I can just stipulate that	18	that are on this thumb drive that you actually reviewed
19	we'll let you know what materials were added that I guess	19	then we can look at that list and decipher here's medical
20	she just got in the last couple of days that you haven't	20	literature that you actually reviewed, correct?
21	got a chance to review. And we can narrow down for you	21	A. Yes.
22	anything that that she hasn't reviewed as of today's	22	Q. Okay. But at the moment everything on this thumb
23	date in preparation of her opinions.	23	drive you didn't review?
24	MR. JONES: I'm not so much worried about what's	24	A. I don't know that I have.
25	been submitted to her the last couple of days. I more	25	Q. Okay.
	Page 59		Page 61
1	want to get the universe of what she reviewed	1	A. I may have. I don't know.
2	MR. WES: Sure.	2	Q. There's just no way to tell?
3	MR. JONES: versus, you know, all the stuff	3	A. I just know that they've sent things that I have
4	that you sent out to her.	4	not reviewed, and I assume they're on that drive.
5	MR. WES: Yes.	5	Q. Okay. We touched on this earlier, but I need to
6	MR. JONES: Can you endeavor to produce a list or	6	go back to it.
7	a thumb drive with materials that she actually looked at	7	Internal Ethicon documents, did you review any?
8	so I can know what she's relying on for her opinions?	8	A. I may have, and if I did, they will be on that
9	MR. WES: Yeah. We can narrow down you know,	9	disc.
10	if there's anything that goes	10	Q. Okay. But at the moment there may be Ethicon
11			
	MR. SNOWDEN: Those are two different questions.	11	documents on this thumb drive that you didn't review?
12	MR. SNOWDEN: Those are two different questions.  MR. JONES: Yeah, you can answer them both if you	11 12	documents on this thumb drive that you didn't review?  A. I don't think so. I just don't recall.
	•		
12	MR. JONES: Yeah, you can answer them both if you	12	A. I don't think so. I just don't recall.
12 13	MR. JONES: Yeah, you can answer them both if you want.	12 13	<ul><li>A. I don't think so. I just don't recall.</li><li>Q. Okay.</li></ul>
12 13 14	MR. JONES: Yeah, you can answer them both if you want.  MR. WES: Right. And so we'll I mean, we will	12 13 14	<ul><li>A. I don't think so. I just don't recall.</li><li>Q. Okay.</li><li>A. I don't think so.</li></ul>
12 13 14 15	MR. JONES: Yeah, you can answer them both if you want.  MR. WES: Right. And so we'll I mean, we will give you the entire universe of what she's reviewed and	12 13 14 15	<ul><li>A. I don't think so. I just don't recall.</li><li>Q. Okay.</li><li>A. I don't think so.</li><li>Q. Okay.</li></ul>
12 13 14 15 16	MR. JONES: Yeah, you can answer them both if you want.  MR. WES: Right. And so we'll I mean, we will give you the entire universe of what she's reviewed and what are how are the questions what's your second	12 13 14 15 16	<ul> <li>A. I don't think so. I just don't recall.</li> <li>Q. Okay.</li> <li>A. I don't think so.</li> <li>Q. Okay.</li> <li>A. If I have them. If I I think I've seen some.</li> <li>Again, I'm not sure what I don't want to sound ignorant, but I'm not really sure what you're asking me</li> </ul>
12 13 14 15 16 17	MR. JONES: Yeah, you can answer them both if you want.  MR. WES: Right. And so we'll I mean, we will give you the entire universe of what she's reviewed and what are how are the questions what's your second question?	12 13 14 15 16 17	<ul> <li>A. I don't think so. I just don't recall.</li> <li>Q. Okay.</li> <li>A. I don't think so.</li> <li>Q. Okay.</li> <li>A. If I have them. If I I think I've seen some.</li> <li>Again, I'm not sure what I don't want to sound</li> </ul>
12 13 14 15 16 17 18	MR. JONES: Yeah, you can answer them both if you want.  MR. WES: Right. And so we'll I mean, we will give you the entire universe of what she's reviewed and what are how are the questions what's your second question?  MR. JONES: It's almost an either/or question.	12 13 14 15 16 17	<ul> <li>A. I don't think so. I just don't recall.</li> <li>Q. Okay.</li> <li>A. I don't think so.</li> <li>Q. Okay.</li> <li>A. If I have them. If I I think I've seen some.</li> <li>Again, I'm not sure what I don't want to sound ignorant, but I'm not really sure what you're asking me</li> </ul>
12 13 14 15 16 17 18 19	MR. JONES: Yeah, you can answer them both if you want.  MR. WES: Right. And so we'll I mean, we will give you the entire universe of what she's reviewed and what are how are the questions what's your second question?  MR. JONES: It's almost an either/or question.  MR. WES: Okay.	12 13 14 15 16 17 18 19	<ul> <li>A. I don't think so. I just don't recall.</li> <li>Q. Okay.</li> <li>A. I don't think so.</li> <li>Q. Okay.</li> <li>A. If I have them. If I I think I've seen some.</li> <li>Again, I'm not sure what I don't want to sound ignorant, but I'm not really sure what you're asking me when you say "internal documents," quite honestly.</li> </ul>
12 13 14 15 16 17 18 19 20	MR. JONES: Yeah, you can answer them both if you want.  MR. WES: Right. And so we'll I mean, we will give you the entire universe of what she's reviewed and what are how are the questions what's your second question?  MR. JONES: It's almost an either/or question.  MR. WES: Okay.  MR. JONES: I either need a list of what she	12 13 14 15 16 17 18 19 20	<ul> <li>A. I don't think so. I just don't recall.</li> <li>Q. Okay.</li> <li>A. I don't think so.</li> <li>Q. Okay.</li> <li>A. If I have them. If I I think I've seen some.</li> <li>Again, I'm not sure what I don't want to sound ignorant, but I'm not really sure what you're asking me when you say "internal documents," quite honestly.</li> <li>Q. Testing that Ethicon ran.</li> </ul>
12 13 14 15 16 17 18 19 20 21	MR. JONES: Yeah, you can answer them both if you want.  MR. WES: Right. And so we'll I mean, we will give you the entire universe of what she's reviewed and what are how are the questions what's your second question?  MR. JONES: It's almost an either/or question.  MR. WES: Okay.  MR. JONES: I either need a list of what she actually did look at	12 13 14 15 16 17 18 19 20 21	<ul> <li>A. I don't think so. I just don't recall.</li> <li>Q. Okay.</li> <li>A. I don't think so.</li> <li>Q. Okay.</li> <li>A. If I have them. If I I think I've seen some.</li> <li>Again, I'm not sure what I don't want to sound ignorant, but I'm not really sure what you're asking me when you say "internal documents," quite honestly.</li> <li>Q. Testing that Ethicon ran.</li> <li>A. I think I've seen some of that, yes.</li> <li>Q. You think you have?</li> <li>A. I think so, yeah.</li> </ul>
12 13 14 15 16 17 18 19 20 21 22	MR. JONES: Yeah, you can answer them both if you want.  MR. WES: Right. And so we'll I mean, we will give you the entire universe of what she's reviewed and what are how are the questions what's your second question?  MR. JONES: It's almost an either/or question.  MR. WES: Okay.  MR. JONES: I either need a list of what she actually did look at  MR. WES: Right.	12 13 14 15 16 17 18 19 20 21	<ul> <li>A. I don't think so. I just don't recall.</li> <li>Q. Okay.</li> <li>A. I don't think so.</li> <li>Q. Okay.</li> <li>A. If I have them. If I I think I've seen some.</li> <li>Again, I'm not sure what I don't want to sound ignorant, but I'm not really sure what you're asking me when you say "internal documents," quite honestly.</li> <li>Q. Testing that Ethicon ran.</li> <li>A. I think I've seen some of that, yes.</li> <li>Q. You think you have?</li> </ul>

	Page 62		Page 64
1	Q. Have not reviewed a single e-mail?	1	THE WITNESS: I've reviewed literature addressing
2	A. I don't think so, no.	2	shrinkage of mesh ex vivo, invitro, not in the body. I
3	Q. Do you have any recall of what type of testing	3	don't know that I've read about any shrinkage in the body.
4	documents from Ethicon you reviewed?	4	That's why I brought it back to pathology.
5	A. Not at this point. No, not at this time.	5	Q. Okay.
6	Q. Okay. And no recall of the specific medical	6	A. But other than that I don't remember or recall
7	literature that you reviewed?	7	any specific literature, but I know that there's
8	A. Not specific. I read a lot of long-term	8	discussion about
9	follow-up studies of mesh material. I've reviewed medical	9	Q. Are you familiar with any pathology articles by
10	literature related to colporrhapy procedures, medical	10	Vladimir Iakolov (phonetic)?
11	literature concerning indications for performing these	11	A. How do you spell that?
12	surgeries, some of the urologic society's statements about	12	Q. I don't know. Does it ring a bell, though, at
13	recommendations for these procedures. Those are the kinds	13	all?
14	of things that I reviewed.	14	A. I don't well, I don't know. I don't think so.
15	Q. Okay. Do you recall reviewing any literature	15	Q. Okay.
16	that would be contrary to the opinions you're giving in	16	A. But I might. If you spelled it, maybe I would
17	this case?	17	know who it was. Is it with a Y?
18	MR. WES: Object to form.	18	Q. It's with an I. I'll take a guess and say it's
19	THE WITNESS: No, I don't know of any literature	19	I-A-K-O-L
20	that would be that would be contrary to what I'm to	20	A. I don't know.
21	my pathology findings. None, no.	21	Q O-V.
22	MR. JONES: Q. What about to your any findings	22	A. It's possible. It will be on there.
23	beyond your pathology findings?	23	Q. Did you review plaintiff's independent medical
24	MR. WES: Object to form.	24	examination?
25	THE WITNESS: Yeah, I don't know what you're	25	A. Who was that?
23	THE WITNESS. Teal, I don't know what you're	25	A. Who was that:
	Page 63		Page 65
1	Page 63 asking.	1	Page 65 Q. I think Dr. Margolis.
1 2		1 2	
	asking.		Q. I think Dr. Margolis.
2	asking.  MR. JONES: Q. Well	2	<ul><li>Q. I think Dr. Margolis.</li><li>A. I reviewed his not his deposition, no. I read</li></ul>
2	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but	2	<ul><li>Q. I think Dr. Margolis.</li><li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li></ul>
2 3 4	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.	2 3 4	<ul><li>Q. I think Dr. Margolis.</li><li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li><li>Q. Okay.</li></ul>
2 3 4 5	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which	2 3 4 5	<ul> <li>Q. I think Dr. Margolis.</li> <li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li> <li>Q. Okay.</li> <li>A. Or maybe that's what I received. I've not read</li> </ul>
2 3 4 5 6	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're	2 3 4 5 6	<ul> <li>Q. I think Dr. Margolis.</li> <li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li> <li>Q. Okay.</li> <li>A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it</li> </ul>
2 3 4 5 6 7	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?	2 3 4 5 6 7	<ul> <li>Q. I think Dr. Margolis.</li> <li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li> <li>Q. Okay.</li> <li>A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it MR. WES: And listen carefully to what he asked.</li> </ul>
2 3 4 5 6 7 8	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's	2 3 4 5 6 7 8	<ul> <li>Q. I think Dr. Margolis.</li> <li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li> <li>Q. Okay.</li> <li>A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it  MR. WES: And listen carefully to what he asked.</li> <li>He asked if you reviewed her his independent medical</li> </ul>
2 3 4 5 6 7 8	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies	2 3 4 5 6 7 8	<ul> <li>Q. I think Dr. Margolis.</li> <li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li> <li>Q. Okay.</li> <li>A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it</li> <li>MR. WES: And listen carefully to what he asked.</li> <li>He asked if you reviewed her his independent medical examination, not his deposition specifically.</li> </ul>
2 3 4 5 6 7 8 9	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no	2 3 4 5 6 7 8 9	<ul> <li>Q. I think Dr. Margolis.</li> <li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li> <li>Q. Okay.</li> <li>A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it  MR. WES: And listen carefully to what he asked.</li> <li>He asked if you reviewed her his independent medical examination, not his deposition specifically.  THE WITNESS: Oh. What's his independent medical</li> </ul>
2 3 4 5 6 7 8 9 10	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no evidence of shrinkage. So in vivo I don't see once	2 3 4 5 6 7 8 9 10	<ul> <li>Q. I think Dr. Margolis.</li> <li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li> <li>Q. Okay.</li> <li>A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it  MR. WES: And listen carefully to what he asked.</li> <li>He asked if you reviewed her his independent medical examination, not his deposition specifically.</li> <li>THE WITNESS: Oh. What's his independent medical examination? Oh. Oh, I don't know that I've I may</li> </ul>
2 3 4 5 6 7 8 9 10 11	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no evidence of shrinkage. So in vivo I don't see once it's in the body, the issue of shrinkage appears to me	2 3 4 5 6 7 8 9 10 11	<ul> <li>Q. I think Dr. Margolis.</li> <li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li> <li>Q. Okay.</li> <li>A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it  MR. WES: And listen carefully to what he asked.</li> <li>He asked if you reviewed her his independent medical examination, not his deposition specifically.  THE WITNESS: Oh. What's his independent medical examination? Oh. Oh, I don't know that I've I may have. He took some photographs. I did see those.</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no evidence of shrinkage. So in vivo I don't see once it's in the body, the issue of shrinkage appears to me based on my readings and what I've seen on the slides a	2 3 4 5 6 7 8 9 10 11 12 13	<ul> <li>Q. I think Dr. Margolis.</li> <li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li> <li>Q. Okay.</li> <li>A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it  MR. WES: And listen carefully to what he asked.</li> <li>He asked if you reviewed her his independent medical examination, not his deposition specifically.  THE WITNESS: Oh. What's his independent medical examination? Oh. Oh, I don't know that I've I may have. He took some photographs. I did see those.  MR. JONES: Q. Okay.</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13 14	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no evidence of shrinkage. So in vivo I don't see once it's in the body, the issue of shrinkage appears to me based on my readings and what I've seen on the slides a moot issue. Not significant.	2 3 4 5 6 7 8 9 10 11 12 13 14	<ul> <li>Q. I think Dr. Margolis.</li> <li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li> <li>Q. Okay.</li> <li>A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it  MR. WES: And listen carefully to what he asked.</li> <li>He asked if you reviewed her his independent medical examination, not his deposition specifically.  THE WITNESS: Oh. What's his independent medical examination? Oh. Oh, I don't know that I've I may have. He took some photographs. I did see those.  MR. JONES: Q. Okay.</li> <li>A. Yes.</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13 14 15	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no evidence of shrinkage. So in vivo I don't see once it's in the body, the issue of shrinkage appears to me based on my readings and what I've seen on the slides a moot issue. Not significant.  There may well be, and I have seen at least some	2 3 4 5 6 7 8 9 10 11 12 13 14 15	<ul> <li>Q. I think Dr. Margolis.</li> <li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li> <li>Q. Okay.</li> <li>A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it. MR. WES: And listen carefully to what he asked. He asked if you reviewed her his independent medical examination, not his deposition specifically.  THE WITNESS: Oh. What's his independent medical examination? Oh. Oh, I don't know that I've I may have. He took some photographs. I did see those.  MR. JONES: Q. Okay.</li> <li>A. Yes.</li> <li>Q. Okay. So it sounds like you have reviewed</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13 14 15	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no evidence of shrinkage. So in vivo I don't see once it's in the body, the issue of shrinkage appears to me based on my readings and what I've seen on the slides a moot issue. Not significant.  There may well be, and I have seen at least some of these studies that talk about shrinkage. Whether that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Q. I think Dr. Margolis. A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet. Q. Okay. A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it MR. WES: And listen carefully to what he asked. He asked if you reviewed her his independent medical examination, not his deposition specifically. THE WITNESS: Oh. What's his independent medical examination? Oh. Oh, I don't know that I've I may have. He took some photographs. I did see those. MR. JONES: Q. Okay. A. Yes. Q. Okay. So it sounds like you have reviewed plaintiff's independent medical examination
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no evidence of shrinkage. So in vivo I don't see once it's in the body, the issue of shrinkage appears to me based on my readings and what I've seen on the slides a moot issue. Not significant.  There may well be, and I have seen at least some of these studies that talk about shrinkage. Whether that has any relevance clinically in this case and in this	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. I think Dr. Margolis. A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet. Q. Okay. A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it MR. WES: And listen carefully to what he asked. He asked if you reviewed her his independent medical examination, not his deposition specifically. THE WITNESS: Oh. What's his independent medical examination? Oh. Oh, I don't know that I've I may have. He took some photographs. I did see those. MR. JONES: Q. Okay. A. Yes. Q. Okay. So it sounds like you have reviewed plaintiff's independent medical examination A. I may have.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no evidence of shrinkage. So in vivo I don't see once it's in the body, the issue of shrinkage appears to me based on my readings and what I've seen on the slides a moot issue. Not significant.  There may well be, and I have seen at least some of these studies that talk about shrinkage. Whether that has any relevance clinically in this case and in this particular patient or in general at this site, I'm not	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. I think Dr. Margolis. A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet. Q. Okay. A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it MR. WES: And listen carefully to what he asked. He asked if you reviewed her his independent medical examination, not his deposition specifically. THE WITNESS: Oh. What's his independent medical examination? Oh. Oh, I don't know that I've I may have. He took some photographs. I did see those. MR. JONES: Q. Okay. A. Yes. Q. Okay. So it sounds like you have reviewed plaintiff's independent medical examination A. I may have. Q by Dr. Margolis?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no evidence of shrinkage. So in vivo I don't see once it's in the body, the issue of shrinkage appears to me based on my readings and what I've seen on the slides a moot issue. Not significant.  There may well be, and I have seen at least some of these studies that talk about shrinkage. Whether that has any relevance clinically in this case and in this particular patient or in general at this site, I'm not I don't necessarily see that it transfers over. So that	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Q. I think Dr. Margolis. A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet. Q. Okay. A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it MR. WES: And listen carefully to what he asked. He asked if you reviewed her his independent medical examination, not his deposition specifically. THE WITNESS: Oh. What's his independent medical examination? Oh. Oh, I don't know that I've I may have. He took some photographs. I did see those. MR. JONES: Q. Okay. A. Yes. Q. Okay. So it sounds like you have reviewed plaintiff's independent medical examination A. I may have. Q by Dr. Margolis? A. I may have. I've seen the pictures anyway.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no evidence of shrinkage. So in vivo I don't see once it's in the body, the issue of shrinkage appears to me based on my readings and what I've seen on the slides a moot issue. Not significant.  There may well be, and I have seen at least some of these studies that talk about shrinkage. Whether that has any relevance clinically in this case and in this particular patient or in general at this site, I'm not I don't necessarily see that it transfers over. So that is my opinion.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. I think Dr. Margolis. A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet. Q. Okay. A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it MR. WES: And listen carefully to what he asked. He asked if you reviewed her his independent medical examination, not his deposition specifically. THE WITNESS: Oh. What's his independent medical examination? Oh. Oh, I don't know that I've I may have. He took some photographs. I did see those. MR. JONES: Q. Okay. A. Yes. Q. Okay. So it sounds like you have reviewed plaintiff's independent medical examination A. I may have. Q by Dr. Margolis? A. I may have. I've seen the pictures anyway. Q. And you reviewed statements from professional
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no evidence of shrinkage. So in vivo I don't see once it's in the body, the issue of shrinkage appears to me based on my readings and what I've seen on the slides a moot issue. Not significant.  There may well be, and I have seen at least some of these studies that talk about shrinkage. Whether that has any relevance clinically in this case and in this particular patient or in general at this site, I'm not I don't necessarily see that it transfers over. So that is my opinion.  Q. Okay.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. I think Dr. Margolis. A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet. Q. Okay. A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it MR. WES: And listen carefully to what he asked. He asked if you reviewed her his independent medical examination, not his deposition specifically. THE WITNESS: Oh. What's his independent medical examination? Oh. Oh, I don't know that I've I may have. He took some photographs. I did see those. MR. JONES: Q. Okay. A. Yes. Q. Okay. So it sounds like you have reviewed plaintiff's independent medical examination A. I may have. Q by Dr. Margolis? A. I may have. I've seen the pictures anyway. Q. And you reviewed statements from professional societies like AUGS?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no evidence of shrinkage. So in vivo I don't see once it's in the body, the issue of shrinkage appears to me based on my readings and what I've seen on the slides a moot issue. Not significant.  There may well be, and I have seen at least some of these studies that talk about shrinkage. Whether that has any relevance clinically in this case and in this particular patient or in general at this site, I'm not I don't necessarily see that it transfers over. So that is my opinion.  Q. Okay.  A. But that's it.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	<ul> <li>Q. I think Dr. Margolis.</li> <li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li> <li>Q. Okay.</li> <li>A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it.</li> <li>MR. WES: And listen carefully to what he asked.</li> <li>He asked if you reviewed her his independent medical examination, not his deposition specifically.</li> <li>THE WITNESS: Oh. What's his independent medical examination? Oh. Oh, I don't know that I've I may have. He took some photographs. I did see those.</li> <li>MR. JONES: Q. Okay.</li> <li>A. Yes.</li> <li>Q. Okay. So it sounds like you have reviewed plaintiff's independent medical examination</li> <li>A. I may have.</li> <li>Q by Dr. Margolis?</li> <li>A. I may have. I've seen the pictures anyway.</li> <li>Q. And you reviewed statements from professional societies like AUGS?</li> <li>A. Is this A-U-G-S that you're talking about? Yes.</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	asking.  MR. JONES: Q. Well  A. I'm sure there's something you're asking me, but I don't know what it is.  Q. You limited it to your pathology findings, which makes me wonder are there other findings that you're speaking about?  A. Oh, no. No, I think that well, I mean, let's just cut to the chase. You are talking about some studies that have shown shrinkage of the mesh, and I see no evidence of shrinkage. So in vivo I don't see once it's in the body, the issue of shrinkage appears to me based on my readings and what I've seen on the slides a moot issue. Not significant.  There may well be, and I have seen at least some of these studies that talk about shrinkage. Whether that has any relevance clinically in this case and in this particular patient or in general at this site, I'm not I don't necessarily see that it transfers over. So that is my opinion.  Q. Okay.  A. But that's it.  Q. So you have reviewed literature that concludes	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	<ul> <li>Q. I think Dr. Margolis.</li> <li>A. I reviewed his not his deposition, no. I read parts of it, but I don't think I've received that yet.</li> <li>Q. Okay.</li> <li>A. Or maybe that's what I received. I've not read it. If I have received it, I have not read it.</li> <li>MR. WES: And listen carefully to what he asked.</li> <li>He asked if you reviewed her his independent medical examination, not his deposition specifically.</li> <li>THE WITNESS: Oh. What's his independent medical examination? Oh. Oh, I don't know that I've I may have. He took some photographs. I did see those.</li> <li>MR. JONES: Q. Okay.</li> <li>A. Yes.</li> <li>Q. Okay. So it sounds like you have reviewed plaintiff's independent medical examination</li> <li>A. I may have.</li> <li>Q by Dr. Margolis?</li> <li>A. I may have. I've seen the pictures anyway.</li> <li>Q. And you reviewed statements from professional societies like AUGS?</li> <li>A. Is this A-U-G-S that you're talking about? Yes.</li> <li>Q. Yes.</li> </ul>

	Page 66		Page 68
1	Q. Did you do an independent literature search?	1	Q. Okay. Are you familiar with the law firm Butler
2	A. No.	2	Snow?
3	Q. All the literature counsel provided to you that	3	A. Yes.
4	you've reviewed?	4	Q. Okay. Have you worked with the law firm Butler
5	A. What is the question?	5	Snow in the past beyond this particular case?
6	Q. Did you review any literature beyond what counsel	6	A. I don't believe so, no.
7	provided to you?	7	Q. Do you know William Gage?
8	A. No.	8	A. No.
9	Q. So it's fair to say all of the literature that	9	Q. Do you know Burt Snell?
10	you've reviewed in forming your opinions in this case has	10	A. S-N-E-L-L. I'm aware of the name. I don't know
11	been provided by Ethicon's counsel?	11	if I have, actually.
12	MR. WES: Objection to form, misstates.	12	Q. Okay.
13	THE WITNESS: Well, my opinion's also based on	13	A. I don't think I've met him, but whether I've
14	sort of, you know, my general pathology and GYN pathology	14	talked to him or not, I don't know.
15	background and training as well, but I didn't go out and	15	Q. And then the third law firm listed Bowman and
16	actively look for an article on transvaginal mesh.	16	Brooke, LLP. Are you familiar with that law firm?
17	MR. JONES: Q. Okay.	17	A. Actually, I don't think I am.
18	A. I may have requested articles from Mr. Snowden.	18	Q. Okay. So you haven't worked for them in the
19	Q. Do you have any recall of what those articles	19	past?
20	were?	20	A. No.
21	A. No. It would have been general not a specific	21	MR. JONES: Okay. I'll put those away. We'll
22	article, but just general topics, but no, I have not	22	mark as Exhibit L-7 an invoice related to this case.
23	pulled there's not anything that I've reviewed that's	23	Go ahead and hand this to you.
24	not on that disc.	24	(Whereupon, Exhibit L-7 was marked for
25	Q. Okay. Will you be testifying about any TVT	25	identification.)
1	Page 67 products other than Abbrevo?	1	Page 69
2	MR. WES: Object to form, outside the scope.	1 2	MR. JONES: Q. What does Exhibit L-7 represent?  A. It's an invoice that my administrative assistant
3	THE WITNESS: I'm not sure I'm really necessarily	3	submitted to I'm not really sure where she submitted
4	testifying about Abbrevo except in this particular	4	it, but she I think Johnson & Johnson ultimately, I
5	example.	5	think, foot the bill the invoice went to, but it says
6	MR. JONES: Okay.	6	Butler/Snowden and Ethicon Gynecare Pelvic Mesh, but I
7	MR. WES: Are we doing okay? We've gone about an	7	think it actually ended up going to Johnson & Johnson.
8	hour and a half. Do you want to take a break?	8	Q. And is that what you've billed for your time in
9	THE WITNESS: Well, if not now, soon.	9	this case so far?
10	MR. JONES: Let's take a break.	10	A. Yes, it is.
11	(Short break taken.)	11	Q. And is that the totality of your time thus far
12	MR. JONES: All right. We're back on the record	12	that you've spent on this case?
13	from a quick break.	13	A. No.
	I want to mark for the record Exhibit L-5, which	14	Q. No?
14			-
14		15	A. This is what I've billed.
	is the deposition notice, Exhibit L-6, which are the response and objections filed to the deposition notice.	15 16	
15	is the deposition notice, Exhibit L-6, which are the		
15 16	is the deposition notice, Exhibit L-6, which are the response and objections filed to the deposition notice.	16	Q. This is what you've billed?
15 16 17	is the deposition notice, Exhibit L-6, which are the response and objections filed to the deposition notice.  (Whereupon, Exhibits L-5 and L-6 were marked	16 17	<ul><li>Q. This is what you've billed?</li><li>A. Yes.</li></ul>
15 16 17 18	is the deposition notice, Exhibit L-6, which are the response and objections filed to the deposition notice.  (Whereupon, Exhibits L-5 and L-6 were marked for identification.)  MR. JONES: Q. If you look real quickly at	16 17 18	<ul><li>Q. This is what you've billed?</li><li>A. Yes.</li><li>Q. Can you estimate beyond what's represented in</li></ul>
15 16 17 18 19	is the deposition notice, Exhibit L-6, which are the response and objections filed to the deposition notice.  (Whereupon, Exhibits L-5 and L-6 were marked for identification.)	16 17 18 19	<ul><li>Q. This is what you've billed?</li><li>A. Yes.</li><li>Q. Can you estimate beyond what's represented in Exhibit L-7 how many hours you've spent on this case?</li></ul>
15 16 17 18 19 20	is the deposition notice, Exhibit L-6, which are the response and objections filed to the deposition notice.  (Whereupon, Exhibits L-5 and L-6 were marked for identification.)  MR. JONES: Q. If you look real quickly at Exhibit L-6, on the top left there's some law firms	16 17 18 19 20	<ul><li>Q. This is what you've billed?</li><li>A. Yes.</li><li>Q. Can you estimate beyond what's represented in Exhibit L-7 how many hours you've spent on this case?</li><li>A. Yes, I can estimate.</li></ul>
15 16 17 18 19 20 21	is the deposition notice, Exhibit L-6, which are the response and objections filed to the deposition notice.  (Whereupon, Exhibits L-5 and L-6 were marked for identification.)  MR. JONES: Q. If you look real quickly at Exhibit L-6, on the top left there's some law firms mentioned. Do you recognize the law firm of Tucker Ellis,	16 17 18 19 20 21	<ul><li>Q. This is what you've billed?</li><li>A. Yes.</li><li>Q. Can you estimate beyond what's represented in Exhibit L-7 how many hours you've spent on this case?</li><li>A. Yes, I can estimate.</li><li>Q. And what is that estimate?</li></ul>
15 16 17 18 19 20 21 22	is the deposition notice, Exhibit L-6, which are the response and objections filed to the deposition notice.  (Whereupon, Exhibits L-5 and L-6 were marked for identification.)  MR. JONES: Q. If you look real quickly at Exhibit L-6, on the top left there's some law firms mentioned. Do you recognize the law firm of Tucker Ellis, Doctor?	16 17 18 19 20 21 22	<ul> <li>Q. This is what you've billed?</li> <li>A. Yes.</li> <li>Q. Can you estimate beyond what's represented in</li> <li>Exhibit L-7 how many hours you've spent on this case?</li> <li>A. Yes, I can estimate.</li> <li>Q. And what is that estimate?</li> <li>A. Would you like that?</li> </ul>

	Page 70		Page 72
1	60 hours review of literature.	1	A. It might be by day. I just don't I honestly
2	Q. You say 50 to 60?	2	do not remember.
3	A. That's an estimate. I could be off a little bit.	3	Q. Okay. That's common. In addition to the \$500 an
4	My AA is keeping recent hours, but she didn't keep the	4	hour that you charge to work on this case, you're also
5	early hours. And so I'm having to go find my notes on	5	reimbursed for travel and other costs associated with this
6	those, and I haven't found them yet.	6	case?
7	Q. And what are you charging per hour?	7	A. Only for testimony.
8	A. \$500 an hour.	8	Q. Okay.
9	Q. So 24 hours with attorneys, an estimate?	9	A. There's no other yeah, only for testimony.
10	A. Yes.	10	Q. So \$500 an hour to review records and medical
11	Q. Fifty to 60 hours looking at medical literature,	11	literature, correct?
12	correct?	12	A. Yes.
13	A. Correct, minimum. Perhaps a little bit more,	13	Q. \$500 an hour to meet with attorneys and discuss
14	correct.	14	the case?
15	Q. How about review of medical records?	15	A. Yes.
16	A. That's included.	16	Q. And then a separate fee for trial testimony,
17	Q. Okay. So 80ish around 80 hours thus far	17	correct?
18	you've spent working on this case?	18	A. Yes.
19	A. Yes, minimum.	19	Q. And then reimbursement of travel expenses, for
20	Q. A minimum of 80 hours so far you've spent working	20	example, to trial and if you are called to testify?
21	on this case?	21	A. Correct.
22	A. Yes.	22	Q. Okay. Does that represent the total universe of
23	Q. At \$500 an hour?	23	the fees that you'll be charging in this case?
24	A. Correct.	24	A. Yes.
25	Q. So we can take your per hour fee, times it times	25	Q. Doctor, do you have a field of specialty inside
1	Page 71 the estimated hours you've spent on this case and get an	1	Page 73 of the field of pathology?
2	estimate of the total fees you will collect in this case?	2	A. Yes.
3	A. Well, that I will bill for them.	3	Q. What is that area of specialty?
4	Q. Okay.		
		4	A. Broadly speaking it's surgical pathology, but
5	A. Yes.	4 5	
5 6	- ·		A. Broadly speaking it's surgical pathology, but
	A. Yes.	5	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic
6	A. Yes. Q. Will you be charging \$500 an hour for your	5 6	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.
6 7	A. Yes. Q. Will you be charging \$500 an hour for your deposition testimony?	5 6 7	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.     Q. Do you have a major emphasis in a particular area
6 7 8	<ul><li>A. Yes.</li><li>Q. Will you be charging \$500 an hour for your deposition testimony?</li><li>A. Yes.</li></ul>	5 6 7 8	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.     Q. Do you have a major emphasis in a particular area related to cancer?
6 7 8 9	<ul> <li>A. Yes.</li> <li>Q. Will you be charging \$500 an hour for your deposition testimony?</li> <li>A. Yes.</li> <li>Q. Do you have a different fee for trial testimony?</li> <li>A. I believe I do, and I do not recall that right now.</li> </ul>	5 6 7 8 9	<ul> <li>A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.</li> <li>Q. Do you have a major emphasis in a particular area related to cancer?</li> <li>A. Most of my research is centered around GYN or GI</li> </ul>
6 7 8 9 10	<ul> <li>A. Yes.</li> <li>Q. Will you be charging \$500 an hour for your deposition testimony?</li> <li>A. Yes.</li> <li>Q. Do you have a different fee for trial testimony?</li> <li>A. I believe I do, and I do not recall that right now.</li> <li>Q. Okay.</li> </ul>	5 6 7 8 9	<ul> <li>A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.</li> <li>Q. Do you have a major emphasis in a particular area related to cancer?</li> <li>A. Most of my research is centered around GYN or GI cancer, yes.</li> </ul>
6 7 8 9 10 11	<ul> <li>A. Yes.</li> <li>Q. Will you be charging \$500 an hour for your deposition testimony?</li> <li>A. Yes.</li> <li>Q. Do you have a different fee for trial testimony?</li> <li>A. I believe I do, and I do not recall that right now.</li> </ul>	5 6 7 8 9 10 11	<ul> <li>A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.</li> <li>Q. Do you have a major emphasis in a particular area related to cancer?</li> <li>A. Most of my research is centered around GYN or GI cancer, yes.</li> <li>Q. Okay. Do you hold yourself out on a Stanford</li> </ul>
6 7 8 9 10 11 12	<ul> <li>A. Yes.</li> <li>Q. Will you be charging \$500 an hour for your deposition testimony?</li> <li>A. Yes.</li> <li>Q. Do you have a different fee for trial testimony?</li> <li>A. I believe I do, and I do not recall that right now.</li> <li>Q. Okay.</li> <li>A. My AA has that.</li> <li>Q. That's something you'd be willing to provide,</li> </ul>	5 6 7 8 9 10 11	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.  Q. Do you have a major emphasis in a particular area related to cancer?  A. Most of my research is centered around GYN or GI cancer, yes.  Q. Okay. Do you hold yourself out on a Stanford website to have a major emphasis in ovarian cancer and ovarian tumors?  A. Yes.
6 7 8 9 10 11 12 13 14 15	<ul> <li>A. Yes.</li> <li>Q. Will you be charging \$500 an hour for your deposition testimony?</li> <li>A. Yes.</li> <li>Q. Do you have a different fee for trial testimony?</li> <li>A. I believe I do, and I do not recall that right now.</li> <li>Q. Okay.</li> <li>A. My AA has that.</li> <li>Q. That's something you'd be willing to provide, though?</li> </ul>	5 6 7 8 9 10 11 12	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.  Q. Do you have a major emphasis in a particular area related to cancer?  A. Most of my research is centered around GYN or GI cancer, yes.  Q. Okay. Do you hold yourself out on a Stanford website to have a major emphasis in ovarian cancer and ovarian tumors?
6 7 8 9 10 11 12 13 14 15 16	<ul> <li>A. Yes.</li> <li>Q. Will you be charging \$500 an hour for your deposition testimony?</li> <li>A. Yes.</li> <li>Q. Do you have a different fee for trial testimony?</li> <li>A. I believe I do, and I do not recall that right now.</li> <li>Q. Okay.</li> <li>A. My AA has that.</li> <li>Q. That's something you'd be willing to provide, though?</li> <li>A. Absolutely, yes. And I really should have</li> </ul>	5 6 7 8 9 10 11 12 13 14 15	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.  Q. Do you have a major emphasis in a particular area related to cancer?  A. Most of my research is centered around GYN or GI cancer, yes.  Q. Okay. Do you hold yourself out on a Stanford website to have a major emphasis in ovarian cancer and ovarian tumors?  A. Yes.  Q. Okay. Most of your research in fact, close to all of your research is related to cancer, correct?
6 7 8 9 10 11 12 13 14 15 16	A. Yes. Q. Will you be charging \$500 an hour for your deposition testimony? A. Yes. Q. Do you have a different fee for trial testimony? A. I believe I do, and I do not recall that right now. Q. Okay. A. My AA has that. Q. That's something you'd be willing to provide, though? A. Absolutely, yes. And I really should have brought it, but I forgot. I knew you would ask that.	5 6 7 8 9 10 11 12 13 14	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.  Q. Do you have a major emphasis in a particular area related to cancer?  A. Most of my research is centered around GYN or GI cancer, yes.  Q. Okay. Do you hold yourself out on a Stanford website to have a major emphasis in ovarian cancer and ovarian tumors?  A. Yes.  Q. Okay. Most of your research in fact, close to all of your research is related to cancer, correct?  MR. WES: Object to form.
6 7 8 9 10 11 12 13 14 15 16 17	A. Yes. Q. Will you be charging \$500 an hour for your deposition testimony? A. Yes. Q. Do you have a different fee for trial testimony? A. I believe I do, and I do not recall that right now. Q. Okay. A. My AA has that. Q. That's something you'd be willing to provide, though? A. Absolutely, yes. And I really should have brought it, but I forgot. I knew you would ask that. Q. Sometime prior to trial	5 6 7 8 9 10 11 12 13 14 15 16 17	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.  Q. Do you have a major emphasis in a particular area related to cancer?  A. Most of my research is centered around GYN or GI cancer, yes.  Q. Okay. Do you hold yourself out on a Stanford website to have a major emphasis in ovarian cancer and ovarian tumors?  A. Yes.  Q. Okay. Most of your research in fact, close to all of your research is related to cancer, correct?  MR. WES: Object to form.  THE WITNESS: Not all not all of it.
6 7 8 9 10 11 12 13 14 15 16 17 18	A. Yes. Q. Will you be charging \$500 an hour for your deposition testimony? A. Yes. Q. Do you have a different fee for trial testimony? A. I believe I do, and I do not recall that right now. Q. Okay. A. My AA has that. Q. That's something you'd be willing to provide, though? A. Absolutely, yes. And I really should have brought it, but I forgot. I knew you would ask that. Q. Sometime prior to trial A. Definitely.	5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.  Q. Do you have a major emphasis in a particular area related to cancer?  A. Most of my research is centered around GYN or GI cancer, yes.  Q. Okay. Do you hold yourself out on a Stanford website to have a major emphasis in ovarian cancer and ovarian tumors?  A. Yes.  Q. Okay. Most of your research in fact, close to all of your research is related to cancer, correct?  MR. WES: Object to form.  THE WITNESS: Not all not all of it.  MR. JONES: Q. The majority of your research is
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Yes. Q. Will you be charging \$500 an hour for your deposition testimony? A. Yes. Q. Do you have a different fee for trial testimony? A. I believe I do, and I do not recall that right now. Q. Okay. A. My AA has that. Q. That's something you'd be willing to provide, though? A. Absolutely, yes. And I really should have brought it, but I forgot. I knew you would ask that. Q. Sometime prior to trial A. Definitely. Q we'll get a copy of that, though.	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.  Q. Do you have a major emphasis in a particular area related to cancer?  A. Most of my research is centered around GYN or GI cancer, yes.  Q. Okay. Do you hold yourself out on a Stanford website to have a major emphasis in ovarian cancer and ovarian tumors?  A. Yes.  Q. Okay. Most of your research in fact, close to all of your research is related to cancer, correct?  MR. WES: Object to form.  THE WITNESS: Not all not all of it.  MR. JONES: Q. The majority of your research is related to cancer, correct?
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Yes. Q. Will you be charging \$500 an hour for your deposition testimony? A. Yes. Q. Do you have a different fee for trial testimony? A. I believe I do, and I do not recall that right now. Q. Okay. A. My AA has that. Q. That's something you'd be willing to provide, though? A. Absolutely, yes. And I really should have brought it, but I forgot. I knew you would ask that. Q. Sometime prior to trial A. Definitely. Q we'll get a copy of that, though. Is it more or less than \$500 an hour?	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.  Q. Do you have a major emphasis in a particular area related to cancer?  A. Most of my research is centered around GYN or GI cancer, yes.  Q. Okay. Do you hold yourself out on a Stanford website to have a major emphasis in ovarian cancer and ovarian tumors?  A. Yes.  Q. Okay. Most of your research in fact, close to all of your research is related to cancer, correct?  MR. WES: Object to form.  THE WITNESS: Not all not all of it.  MR. JONES: Q. The majority of your research is related to cancer, correct?  MR. WES: Same objection.
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Yes. Q. Will you be charging \$500 an hour for your deposition testimony? A. Yes. Q. Do you have a different fee for trial testimony? A. I believe I do, and I do not recall that right now. Q. Okay. A. My AA has that. Q. That's something you'd be willing to provide, though? A. Absolutely, yes. And I really should have brought it, but I forgot. I knew you would ask that. Q. Sometime prior to trial A. Definitely. Q we'll get a copy of that, though. Is it more or less than \$500 an hour? A. Well, I think it includes travel time. I really	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.  Q. Do you have a major emphasis in a particular area related to cancer?  A. Most of my research is centered around GYN or GI cancer, yes.  Q. Okay. Do you hold yourself out on a Stanford website to have a major emphasis in ovarian cancer and ovarian tumors?  A. Yes.  Q. Okay. Most of your research in fact, close to all of your research is related to cancer, correct?  MR. WES: Object to form.  THE WITNESS: Not all not all of it.  MR. JONES: Q. The majority of your research is related to cancer, correct?  MR. WES: Same objection.  THE WITNESS: A substantial amount of my research
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Yes. Q. Will you be charging \$500 an hour for your deposition testimony? A. Yes. Q. Do you have a different fee for trial testimony? A. I believe I do, and I do not recall that right now. Q. Okay. A. My AA has that. Q. That's something you'd be willing to provide, though? A. Absolutely, yes. And I really should have brought it, but I forgot. I knew you would ask that. Q. Sometime prior to trial A. Definitely. Q we'll get a copy of that, though. Is it more or less than \$500 an hour? A. Well, I think it includes travel time. I really don't recall.	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.  Q. Do you have a major emphasis in a particular area related to cancer?  A. Most of my research is centered around GYN or GI cancer, yes.  Q. Okay. Do you hold yourself out on a Stanford website to have a major emphasis in ovarian cancer and ovarian tumors?  A. Yes.  Q. Okay. Most of your research in fact, close to all of your research is related to cancer, correct?  MR. WES: Object to form.  THE WITNESS: Not all not all of it.  MR. JONES: Q. The majority of your research is related to cancer, correct?  MR. WES: Same objection.  THE WITNESS: A substantial amount of my research is related to cancer.
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	A. Yes. Q. Will you be charging \$500 an hour for your deposition testimony? A. Yes. Q. Do you have a different fee for trial testimony? A. I believe I do, and I do not recall that right now. Q. Okay. A. My AA has that. Q. That's something you'd be willing to provide, though? A. Absolutely, yes. And I really should have brought it, but I forgot. I knew you would ask that. Q. Sometime prior to trial A. Definitely. Q we'll get a copy of that, though. Is it more or less than \$500 an hour? A. Well, I think it includes travel time. I really don't recall. Q. You don't have any recall of whether it's more or	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.  Q. Do you have a major emphasis in a particular area related to cancer?  A. Most of my research is centered around GYN or GI cancer, yes.  Q. Okay. Do you hold yourself out on a Stanford website to have a major emphasis in ovarian cancer and ovarian tumors?  A. Yes.  Q. Okay. Most of your research in fact, close to all of your research is related to cancer, correct?  MR. WES: Object to form.  THE WITNESS: Not all not all of it.  MR. JONES: Q. The majority of your research is related to cancer, correct?  MR. WES: Same objection.  THE WITNESS: A substantial amount of my research is related to cancer.  MR. JONES: Q. Have you ever published an
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Yes. Q. Will you be charging \$500 an hour for your deposition testimony? A. Yes. Q. Do you have a different fee for trial testimony? A. I believe I do, and I do not recall that right now. Q. Okay. A. My AA has that. Q. That's something you'd be willing to provide, though? A. Absolutely, yes. And I really should have brought it, but I forgot. I knew you would ask that. Q. Sometime prior to trial A. Definitely. Q we'll get a copy of that, though. Is it more or less than \$500 an hour? A. Well, I think it includes travel time. I really don't recall.	5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Broadly speaking it's surgical pathology, but within the realm of surgical pathology, I'm a gynecologic pathology and GI pathology subspecialist.  Q. Do you have a major emphasis in a particular area related to cancer?  A. Most of my research is centered around GYN or GI cancer, yes.  Q. Okay. Do you hold yourself out on a Stanford website to have a major emphasis in ovarian cancer and ovarian tumors?  A. Yes.  Q. Okay. Most of your research in fact, close to all of your research is related to cancer, correct?  MR. WES: Object to form.  THE WITNESS: Not all not all of it.  MR. JONES: Q. The majority of your research is related to cancer, correct?  MR. WES: Same objection.  THE WITNESS: A substantial amount of my research is related to cancer.

19 (Pages 70 to 73)

	Page 74		Page 76
1	A. No.	1	asking me was there a formal seminar or meeting to discuss
2	Q. Have you ever published an article related to	2	these?
3	stress urinary incontinence?	3	MR. JONES: Q. I'll break it down. First I'll
4	A. No.	4	ask you related to formal seminars or meetings.
5	Q. Have you ever published an article related to	5	A. No.
6	pelvic mesh?	6	Q. Informal discussions?
7	A. No.	7	A. None that I'm aware of.
8	Q. So your area of specialty is not pelvic mesh,	8	Q. Okay. So since 1996 as a member of the
9	correct?	9	International Society of Gynecological Pathologists, you
10	MR. WES: Object to form.	10	have no recall whether in formal meetings or informal
11	THE WITNESS: That's correct. I am not a pelvic	11	conversations of complications resulting from transvaginal
12	mesh product expert	12	mesh?
13	MR. JONES: Q. Okay.	13	MR. WES: Object to form.
14	A or focused on that in research.	14	THE WITNESS: That's correct.
15	Q. Have you published any articles on mesh	15	MR. JONES: Q. Would that hold true for these
16	complications?	16	other societies that you're a member of?
17	A. No.	17	MR. WES: Object to form.
18	Q. Have you taught any courses related to	18	THE WITNESS: Again, there's no I'm not aware
19	polypropylene?	19	of any discussions. I don't go to all these meetings.
20	A. No.	20	There may have been one that occurred, but nothing that
21	Q. Made any presentations related to polypropylene?	21	I'm aware of or attended or even recall being posted that
22	A. No.	22	one would be there would be one.
23	Q. Taught any courses related to pelvic mesh?	23	MR. JONES: Q. If you turn to page 4 under
24	A. No.	24	"Editorial Board," you've listed several journals that you
25	Q. Made any presentations related to pelvic mesh?	25	serve on the Editorial Board for; is that correct?
	Page 75		
			Page 77
1	A. No.	1	A. Yes.
2	<ul><li>A. No.</li><li>Q. Have you reviewed any material safety data sheets</li></ul>	2	<ul><li>A. Yes.</li><li>Q. Since 1996 you've served on the Editorial Board</li></ul>
2 3	A. No. Q. Have you reviewed any material safety data sheets in this case?	2	<ul><li>A. Yes.</li><li>Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology?</li></ul>
2 3 4	<ul><li>A. No.</li><li>Q. Have you reviewed any material safety data sheets in this case?</li><li>A. What are I may have. I'm not sure what a</li></ul>	2 3 4	<ul><li>A. Yes.</li><li>Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology?</li><li>A. Yes.</li></ul>
2 3 4 5	<ul> <li>A. No.</li> <li>Q. Have you reviewed any material safety data sheets in this case?</li> <li>A. What are I may have. I'm not sure what a material safety data sheet is.</li> </ul>	2 3 4 5	<ul> <li>A. Yes.</li> <li>Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology?</li> <li>A. Yes.</li> <li>Q. Do you have any recall of ever seeing a single</li> </ul>
2 3 4 5 6	<ul> <li>A. No.</li> <li>Q. Have you reviewed any material safety data sheets in this case?</li> <li>A. What are I may have. I'm not sure what a material safety data sheet is.</li> <li>Q. Okay.</li> </ul>	2 3 4 5 6	<ul> <li>A. Yes.</li> <li>Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology?</li> <li>A. Yes.</li> <li>Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an</li> </ul>
2 3 4 5 6 7	<ul> <li>A. No.</li> <li>Q. Have you reviewed any material safety data sheets in this case?</li> <li>A. What are I may have. I'm not sure what a material safety data sheet is.</li> <li>Q. Okay.</li> <li>MR. JONES: I'm going to mark as Exhibit L-8 a</li> </ul>	2 3 4 5 6 7	<ul> <li>A. Yes.</li> <li>Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology?</li> <li>A. Yes.</li> <li>Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological</li> </ul>
2 3 4 5 6 7 8	<ul> <li>A. No.</li> <li>Q. Have you reviewed any material safety data sheets in this case?</li> <li>A. What are I may have. I'm not sure what a material safety data sheet is.</li> <li>Q. Okay.</li> <li>MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you.</li> </ul>	2 3 4 5 6 7 8	<ul> <li>A. Yes.</li> <li>Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology?</li> <li>A. Yes.</li> <li>Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?</li> </ul>
2 3 4 5 6 7 8 9	<ul> <li>A. No.</li> <li>Q. Have you reviewed any material safety data sheets in this case?</li> <li>A. What are I may have. I'm not sure what a material safety data sheet is.</li> <li>Q. Okay.</li> <li>MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you.</li> <li>(Whereupon, Exhibit L-8 was marked for</li> </ul>	2 3 4 5 6 7 8 9	<ul> <li>A. Yes.</li> <li>Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology?</li> <li>A. Yes.</li> <li>Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?</li> <li>MR. WES: Object to form.</li> </ul>
2 3 4 5 6 7 8 9	<ul> <li>A. No.</li> <li>Q. Have you reviewed any material safety data sheets in this case?</li> <li>A. What are I may have. I'm not sure what a material safety data sheet is.</li> <li>Q. Okay.</li> <li>MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you.</li> <li>(Whereupon, Exhibit L-8 was marked for identification.)</li> </ul>	2 3 4 5 6 7 8 9	<ul> <li>A. Yes.</li> <li>Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology?</li> <li>A. Yes.</li> <li>Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?</li> <li>MR. WES: Object to form.</li> <li>THE WITNESS: No, I've never reviewed an article</li> </ul>
2 3 4 5 6 7 8 9 10	<ul> <li>A. No.</li> <li>Q. Have you reviewed any material safety data sheets in this case?</li> <li>A. What are I may have. I'm not sure what a material safety data sheet is.</li> <li>Q. Okay.</li> <li>MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you. (Whereupon, Exhibit L-8 was marked for identification.) MR. JONES: Q. I just have a few questions about</li> </ul>	2 3 4 5 6 7 8 9 10	<ul> <li>A. Yes.</li> <li>Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology?</li> <li>A. Yes.</li> <li>Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?</li> <li>MR. WES: Object to form.</li> <li>THE WITNESS: No, I've never reviewed an article on that.</li> </ul>
2 3 4 5 6 7 8 9 10 11	A. No. Q. Have you reviewed any material safety data sheets in this case? A. What are I may have. I'm not sure what a material safety data sheet is. Q. Okay. MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you. (Whereupon, Exhibit L-8 was marked for identification.) MR. JONES: Q. I just have a few questions about your CV. Under professional memberships, page 2, you've	2 3 4 5 6 7 8 9 10 11 12	<ul> <li>A. Yes.</li> <li>Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology?</li> <li>A. Yes.</li> <li>Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?</li> <li>MR. WES: Object to form.</li> <li>THE WITNESS: No, I've never reviewed an article on that.</li> <li>MR. JONES: Q. Have you ever reviewed an article</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13	<ul> <li>A. No.</li> <li>Q. Have you reviewed any material safety data sheets in this case?</li> <li>A. What are I may have. I'm not sure what a material safety data sheet is.</li> <li>Q. Okay.</li> <li>MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you.  (Whereupon, Exhibit L-8 was marked for identification.)</li> <li>MR. JONES: Q. I just have a few questions about your CV. Under professional memberships, page 2, you've been a member of the International Society of</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13	<ul> <li>A. Yes.</li> <li>Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology?</li> <li>A. Yes.</li> <li>Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?</li> <li>MR. WES: Object to form.</li> <li>THE WITNESS: No, I've never reviewed an article on that.</li> <li>MR. JONES: Q. Have you ever reviewed an article on mesh complications?</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13 14	<ul> <li>A. No.</li> <li>Q. Have you reviewed any material safety data sheets in this case?</li> <li>A. What are I may have. I'm not sure what a material safety data sheet is.</li> <li>Q. Okay.</li> <li>MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you. (Whereupon, Exhibit L-8 was marked for identification.) MR. JONES: Q. I just have a few questions about your CV. Under professional memberships, page 2, you've been a member of the International Society of Gynecological Pathologists since 1996, correct?</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14	A. Yes. Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology? A. Yes. Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?  MR. WES: Object to form.  THE WITNESS: No, I've never reviewed an article on that.  MR. JONES: Q. Have you ever reviewed an article on mesh complications? A. For publication?
2 3 4 5 6 7 8 9 10 11 12 13 14 15	<ul> <li>A. No.</li> <li>Q. Have you reviewed any material safety data sheets in this case?</li> <li>A. What are I may have. I'm not sure what a material safety data sheet is.</li> <li>Q. Okay.</li> <li>MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you. (Whereupon, Exhibit L-8 was marked for identification.) MR. JONES: Q. I just have a few questions about your CV. Under professional memberships, page 2, you've been a member of the International Society of Gynecological Pathologists since 1996, correct? A. Correct.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14	A. Yes. Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology? A. Yes. Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?  MR. WES: Object to form.  THE WITNESS: No, I've never reviewed an article on that.  MR. JONES: Q. Have you ever reviewed an article on mesh complications? A. For publication? Q. (Nods head.)
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. No. Q. Have you reviewed any material safety data sheets in this case? A. What are I may have. I'm not sure what a material safety data sheet is. Q. Okay. MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you. (Whereupon, Exhibit L-8 was marked for identification.) MR. JONES: Q. I just have a few questions about your CV. Under professional memberships, page 2, you've been a member of the International Society of Gynecological Pathologists since 1996, correct? A. Correct. Q. Since you've been a member of that organization	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Yes. Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology? A. Yes. Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?  MR. WES: Object to form.  THE WITNESS: No, I've never reviewed an article on that.  MR. JONES: Q. Have you ever reviewed an article on mesh complications? A. For publication? Q. (Nods head.) A. No.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. No. Q. Have you reviewed any material safety data sheets in this case? A. What are I may have. I'm not sure what a material safety data sheet is. Q. Okay. MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you. (Whereupon, Exhibit L-8 was marked for identification.) MR. JONES: Q. I just have a few questions about your CV. Under professional memberships, page 2, you've been a member of the International Society of Gynecological Pathologists since 1996, correct? A. Correct. Q. Since you've been a member of that organization since 1996, has there ever been a discussion of	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Yes. Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology? A. Yes. Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?  MR. WES: Object to form.  THE WITNESS: No, I've never reviewed an article on that.  MR. JONES: Q. Have you ever reviewed an article on mesh complications? A. For publication? Q. (Nods head.) A. No. Q. In your role as an editor on these journals, have
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. No. Q. Have you reviewed any material safety data sheets in this case? A. What are I may have. I'm not sure what a material safety data sheet is. Q. Okay. MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you. (Whereupon, Exhibit L-8 was marked for identification.) MR. JONES: Q. I just have a few questions about your CV. Under professional memberships, page 2, you've been a member of the International Society of Gynecological Pathologists since 1996, correct? A. Correct. Q. Since you've been a member of that organization since 1996, has there ever been a discussion of polypropylene mesh used in mid I'll rephrase the	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Yes. Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology? A. Yes. Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology? MR. WES: Object to form. THE WITNESS: No, I've never reviewed an article on that. MR. JONES: Q. Have you ever reviewed an article on mesh complications? A. For publication? Q. (Nods head.) A. No. Q. In your role as an editor on these journals, have you ever reviewed an article related to polypropylene?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. No. Q. Have you reviewed any material safety data sheets in this case? A. What are I may have. I'm not sure what a material safety data sheet is. Q. Okay. MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you. (Whereupon, Exhibit L-8 was marked for identification.) MR. JONES: Q. I just have a few questions about your CV. Under professional memberships, page 2, you've been a member of the International Society of Gynecological Pathologists since 1996, correct? A. Correct. Q. Since you've been a member of that organization since 1996, has there ever been a discussion of polypropylene mesh used in mid I'll rephrase the question.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Yes. Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology? A. Yes. Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?  MR. WES: Object to form.  THE WITNESS: No, I've never reviewed an article on that.  MR. JONES: Q. Have you ever reviewed an article on mesh complications? A. For publication? Q. (Nods head.) A. No. Q. In your role as an editor on these journals, have you ever reviewed an article related to polypropylene? A. No, or at least not that I remember.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. No. Q. Have you reviewed any material safety data sheets in this case? A. What are I may have. I'm not sure what a material safety data sheet is. Q. Okay. MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you. (Whereupon, Exhibit L-8 was marked for identification.) MR. JONES: Q. I just have a few questions about your CV. Under professional memberships, page 2, you've been a member of the International Society of Gynecological Pathologists since 1996, correct? A. Correct. Q. Since you've been a member of that organization since 1996, has there ever been a discussion of polypropylene mesh used in mid I'll rephrase the question. Since you've been a member of the International	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Yes. Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology? A. Yes. Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?  MR. WES: Object to form.  THE WITNESS: No, I've never reviewed an article on that.  MR. JONES: Q. Have you ever reviewed an article on mesh complications? A. For publication? Q. (Nods head.) A. No. Q. In your role as an editor on these journals, have you ever reviewed an article related to polypropylene? A. No, or at least not that I remember. Q. Okay. Then you have Journal Ad Hoc Reviewers,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. No. Q. Have you reviewed any material safety data sheets in this case? A. What are I may have. I'm not sure what a material safety data sheet is. Q. Okay. MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you. (Whereupon, Exhibit L-8 was marked for identification.) MR. JONES: Q. I just have a few questions about your CV. Under professional memberships, page 2, you've been a member of the International Society of Gynecological Pathologists since 1996, correct? A. Correct. Q. Since you've been a member of that organization since 1996, has there ever been a discussion of polypropylene mesh used in mid I'll rephrase the question. Since you've been a member of the International Society of Gynecological Pathologists, has there ever been	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Yes. Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology? A. Yes. Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?  MR. WES: Object to form.  THE WITNESS: No, I've never reviewed an article on that.  MR. JONES: Q. Have you ever reviewed an article on mesh complications? A. For publication? Q. (Nods head.) A. No. Q. In your role as an editor on these journals, have you ever reviewed an article related to polypropylene? A. No, or at least not that I remember. Q. Okay. Then you have Journal Ad Hoc Reviewers, and you have listed the American Journal of Obstetrics and
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. No. Q. Have you reviewed any material safety data sheets in this case? A. What are I may have. I'm not sure what a material safety data sheet is. Q. Okay. MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you. (Whereupon, Exhibit L-8 was marked for identification.) MR. JONES: Q. I just have a few questions about your CV. Under professional memberships, page 2, you've been a member of the International Society of Gynecological Pathologists since 1996, correct? A. Correct. Q. Since you've been a member of that organization since 1996, has there ever been a discussion of polypropylene mesh used in mid I'll rephrase the question. Since you've been a member of the International Society of Gynecological Pathologists, has there ever been a discussion of complications resulting from transvaginal	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Yes. Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology? A. Yes. Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?  MR. WES: Object to form.  THE WITNESS: No, I've never reviewed an article on that.  MR. JONES: Q. Have you ever reviewed an article on mesh complications? A. For publication? Q. (Nods head.) A. No. Q. In your role as an editor on these journals, have you ever reviewed an article related to polypropylene? A. No, or at least not that I remember. Q. Okay. Then you have Journal Ad Hoc Reviewers, and you have listed the American Journal of Obstetrics and Gynecology, correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. No. Q. Have you reviewed any material safety data sheets in this case? A. What are I may have. I'm not sure what a material safety data sheet is. Q. Okay. MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you. (Whereupon, Exhibit L-8 was marked for identification.) MR. JONES: Q. I just have a few questions about your CV. Under professional memberships, page 2, you've been a member of the International Society of Gynecological Pathologists since 1996, correct? A. Correct. Q. Since you've been a member of that organization since 1996, has there ever been a discussion of polypropylene mesh used in mid I'll rephrase the question. Since you've been a member of the International Society of Gynecological Pathologists, has there ever been a discussion of complications resulting from transvaginal mesh?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Yes. Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology? A. Yes. Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?  MR. WES: Object to form.  THE WITNESS: No, I've never reviewed an article on that.  MR. JONES: Q. Have you ever reviewed an article on mesh complications? A. For publication? Q. (Nods head.) A. No. Q. In your role as an editor on these journals, have you ever reviewed an article related to polypropylene? A. No, or at least not that I remember. Q. Okay. Then you have Journal Ad Hoc Reviewers, and you have listed the American Journal of Obstetrics and Gynecology, correct? A. Correct.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. No. Q. Have you reviewed any material safety data sheets in this case? A. What are I may have. I'm not sure what a material safety data sheet is. Q. Okay. MR. JONES: I'm going to mark as Exhibit L-8 a copy of your CV, which I will give you. (Whereupon, Exhibit L-8 was marked for identification.) MR. JONES: Q. I just have a few questions about your CV. Under professional memberships, page 2, you've been a member of the International Society of Gynecological Pathologists since 1996, correct? A. Correct. Q. Since you've been a member of that organization since 1996, has there ever been a discussion of polypropylene mesh used in mid I'll rephrase the question. Since you've been a member of the International Society of Gynecological Pathologists, has there ever been a discussion of complications resulting from transvaginal	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Yes. Q. Since 1996 you've served on the Editorial Board of the International Journal of Gynecological Pathology? A. Yes. Q. Do you have any recall of ever seeing a single article related to mesh complications in your role as an editor on the International Journal of Gynecological Pathology?  MR. WES: Object to form.  THE WITNESS: No, I've never reviewed an article on that.  MR. JONES: Q. Have you ever reviewed an article on mesh complications? A. For publication? Q. (Nods head.) A. No. Q. In your role as an editor on these journals, have you ever reviewed an article related to polypropylene? A. No, or at least not that I remember. Q. Okay. Then you have Journal Ad Hoc Reviewers, and you have listed the American Journal of Obstetrics and Gynecology, correct?

	Page 78		Page 80
1	A. Correct.	1	Q. Have you taught any courses related to
2	Q. Have you ever reviewed any articles related to	2	polypropylene ever?
3	polypropylene?	3	A. No.
4	A. Not that I'm aware of.	4	Q. Have you ever taught any courses related to
5	Q. Have you ever reviewed any articles related to	5	transvaginal mesh?
6	transvaginal mesh?	6	A. No.
7	A. Not that I'm aware of, no.	7	Q. Okay. On a copy of your CV that I have, it's
8	Q. Have you ever reviewed any articles related to	8	page 26, you've listed quite a few articles where you have
9	mesh complications?	9	been an author, correct?
10	A. No.	10	A. Correct.
11	Q. If you go to page 8. You've listed courses that	11	Q. And I have it as number 71. The title of the
12	you've taught, correct?	12	article is "Ovarian Carcinosarcomas Associated with
13	A. Correct.	13	Prolonged use of Tamoxifen."
14	Q. And at the very bottom there's a course with the	14	A. Correct.
15	date 2013 called "Human Health and Disease," correct?	15	Q. Do you have and that was published in 2009?
16	A. Correct.	16	A. Correct.
17	Q. And that's within the gynecologic pathology	17	Q. Do you have a recall of the subject matter of
18	field, correct?	18	that article?
19	A. Yes. I'm not seeing where you're referring to,	19	A. I think it was a report of some ovarian
20	but yes.	20	carcinosarcomas that occurred in patients who had been
21	Q. Okay. Page 8.	21	using Tamoxifen basically.
22	MR. WES: Is this the version of the CV that we	22	Q. And what is Tamoxifen?
23	just gave you, or is this a different version?	23	A. It's a it's a hormonal really more agonist,
24	MR. JONES: Could be a different version.	24	slash, antagonist for estrogen that's being treated
25	THE WITNESS: Must be.	25	women with breast cancer are treated with.
	Page 79		Page 81
1			
1	MR. WES: Because I think what we gave you was	1	Q. Is it a drug that's been cleared by the FDA?
2	MR. WES: Because I think what we gave you was the most up-to-date CV.	1 2	<ul><li>Q. Is it a drug that's been cleared by the FDA?</li><li>A. Yes.</li></ul>
	the most up-to-date CV.		
2	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV	2	A. Yes.
2	the most up-to-date CV.	2	<ul><li>A. Yes.</li><li>Q. It's been on the market for 40 years,</li></ul>
2 3 4	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've	2 3 4	A. Yes. Q. It's been on the market for 40 years, thereabout?
2 3 4 5	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?	2 3 4 5	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation.
2 3 4 5 6	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes.  Q. And you've listed a course for 2013 called "Human	2 3 4 5 6	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a
2 3 4 5 6 7	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes.	2 3 4 5 6 7	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while.
2 3 4 5 6 7 8	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes.  Q. And you've listed a course for 2013 called "Human Health and Disease," correct?	2 3 4 5 6 7 8	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did
2 3 4 5 6 7 8 9	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes.  Q. And you've listed a course for 2013 called "Human Health and Disease," correct?  A. Yes.	2 3 4 5 6 7 8 9	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian
2 3 4 5 6 7 8 9	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct?  A. Yes. Q. Within the gynecologic pathology	2 3 4 5 6 7 8 9	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas?
2 3 4 5 6 7 8 9 10	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct?  A. Yes. Q. Within the gynecologic pathology A. Yes.	2 3 4 5 6 7 8 9 10	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas? A. There was possible association between ovarian
2 3 4 5 6 7 8 9 10 11	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct?  A. Yes. Q. Within the gynecologic pathology A. Yes. Q correct?	2 3 4 5 6 7 8 9 10 11	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas? A. There was possible association between ovarian carcinosarcomas and Tamoxifen. And that was what he was
2 3 4 5 6 7 8 9 10 11 12 13	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct?  A. Yes. Q. Within the gynecologic pathology A. Yes. Q correct? A. Yes.	2 3 4 5 6 7 8 9 10 11 12 13	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas? A. There was possible association between ovarian carcinosarcomas and Tamoxifen. And that was what he was reporting, the first author, Oscar Lavie.
2 3 4 5 6 7 8 9 10 11 12 13 14	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct?  A. Yes. Q. Within the gynecologic pathology A. Yes. Q correct? A. Yes. Q. What did that course entail?	2 3 4 5 6 7 8 9 10 11 12 13 14	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas? A. There was possible association between ovarian carcinosarcomas and Tamoxifen. And that was what he was reporting, the first author, Oscar Lavie. Q. Okay. Did you also was there also a finding
2 3 4 5 6 7 8 9 10 11 12 13 14 15	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct?  A. Yes. Q. Within the gynecologic pathology A. Yes. Q correct? A. Yes. Q correct? A. Yes. Q. What did that course entail? A. Oh, this is a medical student course, so it's	2 3 4 5 6 7 8 9 10 11 12 13 14	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas? A. There was possible association between ovarian carcinosarcomas and Tamoxifen. And that was what he was reporting, the first author, Oscar Lavie. Q. Okay. Did you also was there also a finding that in that article that it was a delayed response to the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct? A. Yes. Q. Within the gynecologic pathology A. Yes. Q correct? A. Yes. Q correct? A. Yes. Q. What did that course entail? A. Oh, this is a medical student course, so it's about basic endometrial basic uterine service and	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas? A. There was possible association between ovarian carcinosarcomas and Tamoxifen. And that was what he was reporting, the first author, Oscar Lavie. Q. Okay. Did you also was there also a finding that in that article that it was a delayed response to the Tamoxifen?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct? A. Yes. Q. Within the gynecologic pathology A. Yes. Q correct? A. Yes. Q. what did that course entail? A. Oh, this is a medical student course, so it's about basic endometrial basic uterine service and vulvar and vaginal pathology.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas? A. There was possible association between ovarian carcinosarcomas and Tamoxifen. And that was what he was reporting, the first author, Oscar Lavie. Q. Okay. Did you also was there also a finding that in that article that it was a delayed response to the Tamoxifen? A. I don't know that it's a a delayed occurrence.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct?  A. Yes. Q. Within the gynecologic pathology A. Yes. Q correct? A. Yes. Q. what did that course entail? A. Oh, this is a medical student course, so it's about basic endometrial basic uterine service and vulvar and vaginal pathology. Q. Okay.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas? A. There was possible association between ovarian carcinosarcomas and Tamoxifen. And that was what he was reporting, the first author, Oscar Lavie. Q. Okay. Did you also was there also a finding that in that article that it was a delayed response to the Tamoxifen? A. I don't know that it's a a delayed occurrence. And actually probably not even delayed. I mean, it's
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct? A. Yes. Q. Within the gynecologic pathology A. Yes. Q correct? A. Yes. Q correct? A. Yes. Q. What did that course entail? A. Oh, this is a medical student course, so it's about basic endometrial basic uterine service and vulvar and vaginal pathology. Q. Okay. A. That's what it's about.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas? A. There was possible association between ovarian carcinosarcomas and Tamoxifen. And that was what he was reporting, the first author, Oscar Lavie. Q. Okay. Did you also was there also a finding that in that article that it was a delayed response to the Tamoxifen? A. I don't know that it's a a delayed occurrence. And actually probably not even delayed. I mean, it's basically prolonged use.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct? A. Yes. Q. Within the gynecologic pathology A. Yes. Q correct? A. Yes. Q. What did that course entail? A. Oh, this is a medical student course, so it's about basic endometrial basic uterine service and vulvar and vaginal pathology. Q. Okay. A. That's what it's about. Q. Any discussion of polypropylene in that course?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas? A. There was possible association between ovarian carcinosarcomas and Tamoxifen. And that was what he was reporting, the first author, Oscar Lavie. Q. Okay. Did you also was there also a finding that in that article that it was a delayed response to the Tamoxifen? A. I don't know that it's a a delayed occurrence. And actually probably not even delayed. I mean, it's basically prolonged use. Q. Then you have listed some books and book chapters
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct?  A. Yes. Q. Within the gynecologic pathology A. Yes. Q correct? A. Yes. Q. What did that course entail? A. Oh, this is a medical student course, so it's about basic endometrial basic uterine service and vulvar and vaginal pathology. Q. Okay. A. That's what it's about. Q. Any discussion of polypropylene in that course? A. No.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas? A. There was possible association between ovarian carcinosarcomas and Tamoxifen. And that was what he was reporting, the first author, Oscar Lavie. Q. Okay. Did you also was there also a finding that in that article that it was a delayed response to the Tamoxifen? A. I don't know that it's a a delayed occurrence. And actually probably not even delayed. I mean, it's basically prolonged use. Q. Then you have listed some books and book chapters in preparation in your CV, correct?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct? A. Yes. Q. Within the gynecologic pathology A. Yes. Q correct? A. Yes. Q correct? A. Yes. Q. What did that course entail? A. Oh, this is a medical student course, so it's about basic endometrial basic uterine service and vulvar and vaginal pathology. Q. Okay. A. That's what it's about. Q. Any discussion of polypropylene in that course? A. No. Q. Mesh complications?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas? A. There was possible association between ovarian carcinosarcomas and Tamoxifen. And that was what he was reporting, the first author, Oscar Lavie. Q. Okay. Did you also was there also a finding that in that article that it was a delayed response to the Tamoxifen? A. I don't know that it's a a delayed occurrence. And actually probably not even delayed. I mean, it's basically prolonged use. Q. Then you have listed some books and book chapters in preparation in your CV, correct? A. Yes.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	the most up-to-date CV.  MR. JONES: Q. Okay. Well, do you see on the CV you have a copy of where you've listed courses that you've taught?  A. Yes. Q. And you've listed a course for 2013 called "Human Health and Disease," correct? A. Yes. Q. Within the gynecologic pathology A. Yes. Q correct? A. Yes. Q. What did that course entail? A. Oh, this is a medical student course, so it's about basic endometrial basic uterine service and vulvar and vaginal pathology. Q. Okay. A. That's what it's about. Q. Any discussion of polypropylene in that course? A. No. Q. Mesh complications? A. No.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. Yes. Q. It's been on the market for 40 years, thereabout? MR. WES: Object to form, foundation. THE WITNESS: It's been on the market for a while. MR. JONES: Q. Okay. And in what article did you find an association between Tamoxifen and ovarian sarcomas? A. There was possible association between ovarian carcinosarcomas and Tamoxifen. And that was what he was reporting, the first author, Oscar Lavie. Q. Okay. Did you also was there also a finding that in that article that it was a delayed response to the Tamoxifen? A. I don't know that it's a a delayed occurrence. And actually probably not even delayed. I mean, it's basically prolonged use. Q. Then you have listed some books and book chapters in preparation in your CV, correct? A. Yes. Q. And number one, you list yourself as chief editor

	Page 82		Page 84
1	Q. Has that is that still in preparation, or has	1	you've given in your role as an expert witness?
2	that been published yet?	2	A. I think less than 50, but it may be somewhere in
3	A. It's still in preparation.	3	that range.
4	Q. Okay. Is there any discussion within that book	4	Q. How many times have you testified at trial?
5	of polypropylene?	5	A. Maybe half a dozen. Not that often.
6	A. No.	6	Q. Do your fees for your litigation consulting and
7	Q. Transvaginal mesh?	7	expert work make up a significant amount of your salary
8	A. No.	8	and revenue?
9	Q. Mesh complications?	9	A. No.
10	A. No.	10	Q. Have you ever acted as an expert prior to this
11	Q. That's all the questions I have about your CV.	11	case on transvaginal mesh?
12	You can put that away.	12	A. No.
13	Do you specialize in how the body reacts to	13	Q. Hernia mesh?
14	polypropylene?	14	A. No.
15	MR. WES: Object to form.	15	Q. Have you ever worked for Johnson & Johnson prior
16	THE WITNESS: As a pathologist I have expertise	16	to this case?
17	in interpreting tissue response to foreign material in	17	A. I don't think so, but it's a big company with a
18	general, and that would include polypropylene.	18	bunch of subsidiaries so
19	MR. JONES: Q. In your experience as a	19	Q. It is.
20	pathologist, are mesh explants stored in any type of	20	A. But not that I know.
21	material to preserve them?	21	Q. How about Ethicon?
22	A. They're often submitted because there's	22	A. No.
23	associated tissue at some level with them, they're often	23	Q. In this case did you conduct any testing
24	submitted in formalin fixative.	24	yourself?
25	Q. Okay. Is that the customary practice that you	25	A. Other than that S-100 immunohistochemical stain,
	Page 83		Page 85
1	see as a pathologist?	1	no.
2	A. Yes.	2	Q. Are there peroxides that are naturally present
3	Q. Do you have any opinions about that subject	3	inside the vagina?
4	matter that you'll be giving in this case, specifically	4	A. I'm not sure what that what you're asking.
5	related to the formalin that it's preserved in?	5	Q. Okay. Is the vagina a highly acidic area?
6	MR. WES: Object to form, vague.	6	MR. WES: Object to form.
7	THE WITNESS: I think we touched a little bit on	7	THE WITNESS: It has a low ph. I don't know if
8	it earlier in that formalin shrinks tissue.	8	it's highly acidic. And the ph can change depending upon
9	MR. JONES: Q. What about mesh? How does the	9	the flora that's there and whether patients taking
10	formalin affect mesh?	10	antibiotic use, et cetera.
11	MR. WES: Same objection.	11	MR. JONES: Q. Do you have expertise in the
12	THE WITNESS: I don't know how formalin	12	flora or peroxides or ph balance of the vagina?
13	necessarily affects mesh.	13	A. That's not
14	MR. JONES: Q. Okay.	14	MR. WES: Object to form.
15	A. To the extent that there's tissue attached, there	15	THE WITNESS: within the realm of my opinion
16	would be shrinkage as well, but actual mesh material in	16	in this case.
17	interaction with formalin, I don't know.	17	MR. JONES: Q. Perfect. Does the inflammatory
18	Q. Will you be giving any opinions related to	18	response of transvaginal mesh ever stop?
19	degradation of mesh in this case?	19	A. Well, so with any foreign body there will
20	A. No, I will not.	20	always to the best of my knowledge in all my
21	MR. WES: Object to form, outside the scope.	21	experience, there's always a sort of persistent thin
22	MR. JONES: Q. I want to ask you a series of	22	layer, and in some instances it may be even thicker of
23	questions about your experience as a litigation consultant	23	lymphocytes and macrophages associated with that foreign
24	or expert.	24	material. And that would include mesh, yes.
24 25	or expert.  Can you give an estimate of how many depositions	24 25	material. And that would include mesh, yes.  How active that is in terms of causing

	Page 86		Page 88
1	symptomatology is not so certain. The cells are obviously	1	transvaginal mesh?
2	alive and viable, but how much they're really doing other	2	MR. WES: Object to form, outside the scope.
3	than just standing guard, if you will.	3	THE WITNESS: Well, polypropylene is used in
4	Q. Okay. I'm going to name a few articles related	4	suture material and other mesh materials and maybe other
5	to the inflammatory response to transvaginal mesh or	5	things, but those are the only two that come to mind right
6	hernia mesh and ask you if they ring a bell. Are you	6	now.
7	familiar with a Cobb article?	7	MR. JONES: Q. Okay. Do you know if it's used
8	MR. WES: Object to form, foundation.	8	in fishing line?
9	THE WITNESS: It would be so much easier if we	9	MR. WES: Same objection.
10	had the articles.	10	THE WITNESS: My son would know.
11	MR. JONES: Q. If I'll tell you what. If	11	MR. JONES: I'll move on.
12	once we get a list of the articles that you actually	12	Q. Will you be giving any opinions related to
13	looked at, then I'd gladly be would ask you about	13	cytotoxicity in this case?
14	those. But I'm just trying to get	14	MR. WES: Object to form.
15	A. I know.	15	THE WITNESS: Not no, not other than what
16	Q. Okay. Does the name Kosterhalfen ring any bells?	16	I've already talked about in terms of the inflammatory
17	A. Yes, that does.	17	response, no, not specifically.
18	Q. Okay.	18	MR. JONES: Q. Did you review any Ethicon
19	MR. WES: Same objection.	19	testing related to the cytotoxicity of the mesh used in
20	MR. JONES: Q. What's your recall of Bernard	20	the TVT Abbrevo device?
21	Kosterhalfen?	21	A. No.
22	A. I'm not sure right now. I don't remember.	22	MR. WES: Object to form, outside the scope.
23	Q. It's a pretty unique name, and it rings a bell	23	THE WITNESS: And no, I don't recall specifically
24	A. Yes.	24	reviewing any cytotoxicity.
25	Q and you know you've reviewed something related	25	MR. JONES: Q. Would cytotoxicity testing of the
	Q. and you know you've reviewed something remied	23	MR. JOINES. Q. Would cytoloxicity testing of the
	Page 87		Page 89
1	to Klosterhalfen?	1	Page 89 mesh used in the TVT Abbrevo device be something that you
1 2		1 2	
	to Klosterhalfen?		mesh used in the TVT Abbrevo device be something that you
2	to Klosterhalfen? A. I think I have, yes.	2	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in
2	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps	2	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?
2 3 4	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some	2 3 4	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.
2 3 4 5	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a	2 3 4 5	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think
2 3 4 5 6	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?	2 3 4 5 6	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.
2 3 4 5 6 7	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.	2 3 4 5 6	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides
2 3 4 5 6 7 8	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right	2 3 4 5 6 7 8	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you
2 3 4 5 6 7 8 9	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I	2 3 4 5 6 7 8	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?
2 3 4 5 6 7 8 9	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.	2 3 4 5 6 7 8 9	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.
2 3 4 5 6 7 8 9 10	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.  MR. JONES: Q. What about Todd Heniford?	2 3 4 5 6 7 8 9 10	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.  Q. Any e-mail folders that you created specifically
2 3 4 5 6 7 8 9 10 11	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.  MR. JONES: Q. What about Todd Heniford?  MR. WES: Object to form, foundation.	2 3 4 5 6 7 8 9 10 11	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.  Q. Any e-mail folders that you created specifically in response to this case?
2 3 4 5 6 7 8 9 10 11 12	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.  MR. JONES: Q. What about Todd Heniford?  MR. WES: Object to form, foundation.  THE WITNESS: Again, I'm not sure about the name.  MR. JONES: Q. What about Uwe Klinge?	2 3 4 5 6 7 8 9 10 11 12 13	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.  Q. Any e-mail folders that you created specifically in response to this case?  A. No.
2 3 4 5 6 7 8 9 10 11 12 13 14	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.  MR. JONES: Q. What about Todd Heniford?  MR. WES: Object to form, foundation.  THE WITNESS: Again, I'm not sure about the name.	2 3 4 5 6 7 8 9 10 11 12 13 14	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.  Q. Any e-mail folders that you created specifically in response to this case?  A. No.  Q. Any file folders?
2 3 4 5 6 7 8 9 10 11 12 13 14	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.  MR. JONES: Q. What about Todd Heniford?  MR. WES: Object to form, foundation.  THE WITNESS: Again, I'm not sure about the name.  MR. JONES: Q. What about Uwe Klinge?  MR. WES: Same objections.	2 3 4 5 6 7 8 9 10 11 12 13 14	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.  Q. Any e-mail folders that you created specifically in response to this case?  A. No.  Q. Any file folders?  A. No. I have boxes with these but no file folders.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.  MR. JONES: Q. What about Todd Heniford?  MR. WES: Object to form, foundation.  THE WITNESS: Again, I'm not sure about the name.  MR. JONES: Q. What about Uwe Klinge?  MR. WES: Same objections.  THE WITNESS: That name is familiar.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.  Q. Any e-mail folders that you created specifically in response to this case?  A. No.  Q. Any file folders?  A. No. I have boxes with these but no file folders.  Q. Are you a paper person or an electronic person
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.  MR. JONES: Q. What about Todd Heniford?  MR. WES: Object to form, foundation.  THE WITNESS: Again, I'm not sure about the name.  MR. JONES: Q. What about Uwe Klinge?  MR. WES: Same objections.  THE WITNESS: That name is familiar.  MR. JONES: Q. Okay.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.  Q. Any e-mail folders that you created specifically in response to this case?  A. No.  Q. Any file folders?  A. No. I have boxes with these but no file folders.  Q. Are you a paper person or an electronic person when you reviewed these deposition testimony, medical
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.  MR. JONES: Q. What about Todd Heniford?  MR. WES: Object to form, foundation.  THE WITNESS: Again, I'm not sure about the name.  MR. JONES: Q. What about Uwe Klinge?  MR. WES: Same objections.  THE WITNESS: That name is familiar.  MR. JONES: Q. Okay.  A. This is Klinge?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.  Q. Any e-mail folders that you created specifically in response to this case?  A. No.  Q. Any file folders?  A. No. I have boxes with these but no file folders.  Q. Are you a paper person or an electronic person when you reviewed these deposition testimony, medical records?  MR. WES: Object to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.  MR. JONES: Q. What about Todd Heniford?  MR. WES: Object to form, foundation.  THE WITNESS: Again, I'm not sure about the name.  MR. JONES: Q. What about Uwe Klinge?  MR. WES: Same objections.  THE WITNESS: That name is familiar.  MR. JONES: Q. Okay.  A. This is Klinge?  Q. Yes.  A. Yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.  Q. Any e-mail folders that you created specifically in response to this case?  A. No.  Q. Any file folders?  A. No. I have boxes with these but no file folders.  Q. Are you a paper person or an electronic person when you reviewed these deposition testimony, medical records?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.  MR. JONES: Q. What about Todd Heniford?  MR. WES: Object to form, foundation.  THE WITNESS: Again, I'm not sure about the name.  MR. JONES: Q. What about Uwe Klinge?  MR. WES: Same objections.  THE WITNESS: That name is familiar.  MR. JONES: Q. Okay.  A. This is Klinge?  Q. Yes.  A. Yes.  Q. Are you aware that polypropylene is used in	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.  Q. Any e-mail folders that you created specifically in response to this case?  A. No.  Q. Any file folders?  A. No. I have boxes with these but no file folders.  Q. Are you a paper person or an electronic person when you reviewed these deposition testimony, medical records?  MR. WES: Object to form.  THE WITNESS: Mostly I've read the paper.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.  MR. JONES: Q. What about Todd Heniford?  MR. WES: Object to form, foundation.  THE WITNESS: Again, I'm not sure about the name.  MR. JONES: Q. What about Uwe Klinge?  MR. WES: Same objections.  THE WITNESS: That name is familiar.  MR. JONES: Q. Okay.  A. This is Klinge?  Q. Yes.  A. Yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.  Q. Any e-mail folders that you created specifically in response to this case?  A. No.  Q. Any file folders?  A. No. I have boxes with these but no file folders.  Q. Are you a paper person or an electronic person when you reviewed these deposition testimony, medical records?  MR. WES: Object to form.  THE WITNESS: Mostly I've read the paper.  MR. JONES: Q. Did anybody help you work on this
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.  MR. JONES: Q. What about Todd Heniford?  MR. WES: Object to form, foundation.  THE WITNESS: Again, I'm not sure about the name.  MR. JONES: Q. What about Uwe Klinge?  MR. WES: Same objections.  THE WITNESS: That name is familiar.  MR. JONES: Q. Okay.  A. This is Klinge?  Q. Yes.  A. Yes.  Q. Are you aware that polypropylene is used in products besides transvaginal mesh?  A. Yes.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.  Q. Any e-mail folders that you created specifically in response to this case?  A. No.  Q. Any file folders?  A. No. I have boxes with these but no file folders.  Q. Are you a paper person or an electronic person when you reviewed these deposition testimony, medical records?  MR. WES: Object to form.  THE WITNESS: Mostly I've read the paper.  MR. JONES: Q. Did anybody help you work on this case?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	to Klosterhalfen?  A. I think I have, yes.  Q. We talked about Iakolov, I-A-K-O-L-O-V, perhaps on the spelling. He's a pathologist who has written some articles related to transvaginal mesh. Does that ring a bell at all?  MR. WES: Object to form.  THE WITNESS: It's not ringing any bell right now, but it doesn't mean I didn't review it. But I don't I don't recollect it right now.  MR. JONES: Q. What about Todd Heniford?  MR. WES: Object to form, foundation.  THE WITNESS: Again, I'm not sure about the name.  MR. JONES: Q. What about Uwe Klinge?  MR. WES: Same objections.  THE WITNESS: That name is familiar.  MR. JONES: Q. Okay.  A. This is Klinge?  Q. Yes.  A. Yes.  Q. Are you aware that polypropylene is used in products besides transvaginal mesh?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	mesh used in the TVT Abbrevo device be something that you would want to look at in helping you form your opinions in this case?  MR. WES: Object to form, outside the scope.  THE WITNESS: No, it wouldn't I don't think that would have any influence on my opinions on the slides and the tissue, no.  MR. JONES: Q. Did you keep any notes when you worked on this case?  A. No.  Q. Any e-mail folders that you created specifically in response to this case?  A. No.  Q. Any file folders?  A. No. I have boxes with these but no file folders.  Q. Are you a paper person or an electronic person when you reviewed these deposition testimony, medical records?  MR. WES: Object to form.  THE WITNESS: Mostly I've read the paper.  MR. JONES: Q. Did anybody help you work on this case?  A. No.

	Page 90		Page 92
1	Q. Or fellow doctors?	1	A. Oh, he operated on occasion at Stanford.
2	A. No.	2	Q. Okay.
3	Q. Have you set up a corporation to accept payments	3	A. And I'm a GYN pathologist.
4	for your litigation consulting work?	4	Q. So you worked with him?
5	A. No.	5	A. I don't know about with him, but I you know, I
6	Q. Before rendering your opinions in this case, did	6	received pathology materials that he removed.
7	you speak with any pelvic floor surgeons at Stanford	7	Q. What pathology materials were those?
8	University?	8	A. Oh, I don't remember. They were GYN path, but
9	A. No.	9	that was so long ago, I don't remember. And there were
10	Q. Do you know of any of the pelvic floor surgeons	10	discussions that I had, but I have no recollection of the
11	at Stanford University?	11	contents of them. But I definitely remembered him as
12	A. Yes.	12	being a surgeon that was at Stanford.
13	Q. I mean, you're aware that Stanford has a highly	13	Q. Do you have any criticisms of his expertise in
14	respected pelvic floor surgery clinic, correct?	14	the field of urogynecology?
15	A. I would suspect they do.	15	MR. WES: Object to form, foundation.
16	Q. With well respected surgeons who make up that	16	THE WITNESS: He's not an expert in GYN
17	clinic, right?	17	pathology.
18	MR. WES: Object to form.	18	MR. JONES: Q. Any other criticisms?
19	MR. JONES: Q. Do you know Lisa Rogo-Gupta?	19	MR. WES: Same objection.
20	A. No, I don't know her.	20	THE WITNESS: Nothing that I want to say right
21	Q. Okay. Didn't talk to her at all	21	now.
22	A. No.	22	MR. JONES: Q. Right now. Are these criticisms
23	Q before you gave your opinions in this case?	23	that you might share at trial?
24	A. Don't even know her.	24	A. No.
2.5	Q. How about Eric Sokol?	25	Q. You just want to keep those personal, to
	Page 91		Page 93
1	A T1		
	A. I know of nim, ves.	1	yourself?
2	A. I know of him, yes.     Q. Did you talk to him before you rendered your	1 2	yourself?  A. I think so.
2 3	Q. Did you talk to him before you rendered your		A. I think so.
	·	2	<ul><li>A. I think so.</li><li>Q. You realize he set up the urogynecological</li></ul>
3	Q. Did you talk to him before you rendered your opinions in this case?	2	A. I think so.
3 4	<ul><li>Q. Did you talk to him before you rendered your opinions in this case?</li><li>A. No.</li></ul>	2 3 4	A. I think so.     Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at
3 4 5	<ul><li>Q. Did you talk to him before you rendered your opinions in this case?</li><li>A. No.</li><li>Q. Do you have any knowledge of his work on</li></ul>	2 3 4 5	A. I think so.     Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct?
3 4 5 6	<ul><li>Q. Did you talk to him before you rendered your opinions in this case?</li><li>A. No.</li><li>Q. Do you have any knowledge of his work on transvaginal mesh?</li><li>A. No.</li></ul>	2 3 4 5 6	<ul> <li>A. I think so.</li> <li>Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct?</li> <li>A. No, I didn't realize that.</li> </ul>
3 4 5 6 7	<ul><li>Q. Did you talk to him before you rendered your opinions in this case?</li><li>A. No.</li><li>Q. Do you have any knowledge of his work on transvaginal mesh?</li></ul>	2 3 4 5 6 7	<ul> <li>A. I think so.</li> <li>Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct?</li> <li>A. No, I didn't realize that.</li> <li>Q. You didn't know that?</li> </ul>
3 4 5 6 7 8	<ul> <li>Q. Did you talk to him before you rendered your opinions in this case?</li> <li>A. No.</li> <li>Q. Do you have any knowledge of his work on transvaginal mesh?</li> <li>A. No.</li> <li>Q. You didn't review any articles he wrote about</li> </ul>	2 3 4 5 6 7 8	<ul> <li>A. I think so.</li> <li>Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct?</li> <li>A. No, I didn't realize that.</li> <li>Q. You didn't know that?</li> <li>A. No.</li> </ul>
3 4 5 6 7 8 9	<ul> <li>Q. Did you talk to him before you rendered your opinions in this case?</li> <li>A. No.</li> <li>Q. Do you have any knowledge of his work on transvaginal mesh?</li> <li>A. No.</li> <li>Q. You didn't review any articles he wrote about transvaginal mesh?</li> </ul>	2 3 4 5 6 7 8	<ul> <li>A. I think so.</li> <li>Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct?</li> <li>A. No, I didn't realize that.</li> <li>Q. You didn't know that?</li> <li>A. No.</li> <li>MR. WES: Can I get an objection, form,</li> </ul>
3 4 5 6 7 8 9	<ul> <li>Q. Did you talk to him before you rendered your opinions in this case?</li> <li>A. No.</li> <li>Q. Do you have any knowledge of his work on transvaginal mesh?</li> <li>A. No.</li> <li>Q. You didn't review any articles he wrote about transvaginal mesh?</li> <li>A. No.</li> <li>A. No.</li> </ul>	2 3 4 5 6 7 8 9	<ul> <li>A. I think so.</li> <li>Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct?</li> <li>A. No, I didn't realize that.</li> <li>Q. You didn't know that?</li> <li>A. No.  MR. WES: Can I get an objection, form, foundation on the last one?</li> </ul>
3 4 5 6 7 8 9 10 11 12 13	<ul> <li>Q. Did you talk to him before you rendered your opinions in this case?</li> <li>A. No.</li> <li>Q. Do you have any knowledge of his work on transvaginal mesh?</li> <li>A. No.</li> <li>Q. You didn't review any articles he wrote about transvaginal mesh?</li> <li>A. No.</li> <li>Q. We talked about Dr. Margolis earlier. You're</li> </ul>	2 3 4 5 6 7 8 9 10	<ul> <li>A. I think so.</li> <li>Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct?</li> <li>A. No, I didn't realize that.</li> <li>Q. You didn't know that?</li> <li>A. No.  MR. WES: Can I get an objection, form, foundation on the last one?  MR. JONES: Q. And you know that Dr. Margolis is</li> </ul>
3 4 5 6 7 8 9 10 11 12 13 14	<ul> <li>Q. Did you talk to him before you rendered your opinions in this case?</li> <li>A. No.</li> <li>Q. Do you have any knowledge of his work on transvaginal mesh?</li> <li>A. No.</li> <li>Q. You didn't review any articles he wrote about transvaginal mesh?</li> <li>A. No.</li> <li>Q. We talked about Dr. Margolis earlier. You're familiar with Dr. Margolis in that you've read his</li> </ul>	2 3 4 5 6 7 8 9 10 11	A. I think so. Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct? A. No, I didn't realize that. Q. You didn't know that? A. No. MR. WES: Can I get an objection, form, foundation on the last one? MR. JONES: Q. And you know that Dr. Margolis is an expert witness for the plaintiff in this case?
3 4 5 6 7 8 9 10 11 12 13 14 15	<ul> <li>Q. Did you talk to him before you rendered your opinions in this case?</li> <li>A. No.</li> <li>Q. Do you have any knowledge of his work on transvaginal mesh?</li> <li>A. No.</li> <li>Q. You didn't review any articles he wrote about transvaginal mesh?</li> <li>A. No.</li> <li>Q. We talked about Dr. Margolis earlier. You're familiar with Dr. Margolis in that you've read his deposition, correct?</li> <li>MR. WES: Object to form, misstates the testimony.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13	<ul> <li>A. I think so.</li> <li>Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct?</li> <li>A. No, I didn't realize that.</li> <li>Q. You didn't know that?</li> <li>A. No.  MR. WES: Can I get an objection, form, foundation on the last one?  MR. JONES: Q. And you know that Dr. Margolis is an expert witness for the plaintiff in this case?</li> <li>A. Yes, I do know that.</li> <li>Q. Okay. Are you aware of whether or not the Stanford urogynecology clinic specializes in treating mesh</li> </ul>
3 4 5 6 7 8 9 10 11 12 13 14 15 16	<ul> <li>Q. Did you talk to him before you rendered your opinions in this case?</li> <li>A. No.</li> <li>Q. Do you have any knowledge of his work on transvaginal mesh?</li> <li>A. No.</li> <li>Q. You didn't review any articles he wrote about transvaginal mesh?</li> <li>A. No.</li> <li>Q. We talked about Dr. Margolis earlier. You're familiar with Dr. Margolis in that you've read his deposition, correct?</li> <li>MR. WES: Object to form, misstates the testimony.</li> <li>MR. JONES: I'll rephrase the question.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I think so. Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct? A. No, I didn't realize that. Q. You didn't know that? A. No. MR. WES: Can I get an objection, form, foundation on the last one? MR. JONES: Q. And you know that Dr. Margolis is an expert witness for the plaintiff in this case? A. Yes, I do know that. Q. Okay. Are you aware of whether or not the Stanford urogynecology clinic specializes in treating mesh complications?
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	<ul> <li>Q. Did you talk to him before you rendered your opinions in this case?</li> <li>A. No.</li> <li>Q. Do you have any knowledge of his work on transvaginal mesh?</li> <li>A. No.</li> <li>Q. You didn't review any articles he wrote about transvaginal mesh?</li> <li>A. No.</li> <li>Q. We talked about Dr. Margolis earlier. You're familiar with Dr. Margolis in that you've read his deposition, correct?</li> <li>MR. WES: Object to form, misstates the testimony.</li> <li>MR. JONES: I'll rephrase the question.</li> <li>Q. You're familiar with Dr. Margolis in that you've</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. I think so. Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct? A. No, I didn't realize that. Q. You didn't know that? A. No. MR. WES: Can I get an objection, form, foundation on the last one? MR. JONES: Q. And you know that Dr. Margolis is an expert witness for the plaintiff in this case? A. Yes, I do know that. Q. Okay. Are you aware of whether or not the Stanford urogynecology clinic specializes in treating mesh complications? MR. WES: Same objection.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	<ul> <li>Q. Did you talk to him before you rendered your opinions in this case?</li> <li>A. No.</li> <li>Q. Do you have any knowledge of his work on transvaginal mesh?</li> <li>A. No.</li> <li>Q. You didn't review any articles he wrote about transvaginal mesh?</li> <li>A. No.</li> <li>Q. We talked about Dr. Margolis earlier. You're familiar with Dr. Margolis in that you've read his deposition, correct?</li> <li>MR. WES: Object to form, misstates the testimony.</li> <li>MR. JONES: I'll rephrase the question.</li> <li>Q. You're familiar with Dr. Margolis in that you've reviewed pictures Dr. Margolis took of Ms. Perry?</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I think so. Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct? A. No, I didn't realize that. Q. You didn't know that? A. No. MR. WES: Can I get an objection, form, foundation on the last one? MR. JONES: Q. And you know that Dr. Margolis is an expert witness for the plaintiff in this case? A. Yes, I do know that. Q. Okay. Are you aware of whether or not the Stanford urogynecology clinic specializes in treating mesh complications? MR. WES: Same objection. THE WITNESS: No, I'm not aware of that.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	<ul> <li>Q. Did you talk to him before you rendered your opinions in this case?</li> <li>A. No.</li> <li>Q. Do you have any knowledge of his work on transvaginal mesh?</li> <li>A. No.</li> <li>Q. You didn't review any articles he wrote about transvaginal mesh?</li> <li>A. No.</li> <li>Q. We talked about Dr. Margolis earlier. You're familiar with Dr. Margolis in that you've read his deposition, correct?</li> <li>MR. WES: Object to form, misstates the testimony.</li> <li>MR. JONES: I'll rephrase the question.</li> <li>Q. You're familiar with Dr. Margolis in that you've reviewed pictures Dr. Margolis took of Ms. Perry?</li> <li>A. Yes.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I think so. Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct? A. No, I didn't realize that. Q. You didn't know that? A. No. MR. WES: Can I get an objection, form, foundation on the last one? MR. JONES: Q. And you know that Dr. Margolis is an expert witness for the plaintiff in this case? A. Yes, I do know that. Q. Okay. Are you aware of whether or not the Stanford urogynecology clinic specializes in treating mesh complications? MR. WES: Same objection. THE WITNESS: No, I'm not aware of that. MR. JONES: Q. Have you reviewed any videos
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Did you talk to him before you rendered your opinions in this case?  A. No. Q. Do you have any knowledge of his work on transvaginal mesh? A. No. Q. You didn't review any articles he wrote about transvaginal mesh? A. No. Q. We talked about Dr. Margolis earlier. You're familiar with Dr. Margolis in that you've read his deposition, correct?  MR. WES: Object to form, misstates the testimony.  MR. JONES: I'll rephrase the question. Q. You're familiar with Dr. Margolis in that you've reviewed pictures Dr. Margolis took of Ms. Perry? A. Yes. Q. Did you know Dr. Margolis used to work at	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I think so. Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct? A. No, I didn't realize that. Q. You didn't know that? A. No. MR. WES: Can I get an objection, form, foundation on the last one? MR. JONES: Q. And you know that Dr. Margolis is an expert witness for the plaintiff in this case? A. Yes, I do know that. Q. Okay. Are you aware of whether or not the Stanford urogynecology clinic specializes in treating mesh complications? MR. WES: Same objection. THE WITNESS: No, I'm not aware of that. MR. JONES: Q. Have you reviewed any videos posted by the Stanford urogynecology clinic that have been
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Did you talk to him before you rendered your opinions in this case?  A. No. Q. Do you have any knowledge of his work on transvaginal mesh? A. No. Q. You didn't review any articles he wrote about transvaginal mesh? A. No. Q. We talked about Dr. Margolis earlier. You're familiar with Dr. Margolis in that you've read his deposition, correct?  MR. WES: Object to form, misstates the testimony.  MR. JONES: I'll rephrase the question. Q. You're familiar with Dr. Margolis in that you've reviewed pictures Dr. Margolis took of Ms. Perry? A. Yes. Q. Did you know Dr. Margolis used to work at Stanford University?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I think so. Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct? A. No, I didn't realize that. Q. You didn't know that? A. No. MR. WES: Can I get an objection, form, foundation on the last one? MR. JONES: Q. And you know that Dr. Margolis is an expert witness for the plaintiff in this case? A. Yes, I do know that. Q. Okay. Are you aware of whether or not the Stanford urogynecology clinic specializes in treating mesh complications? MR. WES: Same objection. THE WITNESS: No, I'm not aware of that. MR. JONES: Q. Have you reviewed any videos posted by the Stanford urogynecology clinic that have been posted online?
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	<ul> <li>Q. Did you talk to him before you rendered your opinions in this case?</li> <li>A. No.</li> <li>Q. Do you have any knowledge of his work on transvaginal mesh?</li> <li>A. No.</li> <li>Q. You didn't review any articles he wrote about transvaginal mesh?</li> <li>A. No.</li> <li>Q. We talked about Dr. Margolis earlier. You're familiar with Dr. Margolis in that you've read his deposition, correct?</li> <li>MR. WES: Object to form, misstates the testimony.</li> <li>MR. JONES: I'll rephrase the question.</li> <li>Q. You're familiar with Dr. Margolis in that you've reviewed pictures Dr. Margolis took of Ms. Perry?</li> <li>A. Yes.</li> <li>Q. Did you know Dr. Margolis used to work at Stanford University?</li> <li>A. Yes, I did.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I think so. Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct? A. No, I didn't realize that. Q. You didn't know that? A. No. MR. WES: Can I get an objection, form, foundation on the last one? MR. JONES: Q. And you know that Dr. Margolis is an expert witness for the plaintiff in this case? A. Yes, I do know that. Q. Okay. Are you aware of whether or not the Stanford urogynecology clinic specializes in treating mesh complications? MR. WES: Same objection. THE WITNESS: No, I'm not aware of that. MR. JONES: Q. Have you reviewed any videos posted by the Stanford urogynecology clinic that have been posted online? A. I don't think so.
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	<ul> <li>Q. Did you talk to him before you rendered your opinions in this case?</li> <li>A. No.</li> <li>Q. Do you have any knowledge of his work on transvaginal mesh?</li> <li>A. No.</li> <li>Q. You didn't review any articles he wrote about transvaginal mesh?</li> <li>A. No.</li> <li>Q. We talked about Dr. Margolis earlier. You're familiar with Dr. Margolis in that you've read his deposition, correct?</li> <li>MR. WES: Object to form, misstates the testimony.</li> <li>MR. JONES: I'll rephrase the question.</li> <li>Q. You're familiar with Dr. Margolis in that you've reviewed pictures Dr. Margolis took of Ms. Perry?</li> <li>A. Yes.</li> <li>Q. Did you know Dr. Margolis used to work at Stanford University?</li> <li>A. Yes, I did.</li> <li>Q. Do you know Dr. Margolis?</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I think so.  Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct?  A. No, I didn't realize that.  Q. You didn't know that?  A. No.  MR. WES: Can I get an objection, form, foundation on the last one?  MR. JONES: Q. And you know that Dr. Margolis is an expert witness for the plaintiff in this case?  A. Yes, I do know that.  Q. Okay. Are you aware of whether or not the Stanford urogynecology clinic specializes in treating mesh complications?  MR. WES: Same objection.  THE WITNESS: No, I'm not aware of that.  MR. JONES: Q. Have you reviewed any videos posted by the Stanford urogynecology clinic that have been posted online?  A. I don't think so.  Q. Okay. Did you notify the pathology department at
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Q. Did you talk to him before you rendered your opinions in this case?  A. No. Q. Do you have any knowledge of his work on transvaginal mesh? A. No. Q. You didn't review any articles he wrote about transvaginal mesh? A. No. Q. We talked about Dr. Margolis earlier. You're familiar with Dr. Margolis in that you've read his deposition, correct?  MR. WES: Object to form, misstates the testimony.  MR. JONES: I'll rephrase the question. Q. You're familiar with Dr. Margolis in that you've reviewed pictures Dr. Margolis took of Ms. Perry? A. Yes. Q. Did you know Dr. Margolis used to work at Stanford University? A. Yes, I did. Q. Do you know Dr. Margolis? A. I've interacted with him.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	A. I think so. Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct? A. No, I didn't realize that. Q. You didn't know that? A. No. MR. WES: Can I get an objection, form, foundation on the last one? MR. JONES: Q. And you know that Dr. Margolis is an expert witness for the plaintiff in this case? A. Yes, I do know that. Q. Okay. Are you aware of whether or not the Stanford urogynecology clinic specializes in treating mesh complications? MR. WES: Same objection. THE WITNESS: No, I'm not aware of that. MR. JONES: Q. Have you reviewed any videos posted by the Stanford urogynecology clinic that have been posted online? A. I don't think so. Q. Okay. Did you notify the pathology department at Stanford that you would be acting as an expert in this
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	<ul> <li>Q. Did you talk to him before you rendered your opinions in this case?</li> <li>A. No.</li> <li>Q. Do you have any knowledge of his work on transvaginal mesh?</li> <li>A. No.</li> <li>Q. You didn't review any articles he wrote about transvaginal mesh?</li> <li>A. No.</li> <li>Q. We talked about Dr. Margolis earlier. You're familiar with Dr. Margolis in that you've read his deposition, correct?</li> <li>MR. WES: Object to form, misstates the testimony.</li> <li>MR. JONES: I'll rephrase the question.</li> <li>Q. You're familiar with Dr. Margolis in that you've reviewed pictures Dr. Margolis took of Ms. Perry?</li> <li>A. Yes.</li> <li>Q. Did you know Dr. Margolis used to work at Stanford University?</li> <li>A. Yes, I did.</li> <li>Q. Do you know Dr. Margolis?</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I think so.  Q. You realize he set up the urogynecological urogynecology and pelvic reconstructive surgery clinic at Stanford, correct?  A. No, I didn't realize that.  Q. You didn't know that?  A. No.  MR. WES: Can I get an objection, form, foundation on the last one?  MR. JONES: Q. And you know that Dr. Margolis is an expert witness for the plaintiff in this case?  A. Yes, I do know that.  Q. Okay. Are you aware of whether or not the Stanford urogynecology clinic specializes in treating mesh complications?  MR. WES: Same objection.  THE WITNESS: No, I'm not aware of that.  MR. JONES: Q. Have you reviewed any videos posted by the Stanford urogynecology clinic that have been posted online?  A. I don't think so.  Q. Okay. Did you notify the pathology department at

	Page 94		Page 96
1	A. No.	1	THE WITNESS: I think in all likelihood that it
2	Q. Do any other doctors at Stanford know that you're	2	did contribute.
3	acting as an expert in this case?	3	MR. JONES: Q. It's possible that it didn't
4	A. No, I don't think they do.	4	contribute, though, right?
5	Q. I want to go back to real quickly we talked	5	A. Of course.
6	about smoking and diet and diabetes earlier and how it	6	Q. It's possible that her smoking, you know, two
7	relates to wound healing, and I want to focus on the diet.	7	cigarettes a week did not affect her healing capacity,
8	Have you reviewed records in this case related to	8	correct?
9	Ms. Perry that discuss certain diets she was on?	9	MR. WES: Object to form.
10	A. Yes.	10	THE WITNESS: It's yes, it is possible.
11	Q. And what did those records say?	11	MR. JONES: Q. It's also possible that diabetes
12	MR. WES: Object to form. The records will speak	12	didn't impact the wound healing at all, correct?
13	for themselves.	13	MR. WES: Object to form.
14	MR. JONES: Q. Do you have any recollection of	14	THE WITNESS: Yes. All of these things are
15	it?	15	possible, but are we talking about possible or likely?
16	A. I do recall it, yes. It was sounded like an	16	And I think that these are all factors that have been
17	odd diet to me.	17	established to impair wound healing, and if they're active
18	Q. An odd diet?	18	in a particular patient who is having problems with wound
19	A. And it sounded yeah, but most diets sound a	19	healing, one would suspect that in all likelihood they
20	little odd to me, to be quite honest, so but yeah, she	20	were contributory factors.
21	was on a some special diet that she was trying to	21	And that's sort of how medicine works. It's not
22	reduce her weight, correct.	22	an all or none absolute science. It's not like the
23	Q. Okay.	23	non-medical sciences.
24	A. And it looked to me like it was really quite low	24	MR. JONES: Q. Not two plus two equals four?
25	on the calories.	25	A. Exactly. It's not mathematical.
23	on the emories.		11. Dately. It's not interest attention
	Page 95		Page 97
			rage 91
1	Q. Oh, very low calorie intake diet?	1	
1 2	<ul><li>Q. Oh, very low calorie intake diet?</li><li>A. Yes.</li></ul>	1 2	Q. Did you focus at all when you looked at her
2	<ul><li>A. Yes.</li><li>Q. How you about protein? Was there a focus on the</li></ul>	2	Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at
2	<ul><li>A. Yes.</li><li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li></ul>	2	<ul><li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li><li>A. Not specifically.</li></ul>
2 3 4	<ul><li>A. Yes.</li><li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li><li>MR. WES: Object to form, foundation, calls for</li></ul>	2 3 4	<ul> <li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li> <li>A. Not specifically.</li> <li>Q. Okay. Protein the amount of protein in your</li> </ul>
2 3 4 5	<ul><li>A. Yes.</li><li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li></ul>	2 3 4 5	<ul> <li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li> <li>A. Not specifically.</li> <li>Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?</li> </ul>
2 3 4 5 6	<ul> <li>A. Yes.</li> <li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation, calls for speculation.</li> <li>THE WITNESS: Yeah, I don't really specifically</li> </ul>	2 3 4 5 6	<ul> <li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li> <li>A. Not specifically.</li> <li>Q. Okay. Protein the amount of protein in your</li> </ul>
2 3 4 5 6 7	<ul> <li>A. Yes.</li> <li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation, calls for speculation.</li> </ul>	2 3 4 5 6 7	<ul> <li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li> <li>A. Not specifically.</li> <li>Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?</li> <li>A. Oh, of course. Lots of things. But protein's</li> </ul>
2 3 4 5 6 7 8	A. Yes. Q. How you about protein? Was there a focus on the amount of protein in her diet? MR. WES: Object to form, foundation, calls for speculation. THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were.	2 3 4 5 6 7 8	<ul> <li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li> <li>A. Not specifically.</li> <li>Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?</li> <li>A. Oh, of course. Lots of things. But protein's important as well, yes.</li> </ul>
2 3 4 5 6 7 8	A. Yes. Q. How you about protein? Was there a focus on the amount of protein in her diet? MR. WES: Object to form, foundation, calls for speculation. THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were. MR. JONES: Q. But you do specifically recall it was a low calorie intake diet?	2 3 4 5 6 7 8	<ul> <li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li> <li>A. Not specifically.</li> <li>Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?</li> <li>A. Oh, of course. Lots of things. But protein's important as well, yes.</li> <li>Q. Do you have any recall of her not getting proper amount of protein in her diet?</li> </ul>
2 3 4 5 6 7 8 9	<ul> <li>A. Yes.</li> <li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation, calls for speculation.</li> <li>THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were.</li> <li>MR. JONES: Q. But you do specifically recall it was a low calorie intake diet?</li> <li>A. Yes.</li> </ul>	2 3 4 5 6 7 8 9	<ul> <li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li> <li>A. Not specifically.</li> <li>Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?</li> <li>A. Oh, of course. Lots of things. But protein's important as well, yes.</li> <li>Q. Do you have any recall of her not getting proper</li> </ul>
2 3 4 5 6 7 8 9 10	A. Yes. Q. How you about protein? Was there a focus on the amount of protein in her diet? MR. WES: Object to form, foundation, calls for speculation. THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were. MR. JONES: Q. But you do specifically recall it was a low calorie intake diet?	2 3 4 5 6 7 8 9 10	<ul> <li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li> <li>A. Not specifically.</li> <li>Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?</li> <li>A. Oh, of course. Lots of things. But protein's important as well, yes.</li> <li>Q. Do you have any recall of her not getting proper amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation.</li> </ul>
2 3 4 5 6 7 8 9 10 11	A. Yes. Q. How you about protein? Was there a focus on the amount of protein in her diet? MR. WES: Object to form, foundation, calls for speculation. THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were. MR. JONES: Q. But you do specifically recall it was a low calorie intake diet? A. Yes. Q. She was trying to reduce her weight?	2 3 4 5 6 7 8 9 10 11	<ul> <li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li> <li>A. Not specifically.</li> <li>Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?</li> <li>A. Oh, of course. Lots of things. But protein's important as well, yes.</li> <li>Q. Do you have any recall of her not getting proper amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation.</li> <li>THE WITNESS: No, I can't address whether or not she had sufficient protein in her diet.</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13	<ul> <li>A. Yes.</li> <li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation, calls for speculation.</li> <li>THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were.</li> <li>MR. JONES: Q. But you do specifically recall it was a low calorie intake diet?</li> <li>A. Yes.</li> <li>Q. She was trying to reduce her weight?</li> <li>A. Yes.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12	<ul> <li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li> <li>A. Not specifically.</li> <li>Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?</li> <li>A. Oh, of course. Lots of things. But protein's important as well, yes.</li> <li>Q. Do you have any recall of her not getting proper amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation.</li> <li>THE WITNESS: No, I can't address whether or not</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13 14	A. Yes. Q. How you about protein? Was there a focus on the amount of protein in her diet? MR. WES: Object to form, foundation, calls for speculation. THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were. MR. JONES: Q. But you do specifically recall it was a low calorie intake diet? A. Yes. Q. She was trying to reduce her weight? A. Yes. Q. And it was what you phrased as an odd diet?	2 3 4 5 6 7 8 9 10 11 12 13	<ul> <li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li> <li>A. Not specifically.</li> <li>Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?</li> <li>A. Oh, of course. Lots of things. But protein's important as well, yes.</li> <li>Q. Do you have any recall of her not getting proper amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation.</li> <li>THE WITNESS: No, I can't address whether or not she had sufficient protein in her diet.</li> <li>MR. JONES: Q. When she was on this diet, was she malnutritioned?</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13 14 15	<ul> <li>A. Yes.</li> <li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation, calls for speculation.</li> <li>THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were.</li> <li>MR. JONES: Q. But you do specifically recall it was a low calorie intake diet?</li> <li>A. Yes.</li> <li>Q. She was trying to reduce her weight?</li> <li>A. Yes.</li> <li>Q. And it was what you phrased as an odd diet?</li> <li>A. Yes.</li> <li>Q. And it's your opinion that that diet affected her</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14	<ul> <li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li> <li>A. Not specifically.</li> <li>Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?</li> <li>A. Oh, of course. Lots of things. But protein's important as well, yes.</li> <li>Q. Do you have any recall of her not getting proper amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation.</li> <li>THE WITNESS: No, I can't address whether or not she had sufficient protein in her diet.</li> <li>MR. JONES: Q. When she was on this diet, was she malnutritioned?</li> <li>MR. WES: Same objection.</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	<ul> <li>A. Yes.</li> <li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation, calls for speculation.</li> <li>THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were.</li> <li>MR. JONES: Q. But you do specifically recall it was a low calorie intake diet?</li> <li>A. Yes.</li> <li>Q. She was trying to reduce her weight?</li> <li>A. Yes.</li> <li>Q. And it was what you phrased as an odd diet?</li> <li>A. Yes.</li> <li>Q. And it's your opinion that that diet affected her ability to heal the wound from the TVT Abbrevo device?</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	<ul> <li>Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?</li> <li>A. Not specifically.</li> <li>Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?</li> <li>A. Oh, of course. Lots of things. But protein's important as well, yes.</li> <li>Q. Do you have any recall of her not getting proper amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation.</li> <li>THE WITNESS: No, I can't address whether or not she had sufficient protein in her diet.</li> <li>MR. JONES: Q. When she was on this diet, was she malnutritioned?</li> </ul>
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	<ul> <li>A. Yes.</li> <li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation, calls for speculation.</li> <li>THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were.</li> <li>MR. JONES: Q. But you do specifically recall it was a low calorie intake diet?</li> <li>A. Yes.</li> <li>Q. She was trying to reduce her weight?</li> <li>A. Yes.</li> <li>Q. And it was what you phrased as an odd diet?</li> <li>A. Yes.</li> <li>Q. And it's your opinion that that diet affected her ability to heal the wound from the TVT Abbrevo device?</li> <li>MR. WES: Object to form.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?  A. Not specifically.  Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?  A. Oh, of course. Lots of things. But protein's important as well, yes.  Q. Do you have any recall of her not getting proper amount of protein in her diet?  MR. WES: Object to form, foundation.  THE WITNESS: No, I can't address whether or not she had sufficient protein in her diet.  MR. JONES: Q. When she was on this diet, was she malnutritioned?  MR. WES: Same objection.  THE WITNESS: I'm not sure what you mean by "malnutritioned." She may not have been given all the
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	<ul> <li>A. Yes.</li> <li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation, calls for speculation.</li> <li>THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were.</li> <li>MR. JONES: Q. But you do specifically recall it was a low calorie intake diet?</li> <li>A. Yes.</li> <li>Q. She was trying to reduce her weight?</li> <li>A. Yes.</li> <li>Q. And it was what you phrased as an odd diet?</li> <li>A. Yes.</li> <li>Q. And it's your opinion that that diet affected her ability to heal the wound from the TVT Abbrevo device?</li> <li>MR. WES: Object to form.</li> <li>THE WITNESS: It's my opinion that that</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?  A. Not specifically.  Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?  A. Oh, of course. Lots of things. But protein's important as well, yes.  Q. Do you have any recall of her not getting proper amount of protein in her diet?  MR. WES: Object to form, foundation.  THE WITNESS: No, I can't address whether or not she had sufficient protein in her diet.  MR. JONES: Q. When she was on this diet, was she malnutritioned?  MR. WES: Same objection.  THE WITNESS: I'm not sure what you mean by "malnutritioned." She may not have been given all the necessary nutrients.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	<ul> <li>A. Yes.</li> <li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation, calls for speculation.</li> <li>THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were.</li> <li>MR. JONES: Q. But you do specifically recall it was a low calorie intake diet?</li> <li>A. Yes.</li> <li>Q. She was trying to reduce her weight?</li> <li>A. Yes.</li> <li>Q. And it was what you phrased as an odd diet?</li> <li>A. Yes.</li> <li>Q. And it's your opinion that that diet affected her ability to heal the wound from the TVT Abbrevo device?</li> <li>MR. WES: Object to form.</li> <li>THE WITNESS: It's my opinion that that significant reduction in calorie intake when she was</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?  A. Not specifically. Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?  A. Oh, of course. Lots of things. But protein's important as well, yes. Q. Do you have any recall of her not getting proper amount of protein in her diet?  MR. WES: Object to form, foundation.  THE WITNESS: No, I can't address whether or not she had sufficient protein in her diet.  MR. JONES: Q. When she was on this diet, was she malnutritioned?  MR. WES: Same objection.  THE WITNESS: I'm not sure what you mean by "malnutritioned." She may not have been given all the necessary nutrients.  MR. JONES: Q. Do you know one way or another
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	<ul> <li>A. Yes.</li> <li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation, calls for speculation.</li> <li>THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were.</li> <li>MR. JONES: Q. But you do specifically recall it was a low calorie intake diet?</li> <li>A. Yes.</li> <li>Q. She was trying to reduce her weight?</li> <li>A. Yes.</li> <li>Q. And it was what you phrased as an odd diet?</li> <li>A. Yes.</li> <li>Q. And it's your opinion that that diet affected her ability to heal the wound from the TVT Abbrevo device?</li> <li>MR. WES: Object to form.</li> <li>THE WITNESS: It's my opinion that that significant reduction in calorie intake when she was having post surgery and wound repair may well have</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?  A. Not specifically. Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?  A. Oh, of course. Lots of things. But protein's important as well, yes. Q. Do you have any recall of her not getting proper amount of protein in her diet?  MR. WES: Object to form, foundation.  THE WITNESS: No, I can't address whether or not she had sufficient protein in her diet.  MR. JONES: Q. When she was on this diet, was she malnutritioned?  MR. WES: Same objection.  THE WITNESS: I'm not sure what you mean by "malnutritioned." She may not have been given all the necessary nutrients.  MR. JONES: Q. Do you know one way or another whether she was getting the necessary amount of
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	<ul> <li>A. Yes.</li> <li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation, calls for speculation.</li> <li>THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were.</li> <li>MR. JONES: Q. But you do specifically recall it was a low calorie intake diet?</li> <li>A. Yes.</li> <li>Q. She was trying to reduce her weight?</li> <li>A. Yes.</li> <li>Q. And it was what you phrased as an odd diet?</li> <li>A. Yes.</li> <li>Q. And it's your opinion that that diet affected her ability to heal the wound from the TVT Abbrevo device?</li> <li>MR. WES: Object to form.</li> <li>THE WITNESS: It's my opinion that that significant reduction in calorie intake when she was having post surgery and wound repair may well have affected the healing, yes.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?  A. Not specifically. Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?  A. Oh, of course. Lots of things. But protein's important as well, yes. Q. Do you have any recall of her not getting proper amount of protein in her diet?  MR. WES: Object to form, foundation.  THE WITNESS: No, I can't address whether or not she had sufficient protein in her diet.  MR. JONES: Q. When she was on this diet, was she malnutritioned?  MR. WES: Same objection.  THE WITNESS: I'm not sure what you mean by "malnutritioned." She may not have been given all the necessary nutrients.  MR. JONES: Q. Do you know one way or another whether she was getting the necessary amount of  A. No.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	<ul> <li>A. Yes.</li> <li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation, calls for speculation.</li> <li>THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were.</li> <li>MR. JONES: Q. But you do specifically recall it was a low calorie intake diet?</li> <li>A. Yes.</li> <li>Q. She was trying to reduce her weight?</li> <li>A. Yes.</li> <li>Q. And it was what you phrased as an odd diet?</li> <li>A. Yes.</li> <li>Q. And it's your opinion that that diet affected her ability to heal the wound from the TVT Abbrevo device?</li> <li>MR. WES: Object to form.</li> <li>THE WITNESS: It's my opinion that that significant reduction in calorie intake when she was having post surgery and wound repair may well have affected the healing, yes.</li> <li>MR. JONES: Q. It may well have not have</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?  A. Not specifically. Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?  A. Oh, of course. Lots of things. But protein's important as well, yes. Q. Do you have any recall of her not getting proper amount of protein in her diet?  MR. WES: Object to form, foundation.  THE WITNESS: No, I can't address whether or not she had sufficient protein in her diet.  MR. JONES: Q. When she was on this diet, was she malnutritioned?  MR. WES: Same objection.  THE WITNESS: I'm not sure what you mean by "malnutritioned." She may not have been given all the necessary nutrients.  MR. JONES: Q. Do you know one way or another whether she was getting the necessary amount of  A. No. Q nutrients?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	<ul> <li>A. Yes.</li> <li>Q. How you about protein? Was there a focus on the amount of protein in her diet?</li> <li>MR. WES: Object to form, foundation, calls for speculation.</li> <li>THE WITNESS: Yeah, I don't really specifically recall what all the components of the diet were.</li> <li>MR. JONES: Q. But you do specifically recall it was a low calorie intake diet?</li> <li>A. Yes.</li> <li>Q. She was trying to reduce her weight?</li> <li>A. Yes.</li> <li>Q. And it was what you phrased as an odd diet?</li> <li>A. Yes.</li> <li>Q. And it's your opinion that that diet affected her ability to heal the wound from the TVT Abbrevo device?</li> <li>MR. WES: Object to form.</li> <li>THE WITNESS: It's my opinion that that significant reduction in calorie intake when she was having post surgery and wound repair may well have affected the healing, yes.</li> </ul>	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Did you focus at all when you looked at her diet in the association to wound healing, did you focus at all on the amount of protein in her diet?  A. Not specifically. Q. Okay. Protein the amount of protein in your diet is related to wound healing as well, right?  A. Oh, of course. Lots of things. But protein's important as well, yes. Q. Do you have any recall of her not getting proper amount of protein in her diet?  MR. WES: Object to form, foundation.  THE WITNESS: No, I can't address whether or not she had sufficient protein in her diet.  MR. JONES: Q. When she was on this diet, was she malnutritioned?  MR. WES: Same objection.  THE WITNESS: I'm not sure what you mean by "malnutritioned." She may not have been given all the necessary nutrients.  MR. JONES: Q. Do you know one way or another whether she was getting the necessary amount of  A. No.

#### Page 98 Page 100 THE WITNESS: It's a matter of significant 2 Q. So that's outside of the field of your expertise? 2 decrease as well as just the level. You know, 3 A. Correct. Well --3 physiologic, you know, you're sort of used to a certain 4 4 Q. Whether she was -level of intake. And when you do a drastic cut, that has A. -- specific nutritional questions are not part of 5 a bigger effect than long term. 6 6 I mean, a certain amount of nutrients may be my opinion. 7 7 O. Whether she was getting an adequate amount of healthy at some level, but when you do these sudden cuts, 8 8 nutrients in her diet is outside the field of your the body doesn't adapt that quickly. That's my point. 9 expertise? 9 MR. JONES: Q. Okay. It's not so much --10 10 MR. WES: Object to form. A. It's not --11 THE WITNESS: So my opinion is that she's got 11 Q. -- the amount of nutrients that she was getting, inadequate wound healing. Let's just reiterate that -- or 12 12 it's more the decrease in level of the nutrients perhaps 13 due to the low calorie intake diet she was on? 13 insufficient. That wound is not healing. And what were A. Yes. 14 the possible causes? 14 One of them might be this drastic diet she went 15 15 Q. Okay. 16 on. It's a pretty significant cut in calories, I suspect, 16 A. So that diet may be totally, although it seems 17 17 odd, healthy, but I still say these sudden cuts are, you for her, and that may have been a contributing factor. 18 18 And I stand by that. know -- those are the things -- a body doesn't react that 19 fast to those. It takes awhile to get back to steady 19 Now, if you bring a nutritionist in and they say, 2.0 well, that should be enough, it may be enough for somebody 20 state, and that sudden drop could -- could impair wound 21 who is not trying to heal a wound, who is not diabetic, 21 healing, could impair -- you know, resistant to infection, 2.2 who is not with all these other factors. I think it gets 22 all sorts of things, colds. 23 23 Q. Could it cause an erosion of the mesh? to be a complicated issue, but that is an added insult in 2.4 2.4 somebody who is already trying to heal postsurgical. MR. WES: Object to form. 25 25 In fact, they tell you to increase your nutrition THE WITNESS: Yeah, because I'm not sure what you Page 99 Page 101 1 because surgery -- any kind of -- this isn't that major of 1 mean by "erosion of the mesh." 2 2 a surgery, I admit, but any kind of procedure actually MR. JONES: Q. So in this case Ms. Perry was 3 increases catabolism so... 3 implanted with mesh? 4 MR. JONES: Q. Whether or not Ms. Perry was 4 A. Correct. 5 getting an adequate amount of nutrients in her diet is 5 Q. And that mesh eroded through her vaginal tissue, 6 6 outside the field of your expertise? Yes or no? correct? 7 7 MR. WES: Object to form. MR. WES: Object to form. 8 8 THE WITNESS: To the extent that I'm a physician, THE WITNESS: Well, see, that's -- yeah, that's 9 it's still within my area of expertise, but it's not my 9 kind of -- I think that's sort of the crux of the issue is 10 subspecialty, and I think that's what you're asking. So 10 that really -- I mean, what is mesh erosion and what 11 no, that's not something that I am a subspecialist in. 11 causes that? And I'm not a hundred percent clear that I 12 12 It's not nutrition. That would be correct. even understand that reading all the literature about 13 MR. JONES: Q. Okay. And you won't be giving an 13 14 opinion that the diet Ms. Perry was on was not supplying 14 Does mesh eventually come up against the 15 her an adequate amount of nutrients, correct? 15 vaginal tissues and erode or present itself? Yes, that 16 MR. WES: Object to form. 16 is. But what's causing that? And in this particular 17 THE WITNESS: Adequate for what? See, that's the 17 case, the tissue that was removed, as I mentioned, shows a 18 18 problem I'm having. Adequate for what? non-healing wound in the vaginal area of the mucosa, but 19 MR. JONES: Q. Adequate for wound healing. 19 beneath that is an area of submucosal, the normal 20 20 A. It may not have been. submucosal in vaginal tissue that looks fine. And then 21 MR. WES: Objection. 21 the next layer down is where you see the mesh. 22 22 THE WITNESS: It may not have been. So it's not clear that that mesh eroding up is 23 MR. JONES: Q. Do you know the level of 23 what caused or was even causally related. In fact, I 24 24 nutrients that she was getting in her diet? would argue it's not to that mucosal disruption. I think 25 MR. WES: Object to form, foundation. 25 that's postsurgical wound healing that didn't

#### Page 102 Page 104 1 heal. 1 findings in the literature that transvaginal mesh caused 2 MR. JONES: Q. Okay. 2 pain in women? 3 A. Now, that may have eventually, you know --3 MR. WES: Object to form, outside the scope, 4 4 because when you have a non-healing wound, you end up foundation. 5 5 getting a little bit of a depression, and that may have THE WITNESS: There are a lot of papers 6 6 caused that mesh to become closer approximated to that -discussing pain in association with the transvaginal mesh. 7 7 to the -- you know, the vaginal lumen. MR. JONES: O. Okay. 8 But you know, the mesh moving up and eroding the 8 A. And possible hypotheses about what might be 9 mucosa, I don't think that's what happened in this case. 9 causing that pain, yes. 10 10 I think it's more that there's a non-healing wound, and Q. Same for dyspareunia? 11 eventually that mesh, you know, because of the non-healing 11 A. Yes. 12 12 wound became more approximated to the surface of the Q. And you're aware that there's mesh still inside 13 13 of Ms. Perry, correct? 14 Q. You say you reviewed literature related to mesh 14 A. Yes. 15 15 erosions, right? O. And you're aware that that mesh could erode A. Yes. 16 again, correct? 16 17 17 MR. WES: Object to form, foundation, calls for Q. Okay. Fair to say that mesh has eroded in women 18 who don't smoke? 18 speculation, outside the scope. 19 MR. JONES: Q. Will you be giving any opinions 19 MR. WES: Object to form, outside the scope. 20 THE WITNESS: So yeah, it's not -- he's telling 20 about recurring erosions in this case? 21 21 us he's trying to say it's not part of my opinion. I MR. WES: Same objections. 2.2 think that's fair to say, but yeah, I'm not sure I've seen 22 THE WITNESS: I don't think so. I'm not sure. 23 a very nice well-designed study for erosion and, you know, 23 Again, I'm not really sure what the question is. 2.4 pathologic examination and risk factors. I don't think 24 MR. JONES: Q. Well, you've made -- you've given 25 25 that that exists in the literature. opinions related to the wound healing following her mesh Page 103 Page 105 1 MR. JONES: Q. Okay. You talked earlier about 1 procedure, correct? 2 2 why Ms. Perry had the mesh explanted, and you said A. Correct. 3 Ms. Perry wanted it explanted and Mr. Perry wanted it 3 Q. And you understand the mesh is still inside of 4 explanted. You didn't say Mr. Perry wanted it explanted, 4 her, correct? 5 but you made a reference to Mr. Perry, right? 5 A. Correct. 6 6 Q. So your opinions related to the wound healing 7 7 MR. WES: Object to form. following the mesh procedure are not going to be 8 8 MR. JONES: Q. Okay. And flush that out. applicable to any future mesh complications, correct? 9 Explain what you meant when you brought up Mr. Perry 9 MR. WES: Object to form, foundation, calls for 10 related to the explant surgery. 10 11 A. Well, when Mrs. Perry presented back to her 11 THE WITNESS: Assuming there's no further 12 physicians with her complaints of pain, there were two 12 problems with wound healing, then I would expect -- I 13 issues, one, that her husband was complaining of pain 13 guess I'm not still sure what you're asking me. 14 during intercourse of it shafted his penis, feeling 14 MR. JONES: Q. Could there be wound healing 15 something in the -- her anterior vaginal wall. That was 15 impairment in the future for Ms. Perry? 16 his pain. 16 A. There might be, yes. I mean, she's already 17 Her pain was pain on entry predominantly, 17 demonstrated impaired wound healing once, so it's possible 18 dyspareunia. 18 that it could happen again. She did have a second 19 Q. In your literature review of mesh erosions, did 19 surgical procedure presumably that is now well healed and 20 you see references that -- to mesh causing pain? 20 won't break down again, but I don't -- you know, I can't 21 A. I'm sorry, would you repeat that question? 21 say for certain that it wouldn't. 22 Q. Yeah. You reviewed literature related to mesh 22 It appears to me that based on at least the 23 erosions, right? 23 preliminary review of records that it was healing. 24 A. Yes. 24 Q. Have you ever had your opinions excluded by any 25 Q. Within your literature review, did you see 25 jurisdiction?

#### Page 108 Page 106 A. No, I don't think so. question again that he just asked and I responded to about 2 2 Q. Okay. the reliability of what? 3 A. What does that mean when you're asking me that? 3 Yeah, can you read that back? 4 4 Q. Have you ever offered opinions in a case and the (Record read.) 5 THE WITNESS: Okay. So I want to correct -judge has come back and excluded your opinions because 6 6 they weren't relevant to the case? answer that. The findings may be -- it's more -- it could 7 7 A. No. No. be the findings, but it also would be the -- sort of the 8 8 Q. Has a judge ever excluded your opinions on the scientific evidence supporting their conclusions. 9 bases of your lack of expertise? 9 MR. JONES: Q. Okay. 10 10 A. No. A. Right. So some of the opinions stated kind of --11 Q. Has the -- has a judge ever excluded your 11 that's based on their findings in part but --12 12 opinions on the bases that you've given opinions outside Q. One of the things you look at --13 13 of the field of your expertise? A. So it's all of that. It's the entire package. 14 A. No. 14 It's not just the -- you know, the result section. It 15 would be all of that. Okay. 15 Q. Okay. Will you be giving any opinions in this 16 case as to industry bias in the medical device Q. You want as much information as reasonably 16 17 17 possible to assess the data in the article that you're marketplace? 18 18 A. No. reviewing? 19 19 MR. WES: Object to form, outside the scope. A. Yes. 2.0 MR. JONES: Q. Will you be giving any opinions 20 Q. And one of the pieces of information you would as to industry bias in the medical literature? 21 want is whether the authors were being paid by the company 21 22 MR. WES: Same objection. 22 marketing the device that they're studying? 23 23 MR. WES: Object to form. THE WITNESS: No. 2.4 MR. JONES: Q. Correct? MR. JONES: Q. And when you reviewed the medical 2.4 25 25 literature in this case, did you look and examine the bias MR. WES: Foundation. Page 109 Page 107 1 of the authors? 1 THE WITNESS: I pay -- I pay attention to those 2 2 MR. WES: Same objection. Also, foundation, issues as well, yes. That doesn't necessarily imply that 3 calls for speculation. 3 their findings are unreliable, but no, I definitely pay 4 THE WITNESS: I wouldn't use the word "bias," but 4 attention to those things. 5 generally when I review any scientific paper, I try to 5 MR. JONES: Q. But it's something you would want 6 6 take note of who the authors are even though obviously I to know absolutely? 7 7 can't always recall their names but the centers that A. Yes. Yes. 8 8 they're associated with. Q. And when you reviewed literature, you talked 9 I also pay attention to the journal that it's 9 about long-term studies earlier, correct? 10 published in, whether peer reviewed, and if I can discern 10 11 whether it's a respected journal. They have different 11 Q. Did you notice anything in those long-term 12 12 studies where the authors were paid by companies that were levels of peer review journals. 13 So yes, I do that. And that's probably a better 13 marketing the very products that were discussed in the 14 14 way than just call it bias because we want to be sure that study? 15 15 MR. WES: Object to form, foundation, outside the people are presenting good data. 16 Q. The reason why you examine all those factors that 16 scope 17 you discussed because it helps you form a judgment as to 17 THE WITNESS: Yes. So no, there are -- there 18 were -- I don't recall specific -- which specifics, but 18 the reliability of the findings in the article, correct? 19 A. Correct. 19 there certainly are some of those, and that happens in all MR. WES: Object to form. 20 20 the literature of course. 21 MR. JONES: Q. And -- and do you examine --21 MR. JONES: Q. And did you examine whether the 22 strike that. 22 authors in some of those long-term studies were the 23 A. Wait --23 inventors of the products that they were reporting on? 24 24 MR. WES: Same objections. Q. It's something that you would -- go ahead. 25 A. So wait a second. Why don't you -- repeat that 25 MR. JONES: Why would it be important when you're

#### Page 112 Page 110 (Short break taken.) reviewing medical literature to help form your opinions in 2 this case to examine if the authors were, in fact, the 2 MR. JONES: We're back on the record. That's all 3 inventors of the product they were reporting on? 3 the questioning I have for you, Doctor. I'll now pass the 4 4 MR. WES: Object to form, foundation, calls for witness. 5 5 EXAMINATION BY MS. COTA speculation. 6 6 THE WITNESS: Well, it always places things in MS. COTA: Q. Good afternoon, Doctor Longacre. 7 7 context, but you know, other than that -- yeah, you know, My name is Laura Cota. I don't think I introduced myself 8 it's good to know these things, but they don't necessarily 8 earlier. I apologize for that. Our firm represents 9 impact -- they may, but they don't necessarily impact the 9 Dr. Luu in this matter, and I have just a few questions 10 10 validity or dis-validity, if you will, of their findings. for you. I'm going to try not to repeat any of the 11 11 MR. JONES: Q. When you've served on editorial questions that counsel has already asked, but I may. And 12 12 boards for medical journals, have you required that the if I do, I'm going to apologize for that in advance. 13 13 author submit disclosures related to how much money We spoke in the beginning of counsel's 14 they've been paid by companies that they're reporting on? 14 questioning about the documents you have reviewed in your A. Yes. 15 work on this case, and I just want to clarify, you 15 16 16 MR. WES: Object to form. mentioned that you've reviewed some of plaintiff's medical THE WITNESS: All the journals that I review 17 17 records. Did you review the plaintiff's record -- or I'm 18 require disclosures. I don't know that if it's the exact sorry, Ms. Perry -- Ms. Perry's records from Dr. Luu? 18 19 19 dollar amount, but you know, full disclosure is required A. Yes, I did. 20 before publication. 20 Q. And did you review Dr. Luu's complete chart for 21 21 MR. JONES: Q. Have you made comments online Ms. Perry or just portions of it? 22 22 A. I think I reviewed most, if not all, of the related to industry bias in the medical device 23 chart. I think I was given most of it, and I think I 23 marketplace? 24 24 MR. WES: Object to form, foundation, outside the reviewed most of it. 25 25 Q. Okay. And how about -- are you familiar with scope. Page 111 Page 113 1 THE WITNESS: No. 1 Dr. Allen and his involvement with Ms. Perry? 2 2 MR. JONES: Q. You haven't? A. Yes. 3 3 Q. And did you review Dr. Allen's chart of 4 Q. Okay. Do you have social media accounts? 4 Ms. Perry? 5 5 A. No. Q. You don't? 6 6 Q. And how about Dr. Singh? Are you aware of 7 7 A. No. Well, what do you mean? Which kind? Dr. Singh's involvement with Ms. Perry? 8 8 Q. Are you on Twitter? A. Yes. 9 A. No. No. 9 Q. And did you review Dr. Singh's chart --10 Q. Okay. Facebook? 10 A. Yes. 11 Q. -- of Ms. Perry? 11 A. No. 12 A. Yes, I did. 12 Q. LinkedIn? 13 A. Yes. 13 Q. And you're aware that Ms. Perry had the procedure 14 Q. Okay. Have you made any comments online related 14 performed by Dr. Luu at San Joaquin Community Hospital? 15 to concerns about marketing in the medical device 15 A. I don't specifically remember the name of the 16 16 marketplace? hospital. 17 MR. WES: Object to form, foundation, outside the 17 Q. Do you recall if you reviewed the hospital 18 18 records pertaining to Ms. Perry's procedures performed scope. 19 THE WITNESS: No. 19 20 20 MR. JONES: Okay. I think that may be all the A. I may have briefly reviewed them. 21 questions I have. I want to go off record, take a 21 Q. Okay. And we talked a little bit about 22 ten-minute break and then sounds like there may be some 22 deposition transcripts, and I know you said you reviewed 23 more questions. We'll go figure that out. Does that 23 Ms. Perry's and her husband's deposition transcripts. 24 sound like a good plan? 2.4 Did you review Dr. Luu's deposition transcript? 25 MR. WES: Sounds good. 25 A. Yes, I did sometime ago.

	Page 114		Page 116
1	Q. Do you recall how long ago that might have been?	1	you had described as from the posterior repair
2	A. A month or so ago.	2	procedure. It's the
3	Q. Okay. And how about Dr. Allen? Did you review	3	A. Yes.
4	his deposition transcript?	4	Q. Okay. You got that?
5	A. Yes.	5	Okay. What I'm looking at it says, "Tissue ID is
6	Q. And was that the same amount of time ago, about a	6	vaginal wall posterior excision."
7	month and a half ago?	7	Can you tell me what in layman's terms what
8	A. I think that was a little more recent. I think	8	does that mean? What are we talking about?
9	that came in after Dr. Luu's.	9	A. Posterior vaginal wall. So mucosa and some of
10	Q. Okay. And Dr. Singh, did you review his	10	the submucosa.
11	deposition transcript?	11	Q. And that would have been taken from where?
12	A. Yes.	12	A. The vagina.
13	Q. And how long ago did you review Dr. Singh's	13	Q. Can you be any more specific about the location
14	deposition transcript?	14	that this sample would have been taken from?
15	A. A month or so ago.	15	A. Distal posterior vagina from my understanding of
16	Q. Okay. And I believe you testified you have not	16	the surgical procedure.
17	reviewed Dr. Margolis's deposition transcript?	17	Q. And do you know why the sample would have been
18	A. Correct. I've had portions of it relayed to me,	18	taken?
19	but I have not reviewed it. I'm not even sure I received	19	MR. WES: Object to form.
20	it.	20	THE WITNESS: This based on other medical
21	Q. Okay. Do you know what portions of his	21	records, he performed an anterior and posterior
22	transcript have been forwarded to you?	22	colporrhaphy procedure, and it was because there was a
23	A. None were forwarded. I was just read a few	23	cystocele and rectocele.
24	Q. And what portions of Dr. Margolis's deposition	24	MS. COTA: Q. And so the purpose was to
25	testimony were read to you? If you can give me sort of a	25	determine the pathology of the cystocele and or
	Page 115		Page 117
1	Page 115 summary.	1	Page 117  A. No. No, this is part of
1 2		1 2	
	summary.		A. No. No, this is part of
2	summary.  A. I think that he was discussing shrinkage of the	2	A. No. No, this is part of MR. WES: Object to form.
2	summary.  A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point	2 3	<ul><li>A. No. No, this is part of</li><li>MR. WES: Object to form.</li><li>THE WITNESS: Again, my I'm not a surgeon.</li></ul>
2 3 4	summary.  A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.	2 3 4	<ul> <li>A. No. No, this is part of</li> <li>MR. WES: Object to form.</li> <li>THE WITNESS: Again, my I'm not a surgeon.</li> <li>This is not but in terms of my receiving these</li> </ul>
2 3 4 5	summary.  A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was	2 3 4 5	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that
2 3 4 5 6	summary.  A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as	2 3 4 5 6	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort
2 3 4 5 6 7	summary.  A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the	2 3 4 5 6 7	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the
2 3 4 5 6 7 8	summary.  A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?	2 3 4 5 6 7 8 9	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's
2 3 4 5 6 7 8 9	summary.  A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the explant	2 3 4 5 6 7 8 9 10	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's thought to help prevent that rectocele. Same thing for
2 3 4 5 6 7 8 9	summary.  A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the	2 3 4 5 6 7 8 9 10 11	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's
2 3 4 5 6 7 8 9 10	summary.  A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the explant  Q. Explant?  A tissue, yes.	2 3 4 5 6 7 8 9 10 11 12 13	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's thought to help prevent that rectocele. Same thing for the cystocele, but that would be the anterior vaginal mucosa.
2 3 4 5 6 7 8 9 10 11 12 13 14	A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the explant  Q. Explant?  A tissue, yes.  Q. Okay. And I'm sorry, I know counsel asked you	2 3 4 5 6 7 8 9 10 11 12 13 14	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's thought to help prevent that rectocele. Same thing for the cystocele, but that would be the anterior vaginal mucosa.  MS. COTA: Q. Okay. And so is this just a
2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the explant  Q. Explant?  A tissue, yes.  Q. Okay. And I'm sorry, I know counsel asked you this, but I'm not sure what the response was.	2 3 4 5 6 7 8 9 10 11 12 13 14 15	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's thought to help prevent that rectocele. Same thing for the cystocele, but that would be the anterior vaginal mucosa.  MS. COTA: Q. Okay. And so is this just a standard procedure to your knowledge?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the explant  Q. Explant?  A tissue, yes.  Q. Okay. And I'm sorry, I know counsel asked you this, but I'm not sure what the response was.  Dr. Margolis, he prepared a report of his independent	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's thought to help prevent that rectocele. Same thing for the cystocele, but that would be the anterior vaginal mucosa.  MS. COTA: Q. Okay. And so is this just a standard procedure to your knowledge?  A. What
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the explant  Q. Explant?  A tissue, yes.  Q. Okay. And I'm sorry, I know counsel asked you this, but I'm not sure what the response was.  Dr. Margolis, he prepared a report of his independent medical exam of Ms. Perry. Have you reviewed that report?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's thought to help prevent that rectocele. Same thing for the cystocele, but that would be the anterior vaginal mucosa.  MS. COTA: Q. Okay. And so is this just a standard procedure to your knowledge?  A. What MR. WES: Object to form.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the explant  Q. Explant?  A tissue, yes.  Q. Okay. And I'm sorry, I know counsel asked you this, but I'm not sure what the response was.  Dr. Margolis, he prepared a report of his independent medical exam of Ms. Perry. Have you reviewed that report?  A. I may have reviewed that, but I don't I don't	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's thought to help prevent that rectocele. Same thing for the cystocele, but that would be the anterior vaginal mucosa.  MS. COTA: Q. Okay. And so is this just a standard procedure to your knowledge?  A. What MR. WES: Object to form. MS. COTA: Q. To, I guess, get a sample to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the explant  Q. Explant?  A tissue, yes.  Q. Okay. And I'm sorry, I know counsel asked you this, but I'm not sure what the response was.  Dr. Margolis, he prepared a report of his independent medical exam of Ms. Perry. Have you reviewed that report?  A. I may have reviewed that, but I don't I don't have a clear memory of that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's thought to help prevent that rectocele. Same thing for the cystocele, but that would be the anterior vaginal mucosa.  MS. COTA: Q. Okay. And so is this just a standard procedure to your knowledge?  A. What MR. WES: Object to form. MS. COTA: Q. To, I guess, get a sample to pathology to review in this instance?
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the explant  Q. Explant?  A tissue, yes.  Q. Okay. And I'm sorry, I know counsel asked you this, but I'm not sure what the response was.  Dr. Margolis, he prepared a report of his independent medical exam of Ms. Perry. Have you reviewed that report?  A. I may have reviewed that, but I don't I don't have a clear memory of that.  Q. Okay. Do you recall if any of the deposition	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's thought to help prevent that rectocele. Same thing for the cystocele, but that would be the anterior vaginal mucosa.  MS. COTA: Q. Okay. And so is this just a standard procedure to your knowledge?  A. What MR. WES: Object to form. MS. COTA: Q. To, I guess, get a sample to pathology to review in this instance?  A. Most most hospitals require their surgeons to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the explant  Q. Explant?  A tissue, yes.  Q. Okay. And I'm sorry, I know counsel asked you this, but I'm not sure what the response was.  Dr. Margolis, he prepared a report of his independent medical exam of Ms. Perry. Have you reviewed that report?  A. I may have reviewed that, but I don't I don't have a clear memory of that.  Q. Okay. Do you recall if any of the deposition transcript portions that were read to you from	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's thought to help prevent that rectocele. Same thing for the cystocele, but that would be the anterior vaginal mucosa.  MS. COTA: Q. Okay. And so is this just a standard procedure to your knowledge?  A. What MR. WES: Object to form. MS. COTA: Q. To, I guess, get a sample to pathology to review in this instance?  A. Most most hospitals require their surgeons to submit all tissue that's removed from patients to
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the explant  Q. Explant?  A tissue, yes.  Q. Okay. And I'm sorry, I know counsel asked you this, but I'm not sure what the response was.  Dr. Margolis, he prepared a report of his independent medical exam of Ms. Perry. Have you reviewed that report?  A. I may have reviewed that, but I don't I don't have a clear memory of that.  Q. Okay. Do you recall if any of the deposition transcript portions that were read to you from Dr. Margolis's deposition referred to his report?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's thought to help prevent that rectocele. Same thing for the cystocele, but that would be the anterior vaginal mucosa.  MS. COTA: Q. Okay. And so is this just a standard procedure to your knowledge?  A. What MR. WES: Object to form. MS. COTA: Q. To, I guess, get a sample to pathology to review in this instance?  A. Most most hospitals require their surgeons to submit all tissue that's removed from patients to pathology.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the explant  Q. Explant?  A tissue, yes.  Q. Okay. And I'm sorry, I know counsel asked you this, but I'm not sure what the response was.  Dr. Margolis, he prepared a report of his independent medical exam of Ms. Perry. Have you reviewed that report?  A. I may have reviewed that, but I don't I don't have a clear memory of that.  Q. Okay. Do you recall if any of the deposition transcript portions that were read to you from  Dr. Margolis's deposition referred to his report?  A. No, I don't recall that.	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's thought to help prevent that rectocele. Same thing for the cystocele, but that would be the anterior vaginal mucosa.  MS. COTA: Q. Okay. And so is this just a standard procedure to your knowledge?  A. What MR. WES: Object to form. MS. COTA: Q. To, I guess, get a sample to pathology to review in this instance?  A. Most most hospitals require their surgeons to submit all tissue that's removed from patients to pathology. Q. Okay.
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. I think that he was discussing shrinkage of the mesh and he discussed the pathology report at some point and it was that discussion.  Q. Okay. And the pathology report he discussed, was it the the pathology report that you've referred to as the from the I'm sorry, give me one second the posterior repair procedure? Was it that pathology report?  A. No. I think he was mostly just at least the parts that were relayed to me was discussing the explant  Q. Explant?  A tissue, yes.  Q. Okay. And I'm sorry, I know counsel asked you this, but I'm not sure what the response was.  Dr. Margolis, he prepared a report of his independent medical exam of Ms. Perry. Have you reviewed that report?  A. I may have reviewed that, but I don't I don't have a clear memory of that.  Q. Okay. Do you recall if any of the deposition transcript portions that were read to you from Dr. Margolis's deposition referred to his report?	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	A. No. No, this is part of MR. WES: Object to form. THE WITNESS: Again, my I'm not a surgeon. This is not but in terms of my receiving these specimens, my understanding of these procedures is that when they're basically removing excess tissues to sort of tighten it up because the rectocele is basically the rectum is protruding into the vaginal lumen causing prolapse.  And so by removing that redundant tissue, it's thought to help prevent that rectocele. Same thing for the cystocele, but that would be the anterior vaginal mucosa.  MS. COTA: Q. Okay. And so is this just a standard procedure to your knowledge?  A. What MR. WES: Object to form. MS. COTA: Q. To, I guess, get a sample to pathology to review in this instance?  A. Most most hospitals require their surgeons to submit all tissue that's removed from patients to pathology.

30 (Pages 114 to 117)

#### Page 120 Page 118 1 A. Some hospitals don't have the explicit 1 2 requirement as others do. 2 A. Okay. I don't have mine. I don't know why. Do 3 Q. Okay. Very good. Thank you for clarifying that. 3 I? Oh, nope. Here it is. Go ahead. 4 And as part of Dr. Luu's chart, did you review 4 Q. Okay. Page 2. And if we look at -- let's see --5 5 Dr. Luu's operative report of Ms. Perry's procedures? I subsection C, number two, where it says, "Fragments of 6 6 believe they're on March 23rd of 2011. hair bearing skin from perineum." 7 7 A. I'm sorry, did I review the operative procedure? Can you explain how do you know that that's what 8 8 you were looking at? How do you identify skin from the Yes. 9 Q. Okay. So you read Dr. Luu's operative report? 9 perineum? 10 10 A. So that's a fair question. Basically I was A. Yes. 11 Q. And do we know when during this procedure the 11 trying to distinguish vaginal mucosa from cutaneous 12 12 sample that we're talking about in this pathology report tissue, and that's how I knew. I mean, it wasn't just 13 13 would have been obtained? vaginal mucosa that was in the specimen, because that 14 14 A. I have the report here. I guess I'm not sure. looks different from skin. 15 15 What do you mean when was it obtained? Now, because this is a posterior colporrhaphy Q. Do you know when during Dr. Luu's procedures this 16 procedure, the skin would be the perineum. It should be. 16 17 17 sample would have been obtained? If I knew -- how do I distinguish -- if somebody gave me a 18 MR. WES: Object to form, foundation, calls for 18 slide from perineum and a slide from maybe the buttock, 19 19 speculation. would I be able to tell the difference? No. It's skin. 20 THE WITNESS: Short of reading this report, I 20 But there was no reason he would be taking skin 21 21 wouldn't know. from someplace else. If he's taking it -- if the 2.2 MS. COTA: Q. Okay. Well, that's fine. We'll 22 surgeon's removing skin, it would have been in the 23 move on. 23 perineal region. 24 24 I believe, Dr. Longacre, you testified earlier Q. And further, what is the perineum? 25 25 that -- or actually, it says here in your report that A. It's the skin -- in this particular case it would Page 119 Page 121 there are no gross findings because nothing but slides 1 be the skin immediately posterior to the vaginal -- to the 1 2 2 were reviewed by you. introitus, the vaginal opening. 3 A. Correct. 3 Q. And so your description here of it being from the 4 Q. And is it true that based on the pathology 4 perineum is because of -- is based on the procedure that 5 report -- and I apologize I cannot read this physician's 5 Dr. Luu performed? 6 6 name -- this physician would have actually viewed the A. Yes. It's contextual. I can tell that it's 7 7 actual sample? perineum as opposed to vaginal mucosa because there's hair 8 8 MR. WES: Object, form, calls for speculation. and sebaceous glands, and you don't see that in vaginal 9 THE WITNESS: Well, no, there is a gross 9 10 description in the pathology report from the pathologist. 10 Q. Okay. But like you said, you wouldn't be able to 11 MS. COTA: Q. And so that means that this 11 differentiate -- if you didn't know what it was, you 12 12 physician actually viewed the sample? wouldn't be able to differentiate skin from the perineum 13 MR. WES: Same objection. Also, foundational. 13 with skin from -- I think your example was the buttock? 14 14 THE WITNESS: Well, actually that's not the case. A. Correct. 15 The gross description was dictated by one physician, 15 Q. Okay. In your looking at the samples, was it 16 whereas the diagnosis was signed out -- is rendered by a 16 obvious to you that there was something other than mucosal 17 17 tissue on the slide, in the sample? different physician. 18 MS. COTA: Q. Okay. But based on this pathology 18 MR. WES: Object to form. 19 report somebody -- some physician --19 THE WITNESS: Yes. 20 20 A. Yes. MS. COTA: Q. Okay. And then moving down to 21 Q. -- viewed the actual sample? 21 subsection D. And let's see. On -- I guess this is 22 A. Correct. 22 little -- little i, 1, where it says, "Hair bearing skin," 23 Q. Okay. Thank you. And moving on to your list of 23 et cetera. 24 24 Can you, as Counsel would say, flush that out for opinions on page 2 -- and thank you for providing this for 25 us. It made it a lot easier and probably more expedient 25 me and just explain what that means and why it's

#### Page 124 Page 122 1 important? 1 could theoretically cut more sections. 2 A. Again, it's just indicating that during -- that 2 Q. Okay. 3 it wasn't just vaginal mucosal tissue that was removed, it 3 A. So it's not like every --4 4 was skin. It was cutaneous tissue. And again, by context MR. WES: Previous objections. 5 it was -- it was the posterior perineal tissue. 5 MS. COTA: Q. So you haven't looked at the 6 6 entire sample? Is that fair to say? And the reason I know that is because there were 7 7 hair and there were sebaceous glands, and it was a little MR. WES: Same objections. 8 more edematous than -- both -- actually, both the vaginal 8 THE WITNESS: I'm not sure. No, I don't think 9 tissue and the perineal tissue was a little more edematous 9 that's fair to say because I'm not even sure what you're 10 10 than usual, but that's -- yeah, that's a soft finding, if asking. 11 11 you will. It's not surprising if she has prolapse, but MS. COTA: Q. Well, I think you talked about the 12 12 it's not -- it's not an overly significant finding. sample they take and cut and make -- prepare slides out of 13 13 Q. Okay. And what does edematous mean? 14 14 A. Yes. A. Filled with fluid. It's not exactly it, but 15 15 that -- you know, for a lay person, that's sort of what it Q. Do you know if you've viewed -- like if all the 16 means. If you have tissue protruding, it can be a little 16 material has been prepared as slides? 17 17 more edematous. A. No. I don't know that. 18 Q. Okay. So it could be that there's portions of 18 Q. Gotcha. Thank you. And you testified earlier --19 19 and I'm looking at your points here. It the says 13 the sample that you haven't looked at? 20 pieces were perineal -- I hate that word. I can't say 20 MR. WES: Same objections. 21 21 it -- and the remainder eight pieces were of the mucosa. THE WITNESS: There will be -- no. You know, 22 22 what's going to be left is additional level sections of So did you look at 21 slides altogether? 23 23 A. No. That was just the number of pieces of tissue that tissue, but there's not going to be suddenly another 24 that were on the slide -- on the slides in total. 24 piece of tissue that I didn't see. That's highly 25 25 Q. I see. unlikely. That would be not good pathology practice. Page 123 Page 125 1 A. So there were four blocks and in putting --1 You're supposed to cut into your block enough that you've 2 2 adding up all the pieces in each of those four slides that seen all the -- that the pathologist has viewed all the 3 were made from the four blocks, there were that many 3 tissue on those slides. So --4 4 MS. COTA: Q. Okay. fragments of tissue. 5 Q. Do you know if the entire sample was -- I don't 5 A. So there may be additional levels, but there 6 know what the right word is -- prepared and placed on 6 won't be -- there should not be more tissue that I didn't 7 7 8 8 MR. WES: Object to form, foundation, calls for Q. I see. And so would each slide have the four 9 speculation. 9 levels that you described, the mucosa, the 10 THE WITNESS: So do I know for -- personally 10 submucosa, the muscularis and the adventitia? 11 because, no, I didn't do the gross. But based on the path 11 A. Not necessarily. Most of them just have mucosa 12 report, it says, "Sections all, four cassettes." That 12 and submucosa. 13 generally means all the tissue was submitted. That's what 13 Q. Okay. And the skin from the perineum, where 14 that should mean. 14 would -- so that was along with the mucosa or the 15 If they meant something else, then it's not --15 submucosa level that you saw? 16 it's a miscommunication. Generally when we say all, all 16 A. No. No. It's another piece of tissue. And then 17 the tissue's been submitted. 17 we'll have skin. Then you don't call it -- it's not MR. COTA: Q. Okay. Do you know if you have 18 18 mucosae. You call it epidermis and then dermis --19 viewed all of the tissue from the sample that was 19 20 20 A. -- which is the cutaneous correlate for mucosa 21 A. Four cassettes were made, and so there were four 21 and submucosa. 22 sets of slides, so that should be all of the slides of the 22 Q. Gotcha. Okay. Thanks. 23 tissue. 23 A. There was -- most of the fragments were really 24 Now, you could cut additional -- there's still 24 distinct. They were either skin or vaginal mucosa. As I 25 tissue in the blocks, in the paraffin blocks, and you 25 recall, there was one fragment where most of the tissue

#### Page 128 Page 126 introitus? 1 was vaginal mucosa, and then it transitioned into the 2 2 A. Yes. 3 So obviously he had taken tissue right at the 3 Q. But Ms. Perry continues to complain of pain; is 4 junction of the vaginal mucosa and the skin, again --4 that right? 5 5 MR. WES: Object to form, calls for speculation, arguing, again, that it is, in fact, perineum because 6 6 foundation, outside the scope. they're actually connected. 7 7 Q. Okay. And I believe you testified that the -- I MS. COTA: Q. You can answer. 8 could be misstating this, but that the slides you were 8 A. My understanding is because I recently saw a 9 looking at there was some degradation from the process or 9 document that she was, yes. 10 10 something along those lines? Q. Okay. And were you aware that in addition to the 11 A. No, not degradation. 11 complaints of dyspareunia, she also has complained of 12 MR. WES: Objection, form, misstates the 12 vaginal pain? 13 13 MR. WES: Same objections. 14 THE WITNESS: Yes. So there's no degradation. 14 THE WITNESS: Yes. I'm not sure what vaginal 15 There's no disruption. There's no interpretive issues 15 pain is, but yes. 16 with the initial tissue that was removed during the 16 MS. COTA: Q. Okay. 17 A. I understand that she has that. She says she has 17 insertion of the mesh. It was the mesh -- the second 18 procedure when the mesh was removed, that tissue was 18 19 fairly disrupted. 19 Q. Okay. And is it your understanding that she 2.0 MS. COTA: Q. Okay. Okay. I was confusing two 20 continues to complain of vaginal pain, as we sit here 21 2.1 words and two different pathology reports. today? 22 And I know you're familiar with Ms. Perry's 22 MR. WES: Same objections. 23 23 THE WITNESS: I don't know what she -- what's statements in her deposition and her medical records. 24 Have you reviewed any of her responses to any discovery 24 happening today, but I realize that there was -- so 25 requests that have been made in this case? 25 basically, yeah, I was actually pretty surprised because I Page 127 Page 129 1 A. I'm -- I don't know 'cause I'm not sure what 1 thought post the mesh excision things were a lot better, 2 2 you're asking. I don't know what discovery means. and I saw documents that all her pain was gone. And then 3 Q. Okay. Right. Typically we lawyers, you know, 3 it was very recently that I was supplied with a document 4 4 that she has pain again. have to ask lots of questions, and one thing we do in 5 5 preparing for trial is send written questions to the MS. COTA: Q. Okay. 6 6 different parties in the case. And then it's -- you know, A. It sounded -- I thought it had resolved on my 7 7 the party has to respond to them. first review of the postsurgical records. 8 8 I'm just wondering if your counsel had provided Q. Okay. And were you aware that she also 9 any of Ms. Perry's responses to any of those requests to 9 complains -- or complained -- yeah, we'll leave it as 10 10 complain of pelvic pain. you to review? 11 A. They may have. I've seen other material. 11 MR. WES: Same objection. 12 12 Q. Okay. But as far as knowing whether or not THE WITNESS: Yeah, I'm not sure about the pelvic 13 they're discovery responses, you wouldn't be able to tell 13 pain. I'm not so aware of that. I know there's other 14 me? 14 pain issues related to a motor vehicle accident and some 15 A. No. 15 back pain, but I don't -- other than that I don't know a 16 Q. Okay. Do you know, as we sit here today, if 16 lot about that. 17 Ms. Perry continues to complain of pain? 17 MS. COTA: Q. Okay. But even since Dr. Allen's 18 18 A. My understanding is that she is. procedures to excise a portion of the mesh and also widen 19 Q. Okay. And you reviewed Dr. Allen's records, so I 19 the introitus, Ms. Perry continues to complain of pain? 20 20 know that you are aware that she had a portion of the mesh MR. WES: Objection, form, foundation, 21 excised, I believe, in January of 2012; is that right? 21 speculation, outside the scope. 22 22 A. Correct. I believe that's when it was. MS. COTA: Q. You can answer. 23 Q. Okay. And are you aware that during the excision 23 A. Yeah, she's still complaining of some kind of 24 24 procedure that Dr. Allen also performed a procedure to pain -- or has started complaining again, I guess is what 25 basically widen the entrance or the circumference of the 25 I would say, because I thought at some point she was

#### Page 132 Page 130 MS. COTA: Q. And I believe you stated that in reporting it was all resolved, and now it seems to have 2 2 come back. your opinion the plaintiff's complaints of pain were due 3 Q. And is that based on your review of her medical 3 to the colporrhapy procedure; is that right? 4 4 A. I think that her dyspareunia is likely due to the records? 5 5 A. Yes. The records that have been supplied by me, colporrhaphy and that narrowing. 6 6 Q. And what is that opinion based on? yeah. 7 O. Okay. And I know you're aware of Dr. Margolis's 7 A. It's a known complication of colporrhaphy, 8 8 reports, although you haven't had a chance to review it, number one; and number two, there was a substantial amount 9 the report of the IME. So --9 of that perineal tissue that was removed. And the more of 10 10 the perineal tissue, the more likely that there's going to A. The IME? 11 be pain associated with that -- with a posterior 11 Q. Yes, the independent medical exam. I'm sorry. 12 12 colporrhaphy procedure. And that's -- I think that's A. Okay. Q. Okay. So are you aware that in Dr. Margolis's 13 13 pretty well established that there's a significant risk 14 14 report he writes that he is able to replicate or reproduce for that. 15 15 the plaintiff's pain complaints by palpating her vagina Q. And is that something you know from your practice 16 16 where the mesh is? as a pathologist? MR. WES: Objection, form, foundation, calls for 17 A. Yes. Just -- well, practice as a GYN 17 18 18 speculation. This is outside the scope. pathologist, yes. 19 19 Q. Okay. And is that based in any way on any of the THE WITNESS: And I don't recall that. I'm 20 20 material that you reviewed that was provided to you by not --21 21 MS. COTA: Q. Okay. So you're not aware that 22 A. There were some -- there was some literature that 22 Dr. Margolis wrote that in his independent medical exam 23 was provided recently on complications of colporrhaphy, 23 24 24 A. No, not specifically I'm not. and they were actually provided after I made the 25 25 observation there was an awful lot of perineal tissue. Q. Okay. And I know you mentioned earlier you read Page 131 Page 133 1 Patrick Perry's deposition transcript and talked about his 1 And I wondered if that was -- my first thought was maybe 2 2 complaints of pain, and I think you said that his this is what's really causing her dyspareunia, and it was 3 complaints had to do with feeling something, I think you 3 shortly thereafter they provided me with this literature. 4 said, in the posterior or anterior portion of the vagina 4 Q. Okay. Hang on one second here. 5 of material that he could feel on his penis; is that 5 A. And it also corroborates -- I believe Dr. Allen 6 6 right? seemed to think that was part of it. I think he was 7 7 MR. WES: Object to form, foundation, misstates attributing her pain to that as well. 8 8 the testimony. Q. And that's from reading his deposition transcript 9 THE WITNESS: I think it was something was 9 or his medical records? 10 irritating the shaft of his penis during intercourse. 10 A. One or the other. MS. COTA: Q. Do you recall if he testified that 11 11 Q. And you spent some time telling us about the --12 it was -- felt like a Brillo pad? 12 and I'm going to say this wrong -- is it a mucosal 13 A. That part I don't --13 non-healing wound or a non-healing wound in the mucosa 14 MR. WES: Same objection. or --14 15 THE WITNESS: I don't really recall what --15 A. Either way. 16 his --16 Q. Okay. Great. 17 MS. COTA: Q. Okay. 17 A. Yeah. Q. You talked about that. Could that have been 18 A. -- analogy. I don't remember that. 18 19 Q. Okay. Do you recall if he testified that the 19 causing Ms. Perry's pain? 20 narrow opening -- narrow introitus was causing him any 20 MR. WES: Object to form. 21 pain? 21 THE WITNESS: It didn't sound like it. The kind 22 MR. WES: Object to form. 22 of pain she was describing, the dyspareunia, did not sound 23 THE WITNESS: I don't recall that. 23 like that that was -- because she was really just talking 24 MR. WES: Speculation. 24 about pain on entry initially, and that didn't sound like 25 THE WITNESS: No. 25 it was anything to do with any kind of non-healing wound.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1

2

3

12

13

17

18

20

25

### Page 134

MS. COTA: Q. In general, in a non-healing wound of the type you're describing, would that potentially cause someone to suffer some pain?

A. It may or may not. Again, you know, if you're -yeah, it may not. If there's some level of vascular
insufficiency that -- particularly in diabetics. Now,
she's not the classic type I, but she has been diagnosed
with type II. They can have wound healing problems, and
they may not have the same -- they may not notice they

9 they may not have the same -- they may not notice they
10 have injury. Their sensation may not be there. So it's
11 possible that, you know -12 O And I'm sorry, you told us this earlier, and I

Q. And I'm sorry, you told us this earlier, and I said I wasn't going to do this, but when did you first start reviewing materials for this case?

15 A. It was mid or late summer --

Q. Okay.

2

3

4

5

6

7

8

13

14

16

18

2.0

21

23

2.4

25

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

17 A. -- of this year obviously.

Q. And when did you first look at any of the slides?

19 A. I think it was late summer.

Q. Summer. You mean August or September?

A. I think August.

Q. And did you look at all of the slides you

reviewed all at once, or did that happen in stages?

A. There was stages, but I think -- no, I think I did -- I reviewed all the slides the first time, I

Page 136

other than the complaints of dyspareunia; is that right?

MR. WES: Objection, form, calls for speculation,

foundation, outside the scope.

THE WITNESS: My understanding it's more recently she's complaining of different kinds of pain now, yes.

MS. COTA: Q. Okay. And do you have any opinion of what could be causing those complaints of pain?

MR. WES: Objection, outside the scope, calls for speculation.

THE WITNESS: Well, okay. So I -- my response is yes and no as to whether I have an opinion. I do think that post colporrhaphy, even when you try to, you know, fix the pain, that it's continuing and ongoing.

So even though Dr. Allen tried to dilate the -you know, the expand the circumference and dilate the
introitus, there's always a chance that it will -- the
pain, the dyspareunia, will recur for lots of reasons, but
one of them would just be that it just sort of narrows
down again.

So I would suspect that if, in fact, she's redeveloped pain, that's probably still a component of that colporrhaphy procedure. But there are other components of that pain that I have no opinion, 'cause they don't really make sense to me. I don't understand why she has them.

### Page 135

believe. And then there was another set of recuts that I saw again, but they were recuts of the slides I had already seen, as far as I recall.

Q. Okay. So you were actually -- you saw all the slides for purposes of what they revealed to you in August of this year; is that right? That probably wasn't a good question.

MR. WES: Objection, form.

THE WITNESS: I think it was August.

MS. COTA: Q. Okay. And so was it at that time upon your review in August that you came to -- or formed your opinion that there were these fragments of the perineum?

MR. WES: Object to form.

MS. COTA: Q. I'm sorry, was that a yes?

A. Yes. At the time of my first review of the colporrhaphy tissue that was removed, yes, that was my opinion then.

Q. Okay. And prior to your review of the samples, had you received any literature regarding the potential risks or side effects of colporrhaphy procedures?

A. No. No. As I mentioned, those came after I made the observation that there was a significant amount of that perineal tissue that was removed.

Q. Okay. And Ms. Perry, she's complaining of pain

Page 137

Q. Okay. And what --

So I can't address those.

Q. And what -- I'm sorry, were you finished?

4 A. Well, I think she said something about burning 5 vaginal pain without -- just de novo. I don't understand 6 that.

Q. Okay. Any other components of her pain thatdon't make sense to you?

9 A. Well, those are the only one that I recall. When
10 I read it, it didn't make any -- I don't know what that
11 means --

Q. Okay.

A. -- or how to explain that or even --

Q. And her -- what about her complaints of vaginal pain? Does that make any sense to you?

MR. WES: Same objections.

THE WITNESS: No, not really.

MS. COTA: Q. And pelvic pain?

19 A. Well, again --

MR. WES: Same objections.

THE WITNESS: Again, I don't recall reading about the pelvic. I don't know what she means by pelvic pain.

So that I don't know.

24 MS. COTA: Q. Okay. If --

A. Pelvis is a big area, so I don't know where she's

35 (Pages 134 to 137)

#### Page 140 Page 138 talking about or what that's referring to. 1 make clear exactly what is on that flash drive that has 2 Q. Okay. So if you were aware that she -- or if 2 actually been reviewed. 3 she -- if you were aware that she was complaining of 3 MR. JONES: Versus what hadn't been reviewed? 4 pelvic pain, you wouldn't know the cause of that; is that 4 MR. WES: Correct. 5 5 MR. JONES: Okay. Thank you. right? 6 6 Q. Doctor, you understand this trial is set to begin A. I wouldn't --January 12th, 2015, correct? 7 7 MR. WES: Object to form, calls for speculation, 8 8 A. Correct. outside the scope. 9 Go ahead. 9 Q. And I assume you've cleared your schedule and you 10 would be able to come and testify the month of January? 10 MS. COTA: Q. You can answer. A. After the 12th, yes. 11 A. No, I wouldn't know. 11 12 Q. You'll be able to testify? 12 Q. Okay. And Dr. Longacre, I know you've testified 13 A. Yes. 13 and told us that, you know, these opinions, you know, 14 constitute the opinions you'll be giving at trial. 14 Q. Final question. Will you be giving an opinion 15 15 that the AC procedure, anterior colporrhaphy procedure, Are you going to be expressing any opinion of the AC procedure, caused dyspareunia in Ms. Perry? 16 Dr. Luu's procedures that he performed on Ms. Perry? 16 17 MR. WES: Object to form. 17 18 18 Q. Are you going to be making any criticisms of the THE WITNESS: I think -- well, it was an anterior 19 19 procedures that Dr. Luu performed on Ms. Perry? and posterior colporrhaphy, and it's generally the 2.0 20 posterior colporrhaphy part that is thought to be Q. Are you going to be making any criticisms about 21 21 associated with the dyspareunia, not necessarily the 22 22 anterior colporrhaphy. Dr. Luu? 23 MR. JONES: Q. Will you be giving an opinion the 23 A. No. 24 24 MS. COTA: Okay. Thank you very much. I don't PC procedure caused dyspareunia in Ms. Perry? 25 MR. WES: Object to form. 25 have any more questions. Page 141 Page 139 1 EXAMINATION BY MR. JONES 1 THE WITNESS: In all likelihood I think that it 2 MR. JONES: Q. A few issues. Doctor, you 2 did, yes. 3 brought with you some materials today that you could refer 3 MR. JONES: Q. Will you be giving that opinion 4 to, correct? 4 at trial? 5 A. Correct. 5 A. Yes, I will. 6 6 Q. Is that an opinion that's included in this MR. JONES: I'd like to go ahead and mark those 7 7 materials that we haven't already previously marked as summary of opinions list? 8 8 A. I don't know why I keep -- it may not be. Exhibit L-8 (sic). 9 MR. WES: Sure. I think those are going to be 9 Did you find it? This is why we have this 'cause 10 10 I can't even remember what I say let alone what I write the two operative reports. 11 THE WITNESS: Yes. That's what they were. 11 down. 12 12 MR. JONES: Okay. We'll mark those as Exhibit Oh, consistent with findings of the explanter of 13 13 L -a tight band at the introitus. So that's consistent with 14 14 Dr. Allen's findings, and I guess by extrapolation I MS. COTA: The last one I have is L-8, the CV. 15 MR. JONES: Mark L-9. 15 was -- his interpretation that that was probably what was 16 (Whereupon, Exhibits L-9 and L-10 were marked 16 causing the dyspareunia. The literature suggests that, 17 and that's how I'm interpreting it. So that's what that 17 for identification.) 18 THE WITNESS: What happened to L-4? 18 19 Q. So consistent with findings of the explanter of a 19 MR. JONES: A couple of follow-up questions based 20 tight band at the introitus? 20 on information that came about through Laura's 21 21 22 22 Q. What you mean by that is you'll be giving an Well, first off, Josh, you're going to provide a 23 opinion at trial that the posterior repair caused 23 narrow universe of materials that she has actually looked 24 dyspareunia in Ms. Perry? 24 at and reviewed, correct? 25 MR. WES: Object to form. 25 MR. WES: Yes, we will provide you of the list to

#### Page 142 Page 144 THE WITNESS: Yeah, I think -- the opinion is 1 Q. Do you know how -- how wide the introitus was 2 2 that there was a -- there wasn't just vaginal tissue following the PC procedure? 3 removed, there was a fair amount -- significant amount of 3 MR. WES: Object to form, foundation, 4 4 perineal tissue. That perineal tissue -- in all speculation. 5 5 THE WITNESS: Dr. Allen makes a comment about how likelihood that -- the removal of that material in all 6 6 it's, you know, narrowed and how many fingers he could likelihood caused the narrowing, and narrowing of the 7 7 introitus is associated with dyspareunia. insert versus after he dilated it, yes. 8 So in all likelihood, I think that that is what's 8 MS. COTA: Q. Okay. Do you know how wide the 9 caused her dyspareunia, and that was her report of pain on 9 introitus was prior to the PC procedure? 10 10 entry. So I think that's corroborated by Dr. Allen's MR. WES: Same objection. 11 findings, and that's my opinion. 11 THE WITNESS: I don't know that it was reported 12 12 MR. JONES: Q. Okay. Are there any other in that operative report. 13 conclusions that you'll be giving that aren't included in 13 MS. COTA: Q Okay. So is that a no? 14 this summary of opinions? 14 A. Well, I think as -- I think even Doctor -- I'm 15 A. No. 15 blocking on his name -- Luu? 16 Q. Okay. And you said that counsel provided you 16 Q. That's my client. 17 literature related to dyspareunia being associated with 17 A. Is that how you pronounce his name? 18 colporrhaphy procedures, correct? 18 Q. My client, yes. 19 A. Yes. 19 A. I think as he mentioned it, if he had seen -- if 2.0 MR. WES: Object to form. 20 there was an abnormality, he would have reported it. He 2.1 MR. JONES: Q. Did counsel provide you any 21 mentioned that in his deposition. So if there had been an 22 literature related to transvaginal mesh causing 22 abnormally narrow introitus, that would have been in his 23 dyspareunia? 23 op report. 2.4 MR. WES: Object to form. 24 He didn't say that specifically, but I know that 25 THE WITNESS: Counsel provided me a lot of 25 during his deposition he was asked something, and he Page 145 Page 143 1 literature about -- concerning dyspareunia associated 1 basically said it would be in there. If there was 2 2 with -- or with -- you know, associated with mesh, yes. anything abnormal, it would have been in there. 3 MR. JONES: Q. Okay. And once we get the list 3 So I would extrapolate that it wasn't abnormally 4 of materials that you actually are relying on in this 4 narrow at the time he did his mesh procedure and probably 5 5 case, we'll be able to look at that list and locate wasn't, not with all that -- usually with lax tissue, it's 6 6 articles where transvaginal mesh has been associated with usually not narrowed. The enterocele and the recto --7 7 dyspareunia, correct? cystocele. MR. WES: Object to form. 8 8 (Reporter clarification.) THE WITNESS: Transvaginal mesh material that's 9 9 THE WITNESS: Yes. That's another term for 10 been -- I reviewed articles that talked about pain 10 11 associated with transvaginal mesh. 11 MS. COTA: Q. But it's true we don't have any 12 MR. JONES: Okay. 12 documentation similar to Dr. Allen's report where he talks 13 THE WITNESS: Yes. 13 about the number of fingers that he can insert? 14 MR. JONES: That's all the questions I have. 14 A. That's correct. 15 FURTHER EXAMINATION BY MS. COTA 15 MR. WES: Same objection. 16 MS. COTA: And I'm sorry, I have like two 16 MS. COTA: And is the -- whether or not -- well, 17 follow-up questions. 17 strike that. I'm done. 18 Q. Dr. Longacre, you testified that it's your 18 THE WITNESS: Okay. That's all. 19 opinion that the dyspareunia that Ms. Perry complains of 19 MR. WES: Do you have anything else? Go off the 20 is because of a narrow introitus caused by the PC 20 record for just a second. 21 procedure. Is that --21 (Discussion held off the record.) 22 A. Yes. 22 MR. WES: We can go back on. 23 Q. -- accurate? 23 EXAMINATION BY MR. WES 24 MR. WES: Object to form. 24 MR. WES: Q. So just one very brief point of 25 MS. COTA: Thank you. 25 clarification. I think plaintiff's counsel asked you

	Page 146		Page 148
1	earlier if you were being compensated for your deposition	1	STATE OF CALIFORNIA, )
2	testimony today. Is it true that you're being compensated		) ss.
3	for your time today?	2	COUNTY OF SANTA CLARA )
4	A. Yes.	3	
5	Q. Okay. And the opinions you're giving in this	4	I, LISA R. KEELING, a Certified Shorthand
6	case are your opinions; is that right?	5	Reporter in and for the State of California, hereby
7	A. Absolutely.	6	certify that the witness in the foregoing deposition,
8	MR. WES: Those are all the questions I have.	7	TERI A. LONGACRE, M.D.,
9	MR. JONES: Thanks, Doctor.	8	was by me duly sworn to tell the truth, the whole truth
10	MR. WES: Standing order, rough and expedite.	9	and nothing but the truth in the within-entitled cause,
	· ·	10	and that the foregoing is a full, true and correct
11	MR. JONES: Rough for me and expedite.	11	transcript of the proceedings had at the taking of said
12	MS. COTA: Same for me.	12	deposition, reported to the best of my ability and
13	(Whereupon the deposition of	13	transcribed under my direction.
14	TERI A. LONGACRE, M.D.,	14	
15	was concluded at 12:55 p.m.)	15	
16		16	D
17	oOo	17	Date, 2014
18		1.0	LISA KEELING, CSR NO. 10518
19		18	
20		19 20	
21		21	
22		22	
23		23	
24		24	
25		25	
	Page 147		Page 148
1.	Page 147	1	
1 2		1 2	Page 148 ACKNOWLEDGMENT OF DEPONENT
2	ERRATA	2	ACKNOWLEDGMENT OF DEPONENT
2	ERRATA	2	ACKNOWLEDGMENT OF DEPONENT  I,, do hereby
2 3 4	ERRATA PAGE LINE CHANGE	2 3 4	ACKNOWLEDGMENT OF DEPONENT  I,
2 3 4 5	ERRATA PAGE LINE CHANGE	2 3 4 5	ACKNOWLEDGMENT OF DEPONENT  I,
2 3 4 5	ERRATA PAGE LINE CHANGE	2 3 4 5 6	I,
2 3 4 5 6 7	ERRATA PAGE LINE CHANGE REASON:	2 3 4 5	I,
2 3 4 5 6 7 8	ERRATA PAGE LINE CHANGE	2 3 4 5 6 7 8	I,
2 3 4 5 6 7 8	ERRATA  PAGE LINE CHANGE  REASON:  REASON:	2 3 4 5 6 7	I,
2 3 4 5 6 7 8 9	ERRATA PAGE LINE CHANGE REASON:	2 3 4 5 6 7 8	I,
2 3 4 5 6 7 8 9 10	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9	I,
2 3 4 5 6 7 8 9 10 11	ERRATA  PAGE LINE CHANGE  REASON:  REASON:	2 3 4 5 6 7 8 9 10	I,
2 3 4 5 6 7 8 9 10 11 12 13	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9 10 11	I,
2 3 4 5 6 7 8 9 10 11 12 13 14	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9 10 11 12	I,
2 3 4 5 6 7 8 9 10 11 12 13	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9 10 11 12 13	ACKNOWLEDGMENT OF DEPONENT  I,
2 3 4 5 6 7 8 9 10 11 12 13 14	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9 10 11 12 13 14	ACKNOWLEDGMENT OF DEPONENT  I,
2 3 4 5 6 7 8 9 10 11 12 13 14	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	ACKNOWLEDGMENT OF DEPONENT  I,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	ACKNOWLEDGMENT OF DEPONENT  I,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	ACKNOWLEDGMENT OF DEPONENT  I,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	I,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	ACKNOWLEDGMENT OF DEPONENT  I,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	I,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	ACKNOWLEDGMENT OF DEPONENT  I,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	ACKNOWLEDGMENT OF DEPONENT  I,
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	ERRATA  PAGE LINE CHANGE  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:  REASON:	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	ACKNOWLEDGMENT OF DEPONENT  I,

38 (Pages 146 to 148)